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PReface
Atherosclerosis and its complications are the underlying cause for most cardiovascular 
diseases. It is a chronic, multifactorial disease in which lipid accumulates in the arterial 
wall, leading to a local inflammatory reaction and atherosclerotic plaque formation. 
Atherosclerotic disease develops largely asymptomatic over a lifetime. However, plaque 
rupture or erosion can cause the formation of a superimposed thrombus blocking the 
flow of blood. Upon rupture or erosion of an atherosclerotic plaque, platelets, the body’s 
first responders upon endothelial disruption, initiate the formation of a platelet plug, 
which activates the coagulation cascade to form an arterial thrombus. Although in 
principle a protective response, this thrombus formation can cause acute cardiovascular 
events such as myocardial infarction or ischemic stroke 1,2.
Bone marrow derived cells from both the innate and adaptive immune system, 
especially monocytes/macrophages and T cells, and platelets have been implicated in 
the pathophysiology of atherosclerosis 1, The primary site of immune cell and platelet 
production is the bone marrow. During bone marrow hematopoiesis, hematopoietic 
stem cells (HSCs) mature and differentiate until the formed immune cells and platelets 
enter the circulation or home towards their site of action or organ for final maturation 3. 
During homeostasis, hematopoiesis is tightly balanced between the different blood cell 
lineages. In that way, by controlling the output of immune cells and platelets, hema-
topoiesis plays a major role in the resolution or persistence of inflammatory diseases, 
such as atherosclerosis. An increased number of peripheral blood leukocytes, especially 
monocytes and granulocytes, as well as increased platelet counts and reactivity is associ-
ated with occurrence and outcome of cardiovascular disease 4–10. Interestingly, defects in 
cholesterol metabolism and hypercholesterolemia have been shown to affect hemato-
poiesis, immune cell production and platelet counts and reactivity 11,12. Therefore, bone 
marrow cholesterol handling is an interesting target in the battle against cardiovascular 
disease.
This chapter summarizes relevant information to understand the role of cholesterol 
metabolism in the production and reactivity of immune cells and platelets, and its ef-
fects on atherosclerosis and atherothrombosis development.
HeMaToPoIesIs
All circulating blood cells, i.e. erythrocytes, leukocytes and platelets, originate from bone 
marrow, in which they are formed from HSCs through hematopoiesis. Hematopoiesis is 
divided into three main branches: the myeloid, lymphoid and megakaryocyte-erythroid 
arms. HSCs constitute the top of the hematopoietic tree and give rise to committed 
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progenitor cells, which in turn mature into differentiated cells that home towards their 
site of action or organ for final maturation, Figure 1.
HSCs are self-renewing and either multi- or uni-potent. They remain quiescent to 
maintain their undifferentiated state. The HSC pool is divided into long-term HSCs (LT-
HSCs) and short-term HSCs (ST-HSCs). LT-HSCs can provide long term engraftment and 
can serially engraft irradiated mice, whereas ST-HSCs have more limited self-renewal 
capacity in a serial transplantation assay 3. ST-HSCs are believed to give rise to multipo-
tent progenitors (MPPs), which are capable of producing all blood cell linages, but lack 
the capacity for serial transplantation. These MPPs then differentiate further into either 
myeloid or lymphoid lineages. In the classical model of hematopoiesis, the next steps 
are the formation of common myeloid progenitors (CMPs), which give rise to all myeloid 
cells, including the megakaryo-erythroid lineage, and the common lymphoid progeni-
tors (CLPs) 3. However, this classical tree has been subject of debate. Recent evidence 
has suggested that possibly the first step from the HSC pool may not be a lymphoid-
myeloid differentiation decision step, but rather one that allows the megakaryocyte-
erythrocyte lineage to split off, leaving a progenitor with both lymphoid and myeloid 
potential, but without the capacity to form megakaryocytes or erythrocytes. Named a 
lymphoid-primed multipotent progenitor (LMPP), this cell then differentiates into the 
granulocyte-macrophage progenitor (GMP) and CLP 3. The GMP can differentiate into 
a neutrophil, monocyte (which in turn can differentiate into a macrophage or dendritic 
cell in the periphery), or an eosinophil 13. The CLP differentiates into a B cell, a natural 
killer cell (NK cell) or becomes an early thymic progenitor (ETP) that migrates from the 
bone marrow to the thymus to become a CD4+ T cell or a CD8+ T cell13. Megakaryocyte-
erythroid progenitors (MEPs) differentiate further into erythrocytes (through stimula-
tion with erythropoietin) or megakaryocytes (stimulated by thrombopoietin). Cells in 
the erythroid lineage are released into the bloodstream as reticulocytes that mature to 
erythrocytes in the circulation. Megakaryocytes mature fully in the bone marrow, after 
which they release platelets into the bloodstream and perish 14.
cHolesTeRol MeTabolIsM
Cholesterol is an important precursor for steroid hormones and an essential component 
of cell membranes, in which it modulates membrane fluidity. Cholesterol can exist in 
eukaryotic cells in two forms: an unbound, free from in cell membranes, or stored as 
cholesteryl esters. Esterification for storage is important, as excess free cholesterol is 
cytotoxic. See Figure 2 for a schematic overview.
General introduction and thesis outline
13
lipoproteins
General structure and function
Cholesterol is a hydrophobic molecule and is insoluble in aqueous solutions. Therefore, 
it is transported thought the blood circulation by lipoproteins. Lipoproteins are water-
soluble macromolecular complexes, comprised of a hydrophobic core containing cho-
lesteryl esters, neutral lipids, and triglycerides, and a hydrophilic monolayered shell of 
phospholipids, unesterified free cholesterol and specific apolipoproteins. Lipoproteins 
are classified according to their size and density: chylomicrons, very-low-density lipo-
proteins (VLDL), low-density lipoproteins (LDL), and high-density lipoproteins (HDL) 15. 
Chylomicrons and VLDL are the largest and least dense lipoproteins, as they consist 
primarily of a triglyceride rich core. LDL, a remnant of VLDL, and HDL contain a core 
which is comprised primarily of cholesteryl esters 15. Moreover, the different lipoproteins 
can be distinguished by their apolipoprotein composition. Chylomicrons, VLDL and LDL 
have apolipoprotein B (ApoB) as their primary apolipoprotein, whereas apolipoprotein 
A1 (ApoA1) is the principle apolipoprotein of HDL.
The liver plays a central role in cholesterol metabolism, which can be divided in an 







B T NK GR MO E MK 
GMP MEP 
figure 1: schematic overview of hematopoiesis. For explanation see text. LT-HSC: long-term hematopoi-
etic stem cell. ST-HSC: short-term hematopoietic stem cell. MPP: multipotent progenitor. LMPP: lymphoid-
primed multipotent progenitor. CMP: common myeloid progenitor. CLP: common lymphoid progenitor. 
GMP: granulocyte-macrophage progenitor. MEP: megakaryocyte-erythroid progenitor. B: B cell. T: T cell. NK: 
natural killer cell. GR: granulocyte. MO: monocyte. E: erythrocyte. MK: megakaryocyte.
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Exogenous lipid and cholesterol metabolism
The amount of cholesterol and triglycerides absorbed from the diet is a major contribu-
tor the lipid and cholesterol levels in the circulation. Upon absorption by the enterocytes 
dietary triglycerides and cholesteryl esters are, together with intestinal ApoB molecules 
incorporated in nascent chylomicrons. These newly synthesized chylomicrons are then 
exocytosed into the lymph and subsequently enter the blood circulation, where they 
acquire Apolipoprotein E (ApoE) and apolipoprotein C (ApoC) apolipoproteins to form 
mature chylomicrons 16,17. Mature chylomicrons circulate in the blood, where their tri-
glycerides molecules are lipolyzed by lipoprotein lipase (LPL) and taken up for energy 
production and storage 18,19. The formed chylomicron remnants are then removed from 
the circulation through interaction of ApoE with hepatic LDL receptor related protein 
(LRP), remnant receptors, heparin sulphate proteoglycans, and scavenger receptor BI 
(SR-BI) 20–22. In line with the importance of ApoE for removal of lipoproteins and chy-
lomicron remnants from the circulation, targeted deletion of ApoE is associated with 





































figure 2: schematic overview of lipid metabolism. For explanation, see text.
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standard chow diet which does not contain cholesterol, and is strongly aggravated on a 
high-cholesterol diet 23,24.
Endogenous lipid and cholesterol metabolism
Lipids derived from hepatic uptake of lipoprotein remnants and de novo synthesized 
cholesterol are packaged and (re)secreted into the circulation by the liver as ApoB100-
containing nascent VLDL particles 25. In the circulation, VLDL further acquires ApoE and 
ApoC 15. Hydrolysis of triglycerides transforms VLDL to intermediate-density lipoproteins 
(IDL), which are partly taken up by the liver via the LDL receptor (LDLr) and LRP 26. Further 
hydrolysis of IDL particles results in the formation of smaller cholesteryl ester-rich LDL, 
which has ApoB100 as the sole apolipoprotein 26. Finally, LDL is recognized by the LDLr 
mostly on the liver as well as peripheral tissues and removed from the circulation for 
intracellular metabolism. In line with its important role in the removal of VLDL remnants 
and its ultimate remnant LDL from the circulation, mice which are genetically deficient 
for the LDLr have a prolonged half-life of plasma VLDL and LDL 27. These mice display 
a modestly elevated plasma cholesterol level when fed a normal chow diet. However, 
when placed on a cholesterol-rich diet they show strongly elevated plasma cholesterol 
levels (hypercholesterolemia) 28,29.
Reverse cholesterol transport
Reverse cholesterol transport is the pathway through which excess cholesterol from pe-
ripheral tissues is transported back to the liver by HDL for recycling or biliary excretion.
HDL metabolism
HDL is primarily produced by the liver, and to a lesser extent by the intestine, though in-
teraction of lipid-poor ApoA1 with the ATP-binding cassette transporter A1 (ABCA1) 30,31. 
This is an essential part of HDL formation, as both genetic deficiency of ApoA1 as well as 
lack of ABCA1 diminishes circulating HDL levels 32,33. Lipidation of ApoA1 results in the 
formation of nascent pre-β HDL particles 34. These nascent HDL particles are potent ac-
ceptors of excess cholesterol from peripheral tissues. Upon association of, primarily, free 
cholesterol and phospholipids from peripheral tissues, discoidal HDL particles mature to 
spherical HDL3 particles upon conversion of its free cholesterol into cholesteryl esters by 
lecithin:cholesteryl acyltransferase (LCAT) 35 and storage in the core of the particle. HDL3 
is subsequently converted into large α-migrating mature HDL2 by further acquirement 
of phospholipids by transfer through phospholipid transfer protein (PLTP) and apoli-
poproteins that are released during lipolysis of triglycerides in chylomicrons or VLDL. 
Mature HDL circulates in the blood where it takes up excess cholesterol from tissues, 
excreted through cholesterol efflux transporters. The cholesteryl esters are delivered to 
the liver via SR-BI for recycling and biliary excretion or transferred to ApoB containing 
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lipoproteins by cholesteryl ester transfer protein (CETP) for redistribution through the 
endogenous lipid and cholesterol metabolism pathway.
Cholesterol efflux towards ApoA1 and HDL
Cholesterol efflux is an active mechanism, which is regulated by various transporters, 
the most important of which are members of the ATP binding cassette (ABC) transporter 
family. Several members of this family of transmembrane proteins mediate the transport 
of cholesterol between various cellular domains and eventual efflux of cholesterol to 
ApoA1 or HDL on the plasma membrane.
ABCA1 is present on the cellular plasma membrane, and mediates cholesterol efflux 
to lipid poor apolipoproteins, such as ApoA1 and ApoE, but not large HDL particles 36. 
ABCA1 is highly expressed in hepatocytes and enterocytes, the two cell types that to-
gether generate the majority of the plasma HDL 37. As a consequence, ABCA1 knockout 
mice are unable to lipidate circulating ApoA1, resulting in HDL deficiency 32. In line, mu-
tations in the ABCA1 gene in humans are the causal factor in Tangier disease, of which 
HDL deficiency is a major clinical manifestation 38–40. However, ABCA1 is most known for 
its crucial function in lipid homeostasis and cholesterol efflux from macrophages, as the 
deletion of ABCA1 in bone marrow leads to a dramatic increase in foam cell formation 
and subsequent atherosclerosis in hypercholesterolemic mice 41.
Another important cholesterol transporter is ABCG1. ABCG1 is highly expressed 
in macrophages, endothelial cells, epithelial cells and brain. However, in contrast to 
ABCA1, not in hepatocytes or intestinal enterocytes 42. Moreover, contrary to ABCA1, 
which is a full transporter, ABCG1 needs to dimerize with another ABC transporter to 
become functional 43. ABCG1 mediates in cholesterol efflux to mature HDL particles, but 
not lipid-free apolipoproteins 42,44,45. In line, ABCG1 does not facilitate HDL generation 42. 
Interestingly, whereas ABCA1 is present on the plasma membrane and directly binds 
to circulating ApoA1 46, ABCG1 is involved in intracellular sterol movement. Although 
the precise cellular localization of ABCG1 remains elusive, it is involved in trafficking 
of cholesterol over the endoplasmic reticulum membrane and endosomes. In that way 
it does not only increase availability of cholesterol for efflux to lipoprotein acceptors, 
but is also important for the regulation of endoplasmic reticulum-localized cholesterol 
biosynthesis genes 46,47.
Besides ABCA1 and ABCG1, ABCG4 has also been implicated as a cholesterol efflux 
transporter 44. ABCG4 shows high levels of homology to ABCG1, and effluxes to HDL 
particles. Interestingly, it is not expressed in macrophages, but is highly expressed in 
megakaryocytes, the precursor cells of platelets 48.
Besides ABC transporter family members, SR-BI has also been implicated as a choles-
terol efflux transporter, as it induces free cholesterol flux down a cholesterol-concen-
tration gradient 49,50. The exact mechanism by which SR-BI mediates cholesterol efflux 
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is largely unknown. Possibly, SR-BI simply mediates tethering of acceptor HDL particles 
closely to the cell surface 51. Another possibility is that SR-BI reorganizes the lipids in 
cholesterol-rich domains in the plasma membrane, thereby facilitating the movement 
of cholesterol towards HDL 51.
aTHeRoscleRosIs
Atherosclerosis is a chronic, multifactorial disease induced by lipid accumulation in 
the vessel wall and subsequent arterial wall inflammation, leading to atherosclerotic 
plaque formation. Atherosclerosis develops asymptomatic over a lifetime. However, 
when a plaque ruptures or erodes, a superimposed thrombus is formed causing acute 
cardiovascular events such as myocardial infarction or ischemic stroke.
Dyslipidemia is a major risk factor for atherosclerosis
A major risk factor for the development of premature atherosclerosis is dyslipidemia. 
Dyslipidemia is a broad term, which refers to a number of lipid disorders, including el-
evated LDL cholesterol, low HDL cholesterol, excess lipoprotein(a), hypertriglyceridemia, 
and mixed lipid disorders. Although familial causes account for ~20% of these disorders, 
most (~80%) are related to diet and lifestyle 52. It is well established that there is a direct 
relationship between dyslipidemia and cardiovascular risk 53. In healthy individuals, 
cholesterol levels are below 5 mmol/L. A rise of 2 mmol/L cholesterol increases the risk 
of death by cardiovascular disease by 50% 54. This is most likely attributable to high LDL 
cholesterol, the main carrier of cholesterol in human plasma. In contrast, large popula-
tion studies have consistently shown that low HDL cholesterol, as well as ApoA1 levels 
are independent, inverse predictors of cardiovascular disease risk 55–59. Normalization 
of dyslipidemia is therefore a major target in the prevention of atherosclerosis and its 
clinical manifestations.
Pathophysiology of atherosclerosis
Atherosclerotic plaques form at specific arterial sites with differences in blood flow 
dynamics, such as arterial tree branches and bifurcations. Low shear stress, oscillatory 
or turbulent flow, together with dyslipidemia, which can cause lipoprotein retention 
in the subendothelial matrix, cause damage and endothelial dysfunction. This is gen-
erally regarded as the primary step in atherosclerosis development. Damage to the 
endothelium increases arterial wall permeability and increases expression of adhesion 
molecules, and the production of cytokines and chemokines, thereby leading to the 
migration of inflammatory cells such as monocytes, lymphocytes and neutrophils from 
the circulation into the arterial wall intima. Macrophages in the intimal wall then rapidly 
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engulf the accumulated lipids and the first foam cells in the nascent lesion are formed. 
Macrophage foam cell formation is the hallmark of early atherosclerotic lesions, also 
called fatty streaks. These fatty streaks can then progress towards intermediate fibro-
fatty lesions, which consist of several layers of foam cells and vascular smooth muscle 
cells with T cells, surrounded by a relatively poor developed matrix of connective tissue. 
These intermediate plaques can then progress further into advanced fibrous lesions, 
which are characterized by a fibrous cap that covers a core of extracellular lipid and 
necrotic material, together with macrophages, smooth muscle cells and T cells 1. In 
line with the importance of immune cell influx and inflammation in atherosclerosis 
development, studies in mice have indicated a causal relationship between the levels 
of blood monocytes and neutrophils and the extent of atherosclerosis 60–62. Moreover, 
the levels of blood monocytes and neutrophils are predictive of acute cardiovascular 
events 4,5. Importantly, monocytosis in the absence of hyperlipidemia is insufficient to 
induce atherosclerosis 11,63. Only when the endothelium becomes inflamed in response 




Atherosclerotic plaques develop slowly, and remain largely asymptomatic as long as 
they remain intact. However, advanced plaques can cause complications through ath-
erothrombosis formation. Atherothrombosis can occur in two ways: by rupture of an 
unstable lesion, or by erosion of the overlying endothelium. Plaques prone to rupture, 
so-called vulnerable plaques, are characterized by a thin fibrous cap, and a large lipid 
core with a relative abundance of inflammatory leukocytes 67. In contrast, vulnerable 
plaques underlying areas of superficial erosion do not have thin fibrous caps. Moreover, 
they harbor fewer inflammatory cells, and lack large lipid pools 68. From autopsy studies 
done several decades ago, it was suggested that plaque rupture most commonly led to 
fatal coronary atherothrombosis 67,69, whereas a minority of fatal events was caused by 
superficial plaque erosion. However, more recently, questions have been raised about 
the dominant mechanisms implicated in atherothrombosis. Recent evidence suggests 
that plaques with thin fibrous caps and large lipid pools seldomly rupture and cause 
clinical events 70,71. Moreover, recent studies have shown that there is a shift towards 
plaques with significantly more fibrous, non-inflammatory characteristics 72–74. Possibly, 
this shift in plaque characteristics could lead to a subsequent shift in plaque rupture 
versus erosion occurrence 75,76.
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Pathophysiology of atherothrombosis
When a plaque ruptures or erodes, subendothelial collagen and thrombogenic plaque 
material, such as macrophage tissue factor, are exposed to the arterial circulation. This 
leads to thrombus formation on top of the ruptured or eroded plaque 2. Upon the breach 
of the arterial endothelial lining, platelets are the first responders. Within one minute 
after rupture, platelets adhere and aggregate on collagenous plaque components. In 
line with their importance in atherothrombotic development, platelet characteristics 
such as density and volume are associated with the risk of acute coronary syndromes 6–9, 
and implies mean platelet volume, a determinant of platelet reactivity, as both a causal 
and prognostic factor 10. Following the platelet response, approximately three minutes 
after breaching of the endothelial lining, the thrombus is characterized by thrombin 
and fibrin formation, and by tissue factor-triggered coagulation cascade activation 77. 
This thrombus formation can lead to rapid occlusion of the vessel, a cause myocardial 
infarction, ischemic stroke and sudden death. This deadly nature of atherothrombosis 
has made it a critical target for investigation.
Interplay between cholesterol and bone marrow cells in atherosclerosis
Atherosclerosis is generally characterized as an inflammatory response to hypercholes-
terolemia. However, there is increasing evidence that the inflammatory process driving 
the atherogenic response to hypercholesterolemia may be initiated in the bone marrow. 
A large body of evidence indicates that bone marrow functioning and hematopoiesis 
are affected by changes in HSC cholesterol homeostasis, i.e. hypercholesterolemia and 
cholesterol efflux.
Hypercholesterolemia and HSCs
Several studies on the effects of hypercholesterolemia on bone marrow function have 
been done in high-fat, high-cholesterol (HFHC) diet -fed LDLr and ApoE knockout mice. 
Both HFHC diet-fed ApoE knockout, and to a lesser extent HFHC diet-fed LDLr knockout 
mice display and augmented expansion and proliferation of HSCs 64,78,79. This phenotype 
is paralleled by an increase in myeloid cell production and increased circulating counts 
of monocytes and neutrophils 64,78,79.
Interestingly, hypercholesterolemia-induced hyperproliferation of HSCs, as well as the 
consequent leukocytosis, are also evident in recipients of transplanted bone marrow 
from hypercholesterolemic mice 79,80. Thus, long-term intrinsic changes in stem cells are 
induced by the hypercholesterolemia.
Besides HSC proliferation and leukocytosis, hypercholesterolemia also alters platelet 
production and reactivity. Rabbits and guinea pigs fed a high-cholesterol diet develop 
megakaryocytes with increased ploidy and size 81,82. Hypercholesterolemia in humans is 
also associated with higher megakaryocyte ploidy, indicative of altered megakaryocyte 
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maturation 83. Notably, the change in megakaryocyte maturation in hypercholesterol-
emic human subjects coincided with a higher mean platelet volume 83.
Cholesterol efflux and HDL and HSCs
Most of the atherosclerosis-protective properties of APOA1 and HDL are attributed 
to their role in cholesterol efflux and subsequent reverse cholesterol transport from 
macrophage foam cells, as well as direct anti-inflammatory properties 84–86. HSCs utilize 
cholesterol efflux pathways to oppose the excessive production of myeloid cells 11,64,78,87. 
Genetic deletion of ABCA1 and ABCG1 leads to dramatic expansion and proliferation of 
HSCs and an increase in committed myeloid progenitor populations 11. This stimulates 
the development of severe monocytosis and neutrophilia and infiltration of multiple 
organs with myeloid cells and accumulation of macrophage foam cells 11. A similar phe-
notype is observed when ABCA1/ABCG1 double knockout bone marrow is transplanted 
into LDLr homozygous or heterozygous knockout mice 11,88. Interestingly, increased 
HSC numbers and the myeloproliferative phenotype caused by combined deletion 
of ABCA1/ABCG1 in bone marrow could be rescued by transgenic overexpression of 
ApoA1 in recipient mice 11. Infusion of ApoA1 into LDLr/ApoA1 double knockout mice 
also reduces the number of LSK cells in bone marrow 87, and reduces HSC proliferation in 
hypercholesterolemic LDLr knockout mice, and ApoE knockout mice 64,78.
Transplantation of ABCA1 knockout bone marrow into LDLr knockout mice is associ-
ated with lymphocytosis, although no such phenotype is found in total body ABCA1 
knockout mice 41. Similarly, chow-fed ApoA1 knockout mice do not display monocytosis 
or proliferation of HSCs 64. As both ABCA1 and ApoA1 knockout mice are hypocholes-
terolemic through the inability to produce HDL, this indicates that the importance of 
cholesterol efflux may depend on the levels of circulating cholesterol levels. Genetic 
deletion of only ABCG1 has thus far not been shown to affect bone marrow hematopoi-
esis, neither as a total body knockout nor after transplantation to hypercholesterolemic 
recipient mice.
ABCG4 is specifically expressed in MEP cell populations and megakaryocyte progeni-
tors. In line, ABCG4 knockout megakaryocyte progenitors show defective cholesterol 
efflux to HDL and increased MEP and megakaryocyte progenitor cell populations, which 
are relatively more responsive to thrombopoietin. As a consequence, ABCG4 knockout 
transplanted LDLr knockout mice have increased platelet counts 48.
oUTlIne of THe THesIs
Defects in cholesterol metabolism and hypercholesterolemia have been shown to affect 
hematopoiesis, immune cell production and platelet counts and reactivity. Therefore, 
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bone marrow cholesterol handling is an interesting target in the battle against cardio-
vascular diseases, and acute cardiovascular events in particular.
This thesis will describe novel interactions between cholesterol metabolism and the 
production immune cells and platelets, and its effects on atherosclerosis and athero-
thrombosis development.
The first part of this thesis focusses on cholesterol metabolism in hematopoiesis.
It is well established that dyslipidemia is an important risk factor for cardiovascular 
disease. Circulating lipid levels are highly correlated with atherosclerotic plaque devel-
opment. In addition, experimental evidence suggests that lipids also directly influence 
thrombosis and influence the risk and the outcome of acute cardiovascular events. In 
chapter 2, the effects of lipoproteins on three important components of atherothrom-
bosis pathophysiology, i.e. endothelial function, platelets and secondary coagulation, 
are reviewed.
A substantial body of clinical evidence indicates that platelet characteristics such as 
density and volume are associated with increased risk of acute coronary syndromes 6–9, 
and implies mean platelet volume, a determinant of platelet reactivity, as both a causal 
and prognostic factor 10. Therefore, modification of platelet functionality is a promis-
ing therapeutic target in the prevention and treatment of cardiovascular disease. In 
chapter 3, we show that elevated plasma unesterified cholesterol levels impairs mega-
karyopoiesis and platelet production in SR-BI knockout mice. Our findings suggest that 
impaired platelet production, in addition to the previously reported augmented platelet 
clearance, may explain part of the thrombocytopenic phenotype associated with SR-BI 
deficiency. In chapter 4, we describe novel and opposing roles of the cholesterol efflux 
transporters ABCA1 and ABCG1 in megakaryopoiesis, platelet production and effects on 
platelet characteristics.
In addition to effects on hematopoietic stem cell functionality and hematopoiesis, 
ApoA1 and HDL also directly influence inflammatory cell responses 86. In chapter 5, we 
dissociated the direct effects of ApoA1 deficiency on immune cells in the context of 
atherosclerosis from effects that are generated through changes in bone marrow im-
mune cell production.
The second part of this thesis focusses on the development of experimental animal 
models of atherothrombosis.
Although atherosclerosis is widely studied in experimental mouse models, ex-
perimental studies regarding atherothrombosis are hampered due to lack of suitable 
mouse models. In chapter 6 recent advances in the development of mouse models for 
spontaneous atherothrombosis are reviewed. In chapter 7, we describe a novel RNA 
interference-based mouse model for spontaneous atherothrombosis in ApoE knockout 
mice. Further characterization and attempts to optimize this model through administra-
tion of phenylephrine to ApoE knockout mice are described in chapter 8. Murine SR-BI 
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deficiency is associated with increased platelet reactivity and a higher susceptibility for 
FeCl3 damage-induced arterial thrombosis in the carotid artery 12. In chapter 9, we apply 
the developed atherothrombosis model to hypercholesterolemic SR-BI knockout mice.
Finally, all the results obtained in this thesis and future perspectives are summarized 
and discussed in chapter 10.
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Lipoproteins as modulators of 
atherothrombosis: From endothelial 
function to primary and secondary 
coagulation




Atherothrombosis is a complication of atherosclerosis that causes acute cardiovascular 
events such as myocardial infarction and stroke. Circulating lipid levels are highly cor-
related with atherosclerotic plaque development. In addition, experimental evidence 
suggests that lipids also directly influence thrombosis and influence the risk and the 
outcome of acute cardiovascular events. Plasma lipoproteins influence three aspects 
important to atherothrombosis: endothelial function, platelet aggregation (primary co-
agulation) and secondary coagulation. Overall, VLDL, LDL and oxLDL promote thrombus 
formation, whereas HDL shows antithrombotic actions. In this review we will address 
the current knowledge about modulation of atherothrombosis by lipoproteins, sum-
marizing findings from in vitro and in vivo animal studies, as well as from observational 
and interventional studies in humans. We will conclude with future perspectives for lipid 
modulation in the prevention of atherothrombosis.





Pathophysiology of atherosclerosis and atherothrombosis
Atherosclerosis is a lipid-driven progressive inflammatory disease, characterized by 
the accumulation of lipids and fibrous elements in medium and large sized arteries 1. 
Atherosclerosis develops largely asymptomatic over a lifetime. However, as lesion de-
velopment progresses, atherosclerosis can become complicated by atherothrombosis. 
This can be caused by either plaque rupture or superficial erosion of the plaque 2. Upon 
rupture or erosion, subendothelial collagen and thrombogenic plaque material, such 
as macrophage tissue factor (TF), are exposed to the arterial circulation. This leads to 
thrombus formation on top of the ruptured or eroded plaque 3. Within one minute after 
rupture, platelets adhere and aggregate on collagenous plaque components. After 
three minutes, the thrombus is characterized by thrombin and fibrin formation, and 
by the activation of coagulation, a process entirely triggered by plaque-derived TF 2. 
This thrombus formation can lead to rapid occlusion of the vessel, a cause myocardial 
infarction, ischemic stroke and sudden death. This deadly nature of atherothrombosis 
has made it a critical target for investigation.
Plaque rupture versus plaque erosion
Autopsy studies done several decades ago showed that plaque rupture most commonly 
led to fatal coronary atherothrombosis 4,5 , whereas a minority of the fatal events was 
caused by superficial erosion of the plaque. These studies also demonstrated that 
plaques prone to rupture, so-called vulnerable plaques, are characterized by a thin fi-
brous cap, and a large lipid core with a relative abundance of inflammatory leukocytes 5. 
Although the concept of the vulnerable plaque has been largely accepted and widely 
used in research, lately it has been subject of debate. Questions have been raised about 
the dominant mechanisms implicated in atherothrombosis. Recent evidence suggests 
that plaques with thin fibrous caps and large lipid pools seldomly rupture and cause 
clinical events 6,7. Often multiple presumed vulnerable plaques reside in coronary and 
other arteries. However, these do not inevitably rupture.
As opposed to lesions associated with plaque rupture, vulnerable plaques underlying 
areas of superficial erosion do not have thin fibrous caps. Furthermore, they harbor fewer 
inflammatory cells and lack large lipid pools 8. Interestingly, from studying specimens 
from the Athero-express biobank we know that there has been a shift in human athero-
sclerotic plaques morphology over approximately the last 12 years. Plaques obtained 
from more recent patients with symptomatic carotid artery disease show significantly 
more fibrous, non-inflammatory characteristics. Moreover, this trend is also visible in as-
ymptomatic patients 9–11. This shift is possibly due to altered disease demographics and 
changes in risk factor profiles, such as (passive) smoking and lipid lowering treatment 9. 
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Lipid lowering reinforces the fibrous cap, decreases the lipid pool and reduces inflam-
mation in both animals and humans 10–12. Possibly, this shift in plaque characteristics 
could lead to a subsequent shift in plaque rupture versus erosion occurrence 13,14. The 
consequences of this possible shift are under investigation.
lipoproteins
Lipoproteins are macromolecular complexes of lipids and proteins that are essential for 
the transport of cholesterol, triglycerides and fat-soluble vitamins in the blood. Based 
on their relative densities, five major classes of lipoproteins can be distinguished, be-
ing chylomicrons (CM), very-low-density lipoproteins (VLDL), intermediate-density 
lipoproteins (IDL), low-density lipoproteins (LDL) and high-density lipoproteins (HDL). 
CM, VLDL, IDL and LDL serve to deliver dietary and hepatic triglycerides and cholesterol 
to peripheral tissues. In humans, the main structural apolipoprotein (apo) on CM is the 
apoB48 molecule, while VLDL, IDL and LDL are identified by an apoB100 protein. More-
over, a specific subtype of LDL can be distinguished, lipoprotein (a) (Lp(a)), an LDL-like 
particle with an apolipoprotein (apo(a)) moiety attached to it.
Native HDL is primarily formed by the liver and the intestine and serves as a choles-
terol acceptor from peripheral tissues. In that way HDL mediates reverse cholesterol 
transport from the periphery to the liver, where it can be excreted via bile or repackaged 
as VLDL for delivery to tissues or used for the generation of native HDL particles. HDL 
is heterogenous in terms of its density, size, shape, surface charge and composition 15. 
Based on shape, HDL can be divided in spherical and non-spherical particles, which are 
often referred to as pre-β HDL based on their surface charge. Pre-β HDL can be divided 
in lipid-poor apoA-I molecules, single apoA-I molecules complexed with a small number 
of phospholipids, or discoidal particles which contain two or three apoA-I molecules 
complexed with multiple phospholipid molecules and a small amount of unesterified 
cholesterol. Upon esterification of free cholesterol to cholesterol esters by the enzyme 
lecithin cholesterol acyltransferase (LCAT), discoidal HDL can mature into spherical HDL 
particles. Spherical HDL particles can be divided into two major subclasses based on 
density: small dense HDL3, and larger, less dense HDL2. HDL particles can contain over 
80 different proteins, more than 200 lipid species, and several microRNAs. Among these 
proteins, apoA-I is the most abundant on HDL particles, followed by apoA-II. A minor 
subpopulation of HDL carries apoE as their main apolipoprotein 16.
High levels of cholesterol are strongly correlated with the incidence of cardiovas-
cular disease. In healthy individuals, cholesterol levels are below 5 mmol/L. A rise of 2 
mmol/L cholesterol increases the risk of death by cardiovascular disease by 50% 17. This 
is most likely attributable to LDL, the main carrier of cholesterol in human plasma. In 
contrast, large population studies have consistently shown that low HDL cholesterol, 
as well as apoA-I levels are independent, inverse predictors of cardiovascular disease 
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risk 18–22. There is also ample experimental evidence for a causative role for LDL in the 
development of atherosclerosis. At places in the arterial tree with turbulent blood flow, 
LDL can accumulate in the arterial intima, where it is prone to oxidative modification. 
Oxidized LDL (oxLDL) is taken up by macrophages, which, upon excess cholesterol 
loading, become foam cells. Macrophage foam cell formation in the arterial intima is 
the start of an atherosclerotic plaque 23. Epidemiological studies have shown that low 
HDL is associated with an increased risk for CVD as a results of atherosclerotic plaque 
development. Although a causal role for HDL is still under debate, many studies have 
shown protective effects of HDL on the artery wall 24. An important mechanism by which 
HDL is protective lies in their function as cholesterol acceptor. Macrophages are able to 
efflux excess cholesterol by transporting this to HDL particles via ATP binding cassette 
(ABC) transporters, which reduces foam cell formation.
Due to these pivotal roles of LDL and HDL in the initiation and progression of ath-
erosclerotic lesions, it is reasoned that this is their main role in the pathogenesis of 
cardiovascular disease. However, lipoproteins are being more and more recognized as 
multi-purpose players in cardiovascular disease. VLDL, LDL and HDL all carry a variety of 
proteins, aside their lipid constituents and apolipoproteins that influence their functional 
characteristics. On HDL, for example a large number of the proteins present are involved 
in the acute-phase response 25. Furthermore, an analysis of the proteins found on human 
VLDL and LDL revealed that for both particles, 25% of all functional pathways in which 
the proteins were active, are related to coagulation and hemostasis 26,27. Elevated plasma 
cholesterol and elevated lp(a) are identified as risk factors in venous thrombosis. Treat-
ment of hypercholesterolemia by statin therapy reduces the risk of both venous and 
arterial thrombosis 28–32. The protective effects of statins on arterial thrombosis may be 
partly explained by cholesterol-independent mechanisms 33. Nonetheless, it is tempt-
ing to speculate that the reduction in risk of thrombosis caused by statin treatment is 
at least partially due to statin-induced reduction of procoagulant lipoproteins and/or 
enhancement of anticoagulant lipoprotein-mediated reactions.
enDoTHelIal fUncTIon
The endothelium is an important regulator of vascular homeostasis. Among its func-
tions are the regulation of vasomotor tone, platelet activity, thrombosis and fibrinolysis, 
and leukocyte adhesion. Atherosclerosis and hypercholesterolemia are associated with 
endothelial dysfunction 34. Furthermore, there is growing recognition that endothelial 
dysfunction, next to its effects on the development of atherosclerosis, also affects the 
development of atherothrombotic complications. In humans, there are several studies 
that show a predictive effect of endothelial dysfunction on cardiovascular events 35–41. 
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Furthermore, cardiovascular disease risk reduction therapies improve endothelial 
function, whereas the cardiovascular disease risk is increased in subjects in which the 
endothelium fails to respond to the treatment 42.
enos and nitric oxide production
A signaling molecule implicated in the regulation of endothelial function is Nitric Ox-
ide (NO). NO is generated by endothelial nitric oxide synthase (eNOS) in response to 
physical stimulators such as sheer stress, and is a potent platelet inhibitor, as well as 
a regulator of vasodilation 43. In endothelial cells, eNOS activity is strongly correlated 
with its localization in the caveolae 44. Caveolae are flask-shaped invaginations of the 
plasma membrane, enriched in cholesterol, glycosphingolipids, sphingomyelin, and 
lipid-anchored membrane proteins, which is essential for normal caveolae function, and 
eNOS activation and regulation 45.
In vitro studies with endothelial cells showed that exposure to oxLDL, but not native 
LDL or HDL, causes a fall in the sterol content in the caveolae. Experiments with radiola-
beled sterols, showed that these sterols are transferred to oxLDL particles 46. The changes 
in lipid environment in the caveolae caused by oxLDL induces eNOS expression and 
stimulates the movement of eNOS from the caveolae to other cellular compartments 46. 
As a consequence, oxLDL strongly attenuates the activation of eNOS upon stimulation 
with acetylcholine, an important vasodilator 46. This reduced activation was solely due to 
the change in subcellular eNOS localization, rather than eNOS phosphorylation, which is 
known to regulate eNOS activity. The effects of oxLDL on eNOS localization and activa-
tion are mediated by CD36, as was shown by antibody blockade of this receptor 47. In 
line with these in vitro studies, apoE deficient mice, which have high levels of VLDL and 
LDL and develop spontaneous atherosclerosis, display no blood pressure change when 
stimulated with acetylcholine. Furthermore, eNOS is not present in caveolae of these 
mice 47.
The effects of oxLDL are counteracted by HDL 47. The addition of HDL to medium 
containing oxLDL prevented the changes in caveolae lipid environment, and the oxLDL-
mediated changes in subcellular localization of eNOS. This effect of HDL is not caused by 
inhibition of oxLDL-induced cholesterol export from caveolae, but rather by supplying 
cholesterol esters that were depleted. Furthermore, HDL restored the acetylcholine-
induced stimulation of the enzyme. The ability of HDL to reverse the oxLDL-induced 
alteration in eNOS localization is mediated by the HDL receptor Scavenger receptor 
BI (SR-BI), which is highly present in caveolae and colocalized with eNOS 48. Antibody 
blocking of SR-BI prevents the HDL-mediated restoration of eNOS localization and 
activation 47.
Besides its effect on eNOS localization, HDL can also directly stimulate eNOS activity 
in endothelial cells. HDL added to cultured endothelial cells stimulates eNOS activity in 
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a concentration dependent manner 48. LDL and lipoprotein deficient control serum did 
not have this effect. Stimulation with normal serum yields a similar response as HDL. 
However, when endothelial cells were simultaneously stimulated with HDL and excess 
LDL, the activation of eNOS was attenuated. Importantly, eNOS was not activated by 
purified forms of apoA-I or apoA-II 48. Furthermore, anti-apoA-I antibodies block eNOS 
activation by HDL, but lipid-free apoA-I fails to stimulate eNOS activation. These findings 
suggest that apoA-I is necessary but not sufficient for eNOS stimulation 48.
In a recent study by Chiesa and colleagues published in this issue of Vascular Phar-
macology, evidence is provided that LCAT deficient mice, which display a pronounced 
reduction in HDL levels 49, show a lower acetylcholine-induced NO dependent relaxation 
in absence of changes in eNOS expression. Moreover, the aortas of LCAT deficient mice 
showed a reduced contractility when stimulated with noradrenalin. The results, how-
ever, are attributed to an increase in b2-adrenergic receptor mediated relaxation and 
not due to the reduced HDL levels in these animals. In line, the authors show that in 
apoA-I knockout mice the responses are unaltered.
Like its effects on eNOS localization, the capability of HDL to activate eNOS is medi-
ated by SR-BI. HDL enhances eNOS activation and NO-dependent aortic relaxation of 
aortic rings of wild-type but not SR-BI deficient mice 48. Furthermore, infusion of apoA-I 
protected wild-type, but not SR-BI or eNOS deficient mice, from deep vein thrombosis in 
a platelet independent fashion 50.
All together, these studies suggest an important role for lipoproteins in the modula-
tion of eNOS localization and bioavailability. Furthermore, studies with apoE, apoA-I, 
and LCAT deficient mice show that these effects also have functional consequences.
Prostacyclin
In addition to the production of NO, endothelial cells also produce prostacyclin (PGI2), 
which can modify thrombosis by inhibiting platelet aggregation 51. PGI2 is synthesized 
from arachidonic acid in a pathway that involves the enzyme cyclooxygenase (COX), 
which exists in two isoforms: COX-1, which is constitutively expressed, and COX-2, which 
is inducible 52.
HDL stimulates endothelial PGI2 synthesis by the provision of arachidonic acid, as 
well as by inducing COX-2 expression 53–57. Furthermore, HDL was shown to enhance 
the release of prostaglandins, the precursors for PGI2, in isolated hearts from rabbits and 
rats 58,59. Although to a lesser extent than intact HDL, delipidated HDL also enhances PGI2 
synthesis 54 suggesting that both HDL-associated lipids as well as apolipoproteins on the 




Von Willebrand Factor (vWF) is produced by endothelial cells and stored in Weibel-
Palade bodies 60. Upon vascular injury in high sheer stress vessels, such as is the case 
in atherothrombosis, vWF mediates platelet adherence to the endothelium at sites of 
damage. Importantly, patients with hypercholesterolemia have higher plasma levels 
of vWF 61. Levels of circulating vWF are inversely associated with HDL in patients with 
peripheral vascular disease62. Furthermore, LDL and oxLDL induce the release of von 
Willebrand factor from human endothelial cells in vitro 62.
coagulation modulation
Besides the modulation of platelet reactivity, the vascular endothelium also influences 
the coagulation cascade. For example, TF pathway inhibitor (TFPI) is secreted by en-
dothelial cells to inhibit the extrinsic pathway of coagulation. Epidemiological studies 
in humans have shown correlations between hyperlipidemia and circulating TFPI. The 
correlations were highly dependent on the type of hyperlipidemia 63. TFPI was increased 
in patients with familial hypercholesterolemia (FH), whereas it was slightly decreased 
in patients with familial hypertriglyceridemia. TFPI activity was positively correlated 
with lipid and protein components of LDL (LDL-C and apoB) and of HDL (HDL-C and 
apoA-I). TFPI was negatively correlated with the triglyceride level 63. However, in a study 
performed in Japanese coronary artery patients, HDL was negatively correlated with 
TFPI levels 64.
In addition to TFPI, coagulation is also modulated via heparin sulfate proteoglycans 
(HSPG), which are proteoglycans with covalently bound heparin sulfate, and are 
expressed on the endothelial cell surface. HSPGs can bind a wide variety of ligands 
including apoE and lipoprotein lipase, two key molecules in lipoprotein metabolism, as 
well as antithrombin III, an inhibitor of several factors of the coagulation cascade 65–67. 
Endothelial HSPGs are decreased by oxLDL, an effect abolished by the presence of 
HDL 68. Moreover, apoE-containing HDL increases endothelial production of HSPGs rich 
in biologically active heparin-binding domains 65. Pre-incubation of endothelial cells 
with HDL therefore led to significantly higher binding of antihrombin III as compared 
to controls.
apoptosis
An intact endothelial layer is critical for hemostasis in the vascular wall. Induction of 
endothelial apoptosis in vivo drives endothelial denudation. This can lead to superficial 
erosion of atherosclerotic plaques, and subsequent thrombus formation 69–72. In addi-
tion, disturbances in vascular function and acute coronary events may be induced by 
thrombogenic membrance microparticles released from apoptotic endothelial cells 73,74.
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OxLDL promotes apoptosis of human coronary endothelial cells by causing a sustained 
increase in intracellular Ca2+, resulting in the death of endothelial cells 75. This effect 
is reversed by HDL, which prevents the increase in intracellular Ca2+. Purified apoA-I 
mimics this effect 76. HDL also inhibits endothelial cell apoptosis induced by TNF-alpha 
and growth factor deprivation 76,77. ApoA-I partially mimics the effect of HDL, whereas 
apoA-II has no effect on apoptosis. HDL preserves mitochondrial integrity and inhibits 
the release of cytochrome C into the cytoplasm. These effects are mediated by the pro-
tein kinase Akt, an ubiquitous tranducer of antiapoptotic signals 77. Two HDL-associated 
lysosphingolipids, sphingophosphorylcholine and lysosulfatide, also stimulate Akt and 
inhibit apoptosis. Therefore, it is believed that the protective function of HDL is caused 
by the combined activation by lysospingolipids and apoA-I 77.
PlaTeleTs
Platelets are small anucleate cells that play a key role in homeostasis and respond rapidly 
to changes in the endothelial integrity and exposure of subendothelial structures. Plate-
let activation results in cytoskeletal rearrangement and the secretion of storage granule 
content, and as such, platelets are a key player in atherothrombosis 78. An analysis of the 
relative contribution of platelets and other implicated factors (including plaque rupture, 
inflammation, coagulation factors, and cholesterol) in the etiology of acute coronary 
syndromes led to the conclusion that platelet changes are more important than plaque 
rupture in the etiology of acute myocardial infarction 79. Hence, drugs that modify plate-
let behavior have become the cornerstone of therapy for acute coronary syndromes. 
Platelet COX-1 inhibitors (aspirin), platelet ADP receptor antagonists (e.g. clopidogrel) 
and glycoprotein IIb/IIIa antagonists (e.g. tirofiban) are used as part of standard care 
and have proven morbidity and mortality rate benefits 80. Importantly, lipoproteins have 
been shown to affect platelet function at various levels.
Platelet density and volume
Platelets are produced from megakaryocytes in the bone marrow, a process called 
thrombopoiesis. Dyslipidemia leads to altered characteristics of megakaryocytes, which 
can influence platelet count and function, and in this way modulate the risk of athero-
thrombosis via the megakaryocyte-platelet hemostatic axis 81.
Hypercholesterolemic humans, as well as rabbits and guinea pigs, are found to have 
larger megakaryocytes with a higher mean ploidy 82–84. Megakaryocytes with these char-
acteristics are generally considered to produce larger and more active platelets 81. A sub-
stantial body of clinical evidence demonstrates increased platelet density and volume 
in the setting of acute coronary syndromes, and implies mean platelet volume as both 
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a causal and prognostic factor. Multiple studies have shown that patients with acute 
myocardial infarction or unstable angina display an increased mean platelet volume 
and/or platelet density compared to patients with stable coronary disease 85–88. Given 
that the lifespan of a platelet is 10 days, and that 90% of platelets measured shortly after 
acute myocardial infarction would have been circulating before the occlusive event, a 
causal relationship between acute coronary syndromes and platelet density and mean 
platelet volume has been suggested. Platelet density and volume after acute myocardial 
infarction predicted outcome in a study involving 1716 patients, in whom mean platelet 
volume was measured after acute myocardial infarction 89. Mean platelet volume was 
found to be an independent predictor of both recurrent acute myocardial infarction and 
death for up to two years after the first event. Notably, mean platelet volume was inde-
pendently and more powerfully predictive than other variables, such as blood pressure, 
cholesterol, or smoking.
Membrane-cholesterol mediated platelet reactivity
LDL and VLDL increase platelet cholesterol content, and stimulate platelet activation 
in vitro 90,91. Previous studies in animal models have shown that increased platelet 
cholesterol is due to the uptake of circulating lipoproteins by megakaryocytes, which 
subsequently passed on the cholesterol into future platelets 82,83. Both increased plasma 
cholesterol and an increase in platelet membrane cholesterol enhances the sensitivity 
of human platelets to aggregating agents 90–93. Similar results are found in patients with 
FH, whose cells lack or have defective LDL receptors, resulting in elevated plasma LDL 
levels. Platelets of FH patients have increased α-granule secretion 94, increased super-
oxide anion production 95, increased fibrinogen binding 96, and subsequent enhanced 
platelet aggregation after stimulation 94,97,98. In addition, platelets of FH patients and 
hyperlipidemic apoE deficient mice circulate in an activated state 99–101. In contrast to 
the elevated plasma LDL levels in FH patients, plasma from abetalipoproteinemia pa-
tients lack all apoB-containing lipoproteins. In accordance, platelets from these patients 
aggregate poorly and show impaired arachidonic acid release and thromboxane A2 
(TxA2) generation 102. Purified apoE-containing phospholipid vesicles inhibit platelet 
aggregation in response to ADP, epinephrine, thrombin and collagen 103,104. This is prob-
ably the consequence of its cholesterol depleting effects on the cell membrane. In line, 
cholesterol-depleted platelets poorly respond to agonists 90.
Receptor mediated platelet activity
In addition to the effects on membrane cholesterol incorporation, LDL and HDL also 
affect platelet function via a direct interaction. By binding to platelet receptors, lipopro-




Native LDL-induced signaling in platelets is mediated by a splice variant of the 
apoE receptor-2 (apoER2), apoER2’. LDL binds to this receptor via the so-called B-site 
of apoB100 106, and binding of LDL to platelets via apoER2’ results in the formation of 
platelet-activating TxA2 107. Consequently, binding of LDL to platelets leads to enhanced 
platelet aggregation 106. In contrast to LDL, oxLDL enhances the platelet response to 
agonists via an interaction with the scavenger receptors CD36 and scavenger receptor 
A (SR-A) 108–110.
Most studies to date support a direct inhibitory effect of HDL or its major fraction, 
HDL3, on platelet activation and the subsequent formation of venous and arterial 
thrombi 111–114. However, the receptor through which different HDL particles exert their 
function has long been disputable. In early studies, integrin αIIbβ3 has been studied as a 
receptor for HDL3 signaling. However, its role remains controversial until this time 105. In 
2011, SR-BI was identified as the primary binding site for HDL3 115. Binding of HDL3 to SR-
BI on platelets inhibits agonist-induced activation and aggregation. These effects were 
mediated by protein kinase C. SR-BI deficient platelets were not affected by HDL3 115.
The binding affinity of a receptor for HDL is defined by the apolipoprotein moiety 
on the HDL particle. Since HDL3 only contains trace amounts of apoE and apoC, recep-
tor binding by HDL3 is presumably mediated by apoA-I 116. ApoA-I has been found to 
inhibit platelet function 90,103. Furthermore, SR-BI is known to bind apoA-I in other cell 
types, so it is likely that a similar mechanism occurs in platelets. Inhibition of platelet 
activation is observed by HDL2 and apoE-rich HDL 117–122. These particles inhibit platelet 
function such as shape change, inositol phospholipid production, and reduce LDL-
induced NO synthase expression 122,123. Chemical modification of apoE residues in HDL 
abolishes binding to the platelets and prevents its anti-aggregatory effects 118. Binding 
of HDL3 to platelets is inhibited by HDL2, suggesting that HDL3 and HDL2 bind to the 
same receptor 124. However, as the apoER2’ receptor mediates apoE signaling in platelets, 
apoE-rich HDL2 particles possibly also bind to platelets via this receptor 125. Binding of 
apoE-containing lipoproteins to apoER2’ impairs platelet signaling by increasing cGMP 
through NO production 125. As mentioned earlier, LDL binds to apoER2’ via apoB100, 
which enhances platelet activation. ApoER2’ is thus capable of facilitating either activat-
ing or inhibitory signals initiated through the binding of apoB100- or apoE-containing 
lipoproteins, respectively. These differential effects may be explained by the fact that 
multiple apoE molecules on apoE-bearing lipoproteins can induce clustering of apoER2’ 
receptors, while this is not possible for the binding of apoB100, from which there is only 
a single molecule found on an LDL particle 125. A complex of clustered receptors may 
initiate different signaling pathways compared to a single receptor. Further studies are 





Secondary coagulation is the clotting of blood through activation of the coagulation 
cascade. The conversion of the soluble plasma protein fibrinogen into insoluble fibrin 
fibers, mediated by thrombin, is the central step of the coagulation cascade, and, after 
platelet adhesion, the second step in atherothrombosis. It starts with the exposure of 
blood to TF (extrinsic pathway) or negatively charged surfaces (intrinsic pathway), which 
causes a waterfall effect. The waterfall eventually culminates in a common pathway in 
which the prothrombinase complex (FXa and FVa) converts prothrombin into throm-
bin  126,127. Within the coagulation cascade, both negative and positive feedback reac-
tions are important for maintaining homeostasis and, when necessary, a fast, massive 
coagulation response, respectively.
Hypercholesterolemia is associated with hypercoagulability and an increase in venous 
thrombosis risk 128,129. In venous thrombosis, especially the pathological activation of the 
coagulation cascade plays a key role, suggesting a direct effect of hypercholesterolemia 
on secondary coagulation.
Prothrombin activation and thrombin formation
Almost all clotting factors bind lipids, although with varying affinities. Hypertriglyceride-
mia is associated with increased levels of all vitamin K-dependent procoagulant factors. 
Furthermore, binding of clotting factors to lipids alters their activity. Triglyceride-rich 
lipoproteins bind vitamin K-dependent clotting factors and promote the procoagulant 
reaction 130–136. For example, studies using purified lipoproteins and clotting factors 
showed that VLDL enhances prothrombin activation by FXa in the presence of Va. LDL 
and HDL are substantially less capable of inducing prothrombin activation 133,134. On the 
contrary, HDL is inversely correlated with plasma thrombin activation markers such as 
prothrombin fractions F1+2, the peptides cleaved from prothrombin during its conver-
sion to thrombin 137.
Tissue factor and factor VII activation
TF is the primary initiator of the extrinsic coagulation pathway. It is a surface-bound pro-
tein found on many cells in the subendothelial tissue. Furthermore, it is highly present 
in atherosclerotic plaques 138,139. TF expression by endothelial cells and macrophages is 
stimulated by minimally oxidized and acetyl-modified LDL respectively 30,140. In contrast, 
HDL and apoA-I suppress TF activity 141.
Factor VII is the first enzyme encountered in the extrinsic pathway, and is directly 
activated by TF. Lipoproteins enhance the activation of factor VII. Each lipoprotein spe-
cies supports factor VII activation by factor Xa, but not by factor IXa, in the absence of 
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TF. ApoA-II has been shown to inhibit the activation of factor X by the TF-factor VIIa 
complex, inhibiting the first step in of the extrinsic coagulation pathway 142.
fibrinogen
The step from fibrinogen to fibrin is the last step in the coagulation cascade, an is a cru-
cial step for stabilizing the blood clot. Fibrinogen levels are elevated in FH subjects 143,144. 
In multiple population studies it was found that fibrinogen is positively associated with 
LDL cholesterol, Lp(a), and triglycerides. Furthermore, it was inversely associated with 
HDL cholesterol 145–148.
activated Protein c pathway
The protein C pathway provides a major physiological anticoagulant mechanism to 
downregulate thrombin formation by proteolytically inactivating factors Va and VIIIa in 
plasma. HDL enhances anticoagulation via activated protein C (APC). There is a positive 
correlation between plasma apoA-I levels and in vitro inactivation of factor Va by APC 
and protein S 149. However, it has been described that this APC-enhancing activity of HDL 
is only present in the HDL2, but not HDL3 fraction 150.
In 2010, there was a report by Oslakovic et al. that stated that the anticoagulant 
properties attributed to HDL were actually caused by contaminating negatively charged 
phospholipid membranes, and not by HDL itself 151. However, later research by Fer-
nandez et al. showed that HDL loses its anticoagulant properties after a freeze-thaw 
cycle 152. Furthermore, it has also been shown that anti-apoA-I antibodies remove most 
of the HDL ability to enhance APC:protein S activity 152. Antibodies against apoC-III also 
block the ability of HDL to enhance protein C anticoagulant activity, suggesting that 
apolipoproteins on HDL fractions are responsible for this anticoagulant trait of HDL 150.
lIPID MoDUlaTIon as a PoTenTIal TReaTMenT foR acUTe 
caRDIoVascUlaR DIsease anD aTHeRoTHRoMbosIs
Currently, the standard of care for patients at risk for acute coronary artery disease are 
statins, which are 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Numer-
ous long-term, placebo-controlled clinical trials have conclusively demonstrated that 
statins reduce the risk of morbidity and mortality from cardiovascular disease. Further-
more, as mentioned previously, statin therapy also decreases the risk of both venous 
thrombosis and arterial thrombosis 29–32,153,154. Although there are several types of statins 
available today, the typical reduction in relative risk of cardiovascular disease ranges 





Pro-protein convertase subtilisin/kexin type 9 (PCSK9) is a secreted protein that binds 
to the surface LDL receptor (LDLR) and targets it towards lysosomal degradation. As a 
consequence, the number of LDLRs at the cell surface is decreased, and LDL clearance 
is reduced. Inhibition or loss-of-function mutations of PCSK9 result in increased surface 
LDLR and improved LDL clearance 156. Two recent reports describe the results of studies 
with monoclonal antibodies against PCSK9 and their potential effects on CVD events. 
The administration of both alirocumab and evolucumab were associated with a reduced 
rate of major CVD events 157,158. Numerous compounds that inhibit PCSK9 are currently 
under development and tested in clinical trials 159. One small study reported that plasma 
PCSK9 levels are positively associated with platelet counts in stable coronary artery 
disease patients 160. Platelet counts are, in turn, positively associated with cardiovascular 
death 161. However, the implications of these findings remain to be elucidated. Unfortu-
nately, to date, no effects of PCSK9 or PCSK9 inhibition, on endothelial function, blood 
coagulation or thrombosis have been reported. Possibly, the ongoing trials will elucidate 
potential role of this nature.
ceTP inhibitors
Cholesteryl ester transfer protein (CETP) is a plasma protein that facilitates the trans-
port of cholesteryl esters and triglycerides between VLDL, LDL and HDL. When CETP 
is inhibited, cholesterol accumulates in the HDL lipoprotein fraction, as opposed to 
LDL and VLDL lipoproteins, thus improving the overall plasma lipoprotein profile. Tri-
als in humans have shown that CETP inhibitors effectively raise HDL cholesterol levels. 
Unfortunately however, in 2007, the  CETP  inhibitor torcetrapib unexpectedly showed 
increased fatality and cardiovascular events. This was most likely due to increased blood 
pressure and aldosterone levels as trials with novel CETP inhibitors later showed that 
the negative effects of torcetrapib were the consequence of off target effects of the 
compound, and not of CETP inhibition in general 162. The novel CETP inhibitors dalce-
trapib, evacetrapib and anacetrapib did not show harmful effects on blood pressure or 
aldosterone levels 162. Dalcetrapib increased HDL cholesterol levels but did not reduce 
the risk of recurrent cardiovascular events in patients who had had a recent acute coro-
nary syndrome 163. However, this may have been due to polymorphisms in the adenylyl 
cyclase 9 gene (ADCY9) 164. ADCY9 is a membrane-bound protein affected by changes in 
caveolae. The finding that ADCY9 is important in the therapeutic outcome of increasing 
HDL cholesterol has renewed interest in a potential role of HDL in modulating signal 
transduction by changing cholesterol concentration in cellular membrane substruc-
tures 165. Unfortunately, to date, there is no data available of a potential role of CETP, or 




A promising strategy for lipid modulation in thrombosis is the use of synthetic reconsti-
tuted HDL (rHDL) 166. rHDL are HDL-like particles containing phospholipids and human 
apoA-I or one of its variants such as apoA-IMilano, which are functionally more effective. 
In a study by Lerch et al, rHDL was shown to dose-dependently inhibit in vitro platelet 
reactivity after stimulation 167. Moreover, experiments with platelet-rich plasma from 
volunteers who had been infused with rHDL were performed. In these experiments, 
both arachidonic acid- and collagen-induced platelet aggregation were reduced. The 
extent of inhibition negatively correlated with plasma concentrations of apoA-I, HDL-C 
and the dose of rHDL infused. These data correlated with studies in rats, in which admin-
istration of recombinant apoA-IMilano inhibited platelet aggregation and FeCl3-induced 
arterial thrombus formation 168.
In patients with Type 2 Diabetes Mellitus, who exhibit enhanced platelet reactivity 
and an increased risk of cardiovascular disease, rHDL infusion significantly reduced ex 
vivo platelet aggregation and thrombus formation under flow 169. However, in this study, 
the effects were mainly ascribed to the isolated phospholipid component of rHDL, and 
not to apoA-I. rHDL also reduces coagulation responses in LPS-induced endotoxemia, in 
which it lowers plasma levels of prothrombin and tPA 170.
At least four different formulations of rHDL have been tested in clinical trials 166. Al-
though the underlying mechanisms remain to be elucidated, rHDL infusions are a prom-
ising therapeutic strategy to reduce thrombosis risk in a variety of conditions where 
platelet hyperreactivity and hypercoagulability pose a threat. As such rHDL therapy may 
thus possibly also be of benefit for patients at risk for atherothrombotic complications.
lXR targeting
Liver X receptors (LXRs) are nuclear transcription factors that regulate the expression 
of genes involved in cholesterol catabolism to bile acids and cholesterol efflux. Their 
natural ligands are oxysterols, which are cholesterol derivatives 171. Ligand-stimulated 
LXR activation yields anti-inflammatory and athero-protective effects 172–174. The LXR 
family consist of two members: LXRα and LXRβ, each with distinct expression patterns. 
LXRβ is ubiquitously expressed, while LXRα expression is restricted to tissues active in 
lipid metabolism 171. Recently, it was shown that LXRβ is present in human platelets 175. 
LXR ligands inhibit platelet function stimulated through a range of physiologic agonists. 
Furthermore, ligand stimulation inhibits the ability of platelets to form thrombi in vivo, 
affecting both the size and the stability of growing thrombi 175. Importantly, LXR stimula-
tion allowed initial thrombi to form, crucial for tissue repair after vascular injury, but 
prevented occlusion of the vessel through decreased thrombus stability. These prop-
erties render LXR agonism a promising method for inhibiting pathological thrombus 
formation without disturbing physiological homeostasis and wound healing.
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Because of their key roles in cholesterol metabolism, LXRs have since long been a 
target for drug discovery. However, thus fat therapeutic application of LXR agonists has 
been hampered due to the fact that LXR also modulates fatty acid and carbohydrate 
metabolism in tissues such as liver, adipose and skeletal muscle 176. Mice treated with 
a synthetic LXR agonist demonstrate marked hypertriglyceridemia, a condition mainly 
attributed to LXRα expression in hepatocytes 177. In order to eliminate this side effect, 
the use of LXRβ-specific agonists might be beneficial, as the function of both family 
members does not seem to overlap 178. Compounds that selectively target LXRβ are 
currently under development 179. However, no data on the effect of LXRβ agonism on 
platelet function or thrombosis have been reported so far.
conclUsIons anD PeRsPecTIVes
There is great interest in the development of novel pharmacological intervention strate-
gies to reduce atherothrombotic complications of atherosclerosis. From experimental 
studies, it is clear that lipoproteins influence the thrombotic capacity of the blood and in 
that way may alter atherothrombosis. Overall, VLDL, LDL and oxLDL promote thrombus 
formation, whereas HDL shows antithrombotic actions.
Therapies aimed at lowering (V)LDL cholesterol levels are already standard practice 
in patients with high risk for atherothrombotic complications, and will most likely not 
only influence plaque integrity but also thrombosis. In addition to lowering (V)LDL, 
raising HDL levels may be an attractive therapeutic strategy to improve the outcome 
of atherothrombotic complications. However, although low HDL levels are predictive of 
coronary artery disease, increasing HDL has yet to prove its therapeutic value.
In the quest for HDL-raising drugs, it is important to keep in mind that not only the 
circulating levels of HDL cholesterol matter. The particle composition, HDL subclass, 
surface apolipoproteins and phospholipids, are of the utmost importance for its anti-
thrombotic function. Hence, detailed structure-function analysis are needed to identify 
clinically relevant, antithrombotic HDL subpopulations in order to develop effective 
therapeutic approaches to reduce atherothrombotic risk.
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Hypercholesterolemia impairs 
megakaryopoiesis and platelet 






Thrombocytopenia in scavenger receptor BI (SR-BI) knockout mice is suggested to 
result from augmented platelet clearance induced by elevated intracellular unesterified 
cholesterol (UC) levels. We hypothesize that SR-BI deficiency may also influence platelet 
production at the level of its precursor cell in the bone marrow, the megakaryocyte. In 
this study, we compared megakaryopoiesis and platelet production in SR-BI knockout 
and wild-type mice. In line with our hypothesis, megakaryocytes from SR-BI knockout 
mice exhibited UC accumulation while no accumulation of UC was detectable in wild-
type megakaryocytes. Bone marrow expression of transcription factors involved in 
megakaryocyte maturation was induced, but megakaryocyte counts were unchanged in 
bone marrow of SR-BI knockout mice. Interestingly, we did find a striking 62% decrease 
(p<0.01) in proplatelet production by SR-BI knockout megakaryocytes. SR-BI knockout 
mice displayed an impaired increase in circulating platelet concentrations and bone 
marrow megakaryocyte numbers upon thrombopoietin challenge. Importantly, mega-
karyocytes from normolipidemic bone marrow-specific SR-BI knockout mice exhibited 
a normal ability to produce proplatelets. Moreover, bone marrow-specific deletion of 
SR-BI did not impair the thrombopoietin response or induce thrombocytopenia, con-
firming that absence of megakaryocyte SR-BI does not underlie the thrombocytopenic 
phenotype in total body SR-BI knockout mice. In conclusion, the elevation of plasma 
unesterified cholesterol levels impairs megakaryopoiesis and platelet production in SR-
BI knockout mice. Our findings suggest that, in addition to an increased platelet clear-
ance, a decrease in platelet production may also, in part, explain the thrombocytopenic 
phenotype associated with SR-BI deficiency in mice.
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InTRoDUcTIon
Platelets are small anucleate cells that play a key role in hemostasis and respond rapidly 
to changes in the endothelial integrity and exposure of sub-endothelial structures. As 
such, platelets play a key role in the formation of atherothrombosis 1. A substantial 
body of clinical evidence associates platelet characteristics such as density and volume 
with the risk of acute coronary syndromes 2–5, and implies mean platelet volume, a 
determinant of platelet reactivity, as both a causal and prognostic factor 6. Therefore, 
modification of platelet functionality is a promising therapeutic target in the prevention 
and treatment of cardiovascular disease.
Platelets are produced by megakaryocytes, which represent the largest cells of the 
hematopoietic lineage and account for approximately 0.01% of nucleated cells in the 
bone marrow 7. Thrombopoietin (TPO) is the primary regulator of platelet production, 
supporting the formation, proliferation and differentiation of megakaryocytes 8. Upon 
stimulation by TPO, megakaryocytes develop from pluripotent hematopoietic stem 
cells and subsequently mature, i.e. they become polyploid and grow in size. During 
maturation, megakaryocytes also develop an internal demarcation membrane system 
(DMS), granules, and organelles that are packaged in bulk for platelet production 9. DMS 
formation enables the megakaryocytes to produce long, branching extensions called 
proplatelets. Proplatelets extend into the vascular sinusoids of the bone marrow, from 
which eventually platelets are released into the bloodstream 10. Once released, human 
platelets stay in the blood circulation for 7-10 days 11,, while rodent platelets circulate 
for only 4-5 days 12. Aged platelets, recognized by the Ashwell-Morrell receptor through 
the loss of sialic acid on their surface-expressed proteins are cleared by hepatocytes 13. 
Binding of desialylated platelets to the Ashwell-Morrell receptor stimulates hepatic TPO 
production, thereby maintaining overall platelet homeostasis 14.
Previous studies have shown that genetic disruption of scavenger receptor BI (SR-BI) 
function is associated with thrombocytopenia in mice 15–17. SR-BI is a cell surface receptor 
that mediates the selective uptake of cholesteryl esters from lipoproteins and is mostly 
known for its role in reverse cholesterol transport as the functional high-density lipo-
protein (HDL) receptor 18. In mice, disruption of SR-BI functionality results in a 3.2-fold 
increase in circulating unesterified cholesterol (UC) levels due to substrate inhibition 
of the plasma enzyme Lecithin:Cholesterol Acyltransferase (LCAT), resulting in a high 
plasma unesterified-to-total cholesterol ratio (UC:TC) 18–20. As a result, in the SR-BI knock-
out mice, platelets accumulate UC and circulate in an activated state 15–17. Importantly, 
platelet UC accumulation was also observed in humans carrying a functional mutation 
in SCARB1, the gene encoding SR-BI 21. However, heterozygous SR-BI deficiency in hu-
mans does not lead to thrombocytopenia 21. Dole and colleagues have suggested that 
chapter 3
64
the platelet UC accumulation in mice is the cause of the thrombocytopenia associated 
with SR-BI deficiency, as the platelet clearance in SR-BI knockout mice is enhanced 15.
Interestingly, SR-BI is expressed on megakaryocytes 22. Recent studies have suggested 
that HDL can directly impact on megakaryopoiesis and platelet production. More spe-
cifically, Murphy and colleagues have demonstrated that infusion of reconstituted HDL 
in mice decreases platelet counts by inhibiting bone marrow megakaryocyte progenitor 
proliferation 23. The relevance of the interaction of HDL with SR-BI on megakaryocytes 
in this context is currently unknown. In the study by Dole et al., SR-BI deficiency did not 
affect bone marrow megakaryocyte counts 15. However, Dole et al. focused on platelet 
clearance and did not execute an in-depth investigation into the impact of SR-BI defi-
ciency on megakaryocyte function, leaving the question regarding a potential impact 
of SR-BI on megakaryopoiesis and platelet production unanswered. In this study, we 
therefore examined the effect of SR-BI deficiency on megakaryopoiesis and platelet 
production to uncover a possible contribution to the thrombocytopenic phenotype.
MaTeRIals anD MeTHoDs
Mice
Wild-type and Scarb1-/- (SR-BI knockout) mice on a C57Bl6/J background were bred in 
house at the Gorlaeus Laboratories (Leiden, the Netherlands). All mice were fed a regular 
chow diet (Special Diet Services, Witham, UK) and were group housed in filter top cages. 
All animal experiments were performed in accordance with the national guidelines for 
animal experimentation. All experimental protocols were approved by the Ethics Com-
mittee for Animal Experiments of Leiden University.
For all measurements comparing non-treated wild-type and SR-BI knockout mice, 
9-14 weeks old female mice were used. For the TPO challenge, male wild-type and SR-BI 
knockout mice of 42-47 weeks old were used. For bone marrow transplantation experi-
ments, 16 weeks old female wild-type and SR-BI knockout donor mice and 11-20 weeks 
old female wild-type recipients were used.
bone marrow transplantation
Donor bone marrow of wild-type and SR-BI knockout mice was isolated by flushing the 
femurs and tibias with PBS. Recipient wild-type mice were irradiated with 2x4.5 Gy total 
body radiation using a 225 Smart Röntgen source (YXLON international, Copenhagen, 
Denmark) one day before transplantation, and received a single cell suspension of 5x106 
bone marrow cells in PBS by intravenous injection into the tail vein. The drinking water 
of the recipient mice was supplemented with antibiotics (83 mg/L ciprofloxacin and 
67 mg/L polymixin B sulfate) and 6.5 g/L sucrose from 7 days prior to 4 weeks after 
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transplantation. At 13-15 weeks post transplantation, mice were anesthetized with a mix 
of xylazine (70 mg/kg), ketamine (350 mg/kg) and atropine (1.8 mg/kg) and sacrificed 
by orbital exsanguination, after which the organs, femurs and tibias were collected for 
further analysis.
TPo challenge
Blood was drawn from the tail vein prior to, and 2 and 5 days post intraperitoneal injec-
tion with 17.5 µg/kg rmTPO (Peprotech, Londen, UK) in PBS.
Platelet count
Blood obtained from the tail vein was collected in EDTA-coated tubes and diluted 1:4 
in PBS for analysis of platelet count. Blood obtained from orbital exsanguination was 
collected in EDTA-coated tubes and was analyzed non-diluted. Platelet counts were ana-
lyzed using an automated XT-2000iV veterinary hematology analyzer (Sysmex Europe 
GMBH, Norderstedt, Germany).
Plasma cholesterol analysis
Plasma from orbital bleeding-obtained blood was attained by centrifugation (10 min-
utes, 6000 RPM, room temperature) and stored at −20°C until further use. Plasma UC and 
TC levels were measured by enzymatic colorimetric assays as described by Out et al. 24.
bone marrow explants and proplatelet formation
Ex vivo megakaryocyte maturation and proplatelet production in the native bone 
marrow environment was measured using the bone marrow explant method originally 
developed by Eckly and colleagues 25. Bone marrow, isolated by flushing femurs and 
tibias with PBS, was cut in 0.5 mm thick sections. 5-6 sections were transferred into an 
incubation chamber and incubated at 37°C for 6 hours in Hepes Tyrodes buffer contain-
ing 3,5 g/L human serum albumin (MP biomedicals, Santa Ana, California, USA) and 1 
g/L glucose (pH 7.3) supplemented with 5% serum from the donor mouse. Proplatelet-
forming megakaryocytes were counted every 1.5 hours using phase contrast micros-
copy. Images of proplatelet formation were made using a Bio-Rad ZOE™ Fluorescent Cell 
Imager (Bio-Rad Laboratories, Veenendaal, Netherlands).
bone marrow megakaryocyte counts
Bone marrow was obtained by flushing the femurs and tibias with PBS, fixed for 24 h in 
3.7% neutral-buffered formalin (Formal-Fixx, Shandon Scientific Ltd, UK), and embedded 
in paraffin for sectioning. Bone marrow was sectioned using Leica RM2235 microtome 
at 5 μm thickness with a 25 μm interval. Serial sections were routinely stained with 
hematoxylin and eosin for general histology. Megakaryocyte counts were analyzed by 
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a blinded observer using a Leica DM-RE microscope and LeicaQwin software (Leica Ltd, 
Cambridge, UK). Four fields of 300x300µm were analyzed in each of four sections per 
mouse.
Gene eXPRessIon analYsIs
Total RNA was isolated from bone marrow and livers by phenol-chloroform extraction. 
Equal amounts of RNA were reverse transcribed and subsequently real-time quantitative 
PCR analysis was executed on the cDNA using an ABI Prism 7500 apparatus (Applied Bio-
systems, Foster City, CA, USA) according to the manufacturer’s instructions. Ribosomal 
Protein 37 (RPL37), Acidic Ribosomal Phosphoprotein P0 (36B4), and Peptidylprolyl 
Isomerase A (PPIA), were used as reference genes for normalization. Primer sequences 
are available upon request.
floW cYToMeTRY
A single cell suspension of bone marrow cells was obtained by straining flushed bone 
marrow from the femurs and tibias through a 70 µm nylon mesh (Greiner Bio-One, 
Kremsmünster, Austria) with PBS. Fc receptors were blocked with an unconjugated anti-
body against CD16/CD32 (Clone 93, BioLegend, San Diego, California, USA). Cell viability 
in all samples was determined using Fixable Viability Dye eFluor® 780 (ThermoFisher 
Scientific, Waltham, Massachusetts, USA). To determine megakaryocyte ploidy, 5x106 
cells per sample were stained with Brilliant Violet 421™-conjugated anti-CD41 (clone 
MWReg30, BioLegend) and fixed with ice-cold methanol. Fixed cells were subjected to 
RNAse treatment (Sigma-Aldrich, Zwijndrecht, The Netherlands) and propidium iodide 
staining (Sigma-Aldrich) for DNA content measurement. To determine megakaryocyte 
UC content, 5x106 cells per sample were stained with APC-conjugated anti-CD41 (clone 
eBioMWReg30, eBioscience, San Diego, California, USA) and filipin III (Cayman Chemi-
cal, Ann Arbor, Michigan, US), and fixed with 0.5% paraformaldehyde. Flow cytometric 
analysis was performed on a Cytoflex S flow cytometer (Beckman Coulter, Brea, Cali-
fornia, USA) and the acquired data were analyzed using FlowJo software (FlowJo LLC, 
Ashland, Oregon, USA). Gates were set according to unstained controls and fluorescence 
minus one (FMO) controls.
statistical analysis
Statistical analysis was performed using Graphpad Instat software and/or Graphpad 
Prism software (San Diego, USA, http://www.graphpad.com). Outlier detection was 
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performed using Grubbs’ test for outliers. The significance of differences was calculated 
using a two-tailed unpaired t-test, or two-way analysis of variance (ANOVA) in experi-
ments with multiple variables. Probability values (p) <0.05 were considered significant.
ResUlTs
To study the role of SR-BI in megakaryopoiesis and platelet production, we used wild-
type and SR-BI knockout mice. We confirmed a strong increase in plasma UC and TC levels 
in SR-BI knockout mice (2.9- and 2-fold, respectively; p<0.0001 for both; Supplemental 
figure 1A and B), and a 1.5-fold increase in the UC:TC ratio (p<0.0001; Supplemental 
figure 1C). Moreover, a marked decrease (-47%; p<0.0001) in blood platelet levels was 
detected (Supplemental figure 1D), confirming the thrombocytopenia phenotype found 
























figure 1: sR-bI deficiency is associated with a minor increase in megakaryocyte maturation, without 
a change in bone marrow megakaryocyte count. (A) Hepatic gene expression of Thpo in wild-type (WT) 
and SR-BI knockout (SR-BI KO) mice. (B) Relative expression of genes associated with megakaryocyte matu-
ration in bone marrow of wild-type and SR-BI knockout mice. (C) The percentage of CD41+ megakaryo-
cytes in wild-type and SR-BI knockout bone marrow. (D) Quantification of bone marrow megakaryocytes 
and representative pictures of hematoxylin/eosin-stained bone marrow sections from wild-type and SR-BI 
knockout mice showing the presence of megakaryocytes (black arrows). Bar represents 50 µm. (E) Ploidy of 
CD41+ bone marrow megakaryocytes from wild-type and SR-BI knockout mice. Data represent means+SEM 
of 11 mice per group. *p<0.05, ***p<0.001.
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increase in mean platelet volume (p<0.001; Supplemental figure 1E) and platelet volume 
distribution (p<0.05; Supplemental figure 1F).
Hepatic Thpo expression did not differ between the two genotypes (Figure 1A). In 
contrast, relative gene expression levels of several key transcription factors that aid in 
the generation of mature megakaryocytes from bone marrow stem cells as well as that 
of the TPO receptor c-MPL were mildly increased in bone marrow of SR-BI knockout mice 
as compared to that of wild-type mice (Figure 1B). This increase in gene expression did 
not translate into an increase in bone marrow megakaryocyte counts. Both the amount 
of CD41+ cells as measured by flow cytometry (Figure 1C), as well as histological quantifi-
cation showed similar levels of bone marrow megakaryocyte numbers (Figure 1D). SR-BI 
deficiency did not lead to apparent differences in in megakaryocyte ploidy (Figure 1E).
Mature megakaryocytes in the bone marrow migrate to the vascular niche to produce 
proplatelets and eventually release platelets into the bloodstream. To determine if the 
minor increase in ploidy in megakaryocytes from SR-BI knockout mice coincided with 
differences in the final step of platelet production, we measured proplatelet production 
by primary megakaryocytes from wild-type and SR-BI knockout mice. Interestingly, there 
was a striking decrease in proplatelet production by SR-BI knockout megakaryocytes 
(two-way ANOVA: p<0.01 for genotype), which translated in a 62% decrease (p<0.05) in 
the amount of proplatelets at the final 6-hour time point (Figure 2A). Plasma crossover 
experiments indicated that the overall SR-BI knockout genotype effect could not be fully 
replicated by incubation of wild-type bone marrow explants with hypercholesterolemic 
SR-BI knockout serum. Importantly, we did note a clear trend towards a decrease in the 
amount of proplatelet forming megakaryocytes as compared to wild-type explants ex-
posed to wild-type serum (6 hours: 12.4±4.6% vs. 16.3±2.5; Two-way ANOVA: p=0.16 for 
serum type). However, given the limited exposure time of 6 hours, it cannot be excluded 
that hypercholesterolemia is the driving force in the effects of SR-BI deficiency on pro-
platelet formation. No evident changes in megakaryocyte or proplatelet morphology 
were observed (Figure 2B). However, as evident from Figure 2C, megakaryocytes from 
SR-BI knockout mice exhibited UC accumulation while no accumulation of UC was de-
tectable in wild-type megakaryocytes. These combined findings suggest that an increase 
in cellular UC levels may underlie the impaired ability of SR-BI knockout megakaryocytes 
to produce proplatelets.
To confirm that the diminished megakaryocyte functioning ex vivo translated into 
functional differences in the ability to produce platelets in vivo, we administered TPO 
to wild-type and SR-BI knockout mice. Given the similar number of megakaryocytes in 
wild-type and SR-BI knockout mice, mice from both genotypes were anticipated to pro-
duce a similar increase in absolute numbers of platelets upon stimulation with TPO. As 
expected, wild-type mice challenged with TPO displayed a strong increase (+774x109/L; 
p<0.01) in blood platelet numbers at 5 days post injection (Figure 3A). In contrast, ad-
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ministration of TPO to SR-BI knockout mice led to a much smaller, non-significant rise in 
blood platelet counts (+301x109/L; Figure 3A). The difference in the response to gener-
ate platelets coincided with a significant difference in the bone marrow megakaryocyte 
numbers after the TPO challenge. Bone marrow megakaryocyte numbers were 32% 
percent lower (p<0.001) in TPO-stimulated SR-BI knockout mice as compared to TPO-
stimulated wild-type mice (Figure 3B). It thus appears that SR-BI knockout mice exhibit a 
limited ability to upregulate platelet production in response to TPO stimulation.
Previous studies have shown that SR-BI is present on megakaryocytes and platelets 
15,21,22. To determine whether the effect of total body SR-BI deficiency on megakaryocyte 
functioning was due to megakaryocyte-specific SR-BI deficiency, we applied the bone 
marrow transplantation technique to specifically delete SR-BI in all bone marrow-derived 
cells, including megakaryocytes. As previously reported 16, wild-type mice reconstituted 



















figure 2: sR-bI knockout megakaryocytes have a decreased ability to form proplatelets and an in-
creased Uc content. (A) Percentage of megakaryocytes producing proplatelets in an ex vivo native bone 
marrow environment of wild-type (WT; n=15) and SR-BI knockout (SR-BI KO; n=3) mice. (B) Representative 
pictures of proplatelet forming megakaryocytes from wild-type and SR-BI knockout mice in an ex vivo na-
tive bone marrow environment. Black arrows: body of a proplatelet-forming megakaryocyte. Bar represents 
30 µm. (C) Flow cytometry histogram of filipin fluorescent intensity of wild-type (dotted black line), SR-BI 
knockout (solid black line), and FMO control (grey shading), and quantification of filipin median fluorescent 
intensity of CD41+ cells of wild-type and SR-BI knockout mice (n=11 per group), corrected for FMO controls. 
Data represent means±SEM. *p<0.05; ****p<0.0001.
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within the normolipidemic range (data not shown). Moreover, specific deletion of SR-BI 
in bone marrow was not associated with the thrombocytopenia found in total body 
knockout mice. Platelet levels were virtually identical in the two groups of bone marrow 
recipients (Figure 4A). In accordance with the unchanged basal platelet concentrations, 
investigation of the megakaryocyte function revealed that SR-BI knockout megakaryo-
cytes had a normal ability to produce proplatelets (Figure 4B) and normal capacity to 
increase platelet levels in response to TPO stimulation in vivo (Figure 4C). Furthermore, 
megakaryocyte counts were similar between mice reconstituted with wild-type and 



































    
figure 4: bone marrow-specific sR-bI deficiency in normolipidemic c57bl/6 mice does not alter plate-
let count, megakaryopoiesis, or megakaryocyte function under basal and TPo-stimulated conditions. 
(A) Blood platelet counts in mice that received wild-type (WT; n=19) or SR-BI knockout (SR-BI KO; n=18) 
bone marrow. (B) Ex vivo proplatelet formation of megakaryocytes in a native bone marrow environment 
from mice transplanted with wild-type and SR-BI knockout bone marrow (n=3 per group). (C) Blood platelet 
counts of wild-type (n=7) and SR-BI knockout bone marrow transplanted mice (n=6) before and after treat-
ment with TPO. (D) Quantification of bone marrow megakaryocytes in wild-type and SR-BI knockout bone 
marrow transplanted mice that have (wild-type: n=2; SR-BI knockout : n=5) or have not (n=3 per group) re-
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
figure 3: sR-bI knockout mice display a de-
creased responsiveness to TPo. (A) Blood platelet 
levels of wild-type (WT) and SR-BI knockout (SR-BI 
KO) mice before and after treatment with TPO (n=7 
per group; 2-way ANOVA: p<0.0001 for genotype). 
(B) Histological quantification of bone marrow 
megakaryocytes after TPO administration (wild-
type: n=3; SR-BI knockout : n=4). Data represent 
means±SEM. ns = p>0.05, **p<0.01, ***p<0.001.
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DIscUssIon
In the current study we investigated if SR-BI deficiency impacts on megakaryopoiesis and 
platelet production and in that way contributes to the thrombocytopenia found in SR-BI 
knockout mice. We show that SR-BI knockout mice exhibit an increased megakaryocyte 
UC content and minor changes in megakaryopoiesis. The ability of megakaryocytes to 
form proplatelets, however, was markedly decreased in SR-BI knockout mice. Impor-
tantly, these effects are not a direct effect of the absence of megakaryocyte SR-BI but 
is rather due to an indirect effect of the SR-BI deficiency associated UC accumulation.
Previously, Murphy et al. have shown that reconstituted HDL decreases platelet levels 
due to a decrease in bone marrow megakaryocyte progenitor proliferation 23. Based on 
these studies, we hypothesized that possibly a direct interaction of HDL and its receptor 
SR-BI would affect megakaryopoiesis and platelet production. Interestingly, although 
megakaryopoiesis and proplatelet production were altered in hypercholesterolemic 
total body SR-BI knockout mice, normolipidemic, bone marrow-specific SR-BI knockout 
mice displayed a normal ability to produce proplatelets. Moreover, specific deletion 
of SR-BI in bone marrow did not result in thrombocytopenia and showed a normal 
response to TPO stimulation. Therefore, it is suggested that the elevation of plasma 
UC levels and not the disruption of the megakaryocyte SR-BI / HDL interaction, impairs 
megakaryopoiesis and platelet production in total body SR-BI knockout mice.
The increase in plasma UC:TC ratio observed in SR-BI deficient mice is related to the 
reduced activity of LCAT 18–20. Altered platelet number and function have been observed 
in LCAT-deficient mice, especially on a SR-BI-deficient background 26. Deletion of LCAT 
rescues the thrombocytopenic phenotype in SR-BI knockout mice, despite increasing 
the plasma UC:TC ratio 26. However, reduced LCAT activity lowers plasma lysophosphati-
dylcholine levels, which is associated with increased megakaryocyte number and func-
tion in rats 27. It can therefore be suggested that the increased platelet number in LCAT / 
SR-BI double knockout mice can be attributed to increased megakaryopoiesis. However, 
we did not observe increased megakaryocyte numbers in SR-BI KO mice, suggesting 
that the influence of the reduced LCAT activity and subsequent lysophosphatidylcholine 
levels in our experimental setting is minimal.
Mature megakaryocytes produce the DMS to serve as a membrane reservoir for the 
generation of proplatelets, which extend into the vascular nice to release platelets 
into the bloodstream 28,29. It has long been known that membrane cholesterol affects 
membrane fluidity 30. In erythrocytes, an increased cholesterol:phospholipid ratio in-
creases cell rigidity and microviscosity 30,31. Accordingly, in SR-BI knockout mice, a 2-fold 
increase in the cholesterol:phospholipid ratio causes an increase in cell rigidity and a 
decrease in deformability of erythrocytes 32. In the present study we have shown that 
UC accumulates in the megakaryocytes in SR-BI knockout mice. Moreover, the amount 
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of proplatelet forming cells was decreased in SR-BI knockout bone marrow. Possibly, 
the high membrane cholesterol content inhibits the process of DMS and proplatelet 
production due to an increase in membrane rigidity. In accordance with this hypothesis, 
transplantation of SR-BI knockout bone marrow into a normolipidemic environment 
did not replicate the phenotype of decreased proplatelet formation observed in total 
body SR-BI knockout mice. Further studies on the effect of cholesterol loading of mega-
karyocyte membranes on DMS functionality and proplatelet formation are warranted to 
provide further mechanistic support for this hypothesis.
Our findings in hypercholesterolemic SR-BI knockout mice complement previous 
in vivo observations that hypercholesterolemia changes megakaryocyte and platelet 
characteristics. Two groups have independently shown that rabbits and guinea pigs 
fed a high cholesterol diet develop megakaryocytes with increased ploidy and size 33,34. 
Hypercholesterolemia in humans is also associated with higher megakaryocyte ploidy, 
indicative of altered megakaryocyte maturation 35. Notably, the change in megakaryo-
cyte maturation in hypercholesterolemic human subjects coincided with a higher mean 
platelet volume 35.
Platelets in SR-BI knockout mice are 1.2- to 1.4-fold larger than wild-type platelets 15,16, 
which was confirmed by our findings. Dole et al., as well as our own group, have sug-
gested that this larger size can be attributed to cholesterol accumulation in platelets 
acquired via non-specific lipid exchange from UC-rich HDL particles in the circulation. 
In support, infused platelets - regardless of donor and recipient genotype - obtain 
UC levels comparable to resident platelets within 24 hours 15. Notably, cholesterol in 
platelets can also be derived from cholesterol taken up by megakaryocytes as these 
cells can transfer cellular cholesterol to their platelet progeny 36. In support of the latter, 
the increase in cholesterol in megakaryocytes in response to a high cholesterol diet 
challenge appears to precede that in platelets (4-5 day lag time from the start of cho-
lesterol feeding, consistent with the turnover time of platelets). In this study, we have 
shown that megakaryocytes of SR-BI knockout mice are loaded with excess UC. When 
taking the aforementioned findings in account, we anticipate that the accumulation of 
cholesterol in platelets and the observed overall change in platelet count, phenotype 
and function in SR-BI knockout mice is not only the result of increased passive transfer 
from the plasma compartment but may - in part - also be inherited from cholesterol 
accumulation in their megakaryocyte progenitors.
In conclusion, elevation of plasma UC levels impairs megakaryopoiesis and platelet 
production in SR-BI knockout mice. Our findings suggest that impaired platelet produc-
tion, in addition to the previously reported augmented platelet clearance, may explain 
part of the thrombocytopenic phenotype associated with SR-BI deficiency. Hence, our 
studies highlight megakaryocyte cholesterol homeostasis regulation as a potential 
therapeutic target in the prevention and treatment of cardiovascular disease.
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supplemental figure 1: Total body sR-bI deficiency is associated with hypercholesterolemia and 
thrombocytopenia. Plasma UC (A) and TC (B) levels, the plasma UC:TC ratio (C), and blood platelet con-
centrations (D) in wild-type (WT) and SR-BI knockout (SR-BI KO) mice. Data represent means+SEM of 4 mice 
per group. ****p<0.0001.
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Cholesterol efflux transporters ABCA1 
and ABCG1 differentially influence 






Platelets, produced by megakaryocytes in the bone marrow, play an important role 
in atherothrombosis. Cholesterol efflux capacity of megakaryocytes can influence 
megakaryocyte formation, function and platelet production. In this study, we investi-
gated whether disruption of the cholesterol efflux transporters ATP-Binding cassette 
transporter A1 (ABCA1) and ABCG1 influence megakaryopoiesis and proplatelet pro-
duction. ABCA1/ABCG1 DKO mice displayed similar amounts of megakaryocytes in the 
bone marrow compared to control mice. Interestingly, there was a significant increase 
(p<0.01) in proplatelet production by megakaryocytes from ABCA1/ABCG1 DKO mice 
in bone marrow explants. Moreover, combined deletion of ABCA1 and ABCG1 had 
no effect on basal platelet counts or thrombopoietin stimulated platelet production. 
Notably, platelets of ABCA1/ABCG1 DKO mice did display an increase in platelet volume 
and volume distribution width. However, this increase was not associated with changes 
in the unesterified cholesterol content of ABCA1/ABCG1 DKO megakaryocytes. Single 
ABCA1 and ABCG1 knockout (KO) mice also had similar bone marrow megakaryocyte 
numbers compared to wild-type mice. Surprisingly, the amount of proplatelet forming 
megakaryocytes in single ABCG1 KO bone marrow explants was substantially higher as 
compared to ABCA1/ABCG1 DKO explants (AUC: 3-fold vs 1.6-fold compared to wild-type 
mice). Moreover, megakaryocytes from ABCA1 KO mice surprisingly showed decreased 
proplatelet formation, explaining the suppressed increase in proplatelet formation upon 
combined deletion of ABCA1 and ABCG1. In conclusion, we show that the cholesterol 
efflux transporters ABCA1 and ABCG1 have differential effects on proplatelet formation. 
Our findings suggest that ABCA1 and ABCG1 do not play a major role in megakaryocyte 
cholesterol efflux towards extracellular cholesterol acceptors, but may play a crucial role 
in the regulation of the final steps of thrombopoiesis.
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InTRoDUcTIon
Platelets are key players in atherothrombosis, as they are the first responders to changes 
in the endothelial integrity and exposure of sub-endothelial structures 1. Platelet charac-
teristics such as density and volume are associated with increased risk of acute coronary 
syndromes 2–5. Moreover, mean platelet volume, a determinant of platelet reactivity, is 
implied as both a causal as well as a prognostic factor in cardiovascular disease 6.
Platelets are produced by megakaryocytes in the bone marrow through the process 
of thrombopoiesis. Dyslipidemia alters megakaryocyte functioning, and can in this 
way modulate the risk of atherothrombosis via the megakaryocyte-platelet hemostatic 
axis 7. High-cholesterol diet-fed rabbits and guinea pigs develop megakaryocytes with 
increased ploidy and size 8,9. Moreover, hypercholesterolemia in humans is associated 
with higher megakaryocyte ploidy, indicative of altered megakaryocyte maturation, and 
higher mean platelet volume 10. Together, these data imply regulation of megakaryocyte 
cholesterol homeostasis as a potential therapeutic target to modulate platelet charac-
teristics and prevent or treat cardiovascular disease.
Cellular cholesterol homeostasis is maintained through a delicate balance involving 
the uptake of lipoprotein-derived cholesterol, de novo synthesis and cholesterol efflux 
to apolipoprotein A1 (ApoA1) and high-density lipoproteins (HDL). Previous research 
has indicated that cholesterol efflux capacity of megakaryocytes can influence mega-
karyocyte formation, function and platelet production. Murphy et al showed that the 
cholesterol efflux transporter ATP-Binding cassette transporter G4 (ABCG4), a half-size 
ABC transporter, is highly expressed in megakaryocyte progenitors 11. ABCG4 is pre-
dominantly found in the trans-Golgi, where it may act indirectly to influence plasma 
membrane cholesterol content and HDL-mediated cholesterol efflux 11. In agreement, 
ABCG4 knockout (KO) megakaryocyte progenitors showed defective cholesterol efflux 
to HDL, and increased unesterified cholesterol accumulation, with prominent accumula-
tion in the plasma membrane 11. This is accompanied by increased surface expression 
of the thrombopoietin receptor c-MPL and enhanced proliferation of megakaryocyte 
progenitor cells, leading to increased platelet production.
The most studied cholesterol efflux transporters are ABCA1 and ABCG1. ABCA1 is a full 
transporter, and is ubiquitously present on cellular plasma membranes, and mediates 
cholesterol efflux to lipid poor ApoA1, but not large HDL particles 12. In contrast ABCG1 
needs to dimerize with another ABC transporter to become functional 13. ABCG1 medi-
ates cholesterol efflux to mature HDL particles, but not lipid-free apolipoproteins 14–16. 
Interestingly, whereas ABCA1 is present on the plasma membrane and directly binds 
to circulating ApoA1 17, ABCG1 is involved in intracellular sterol movement. It increases 
the availability of cholesterol for efflux to lipoprotein acceptors and the regulation of 
endoplasmic reticulum-localized cholesterol biosynthesis genes 17,18. ABCA1 and ABCG1 
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are highly expressed in hematopoietic stem cells and myeloid progenitors, but expres-
sion in megakaryocyte-erythrocyte progenitors is decreased 11. Notably, stimulation 
of the nuclear oxysterol receptor liver X receptor (LXR) upregulates ABCA1 and ABCG1 
in megakaryocyte-erythrocyte progenitors, suggesting that these transporters may 
play a physiological role in the control of megakaryocyte cholesterol homeostasis in a 
cholesterol-loading context, i.e. under hyperlipidemic conditions 11.
Because of their differential localization and possible roles in (intra)cellular cholesterol 
transport, we hypothesize that ABCA1 and ABCG1 may have roles in megakaryocyte 
functioning that are distinct from ABCG4. In this study, we have for the first time exam-
ined the roles of these transporters in megakaryopoiesis and platelet production. Hereto, 
we used unique ABCA1/ABCG1 double knockout (DKO) mice that as a result of a severe 
disruption of the cellular cholesterol efflux pathway show massive cholesterol accumula-
tion in various tissues rich in macrophages despite low serum cholesterol levels 22.
MaTeRIals anD MeTHoDs
Mice
8-35 weeks old, male and female wild-type C57Bl6/J, ABCA1 KO, ABCG1 KO and ABCA1/
ABCG1 double KO (DKO) mice were bred in house at the Gorlaeus Laboratories (Leiden, 
the Netherlands). All mice were fed a regular chow diet (Special Diet Services, Witham, 
UK) and were group housed in filter top cages. All animal experiments were performed 
in accordance with the national guidelines for animal experimentation. All experimental 
protocols were approved by the Ethics Committee for Animal Experiments of Leiden 
University.
TPo challenge
Blood was drawn from the tail vein of female mice prior to, and 2 and 5 days post intra-
peritoneal injection with 17.5 µg/kg rmTPO (Peprotech, Londen, UK) in PBS.
Platelet analysis
Blood obtained from the tail vein or orbital exsanguination of male and female mice 
was collected in EDTA-coated tubes. Platelet counts and characteristics were analyzed 
using an automated XT-2000iV veterinary hematology analyzer (Sysmex Europe GMBH, 
Norderstedt, Germany).
bone marrow explants and proplatelet formation
Ex vivo megakaryocyte maturation and proplatelet production in the native bone 
marrow environment of female mice was measured using the bone marrow explant 
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method originally developed by Eckly and colleagues 19. Bone marrow, isolated by 
flushing femurs and tibia with PBS, was cut in 0.5 mm thick sections. 5-6 sections were 
transferred into an incubation chamber and incubated at 37°C for 6 hours in Hepes 
Tyrodes buffer containing 3.5 g/L human serum albumin (MP biomedicals, Santa Ana, 
California, USA) and 1 g/L glucose (pH 7.3) supplemented with 5% serum from the donor 
mouse. Proplatelet-forming megakaryocytes were counted every 1.5 hours using phase 
contrast microscopy.
bone marrow megakaryocyte counts
Bone marrow from female mice was obtained by flushing the femurs and tibia with PBS, 
fixed for 24 h in 3.7% neutral-buffered formalin (Formal-Fixx, Shandon Scientific Ltd, 
UK), and embedded in paraffin for sectioning. Bone marrow was sectioned using Leica 
RM2235 microtome at 5 μm thickness with a 25 μm interval. Serial sections were rou-
tinely stained with hematoxylin and eosin for general histology. Megakaryocyte counts 
were analyzed by a blinded observer using a Leica DM-RE microscope and LeicaQwin 
software (Leica Ltd, Cambridge, UK). Six fields of 200x200µm were analyzed in each of 
four sections per mouse.
Megakaryocyte cultures
Single cell suspensions of lineage negative cells (2.0x106 cells/mL) from female mice were 
isolated from bone marrow of 8-12 week old female wild-type mice using a Hematopoi-
etic Progenitor Cell Enrichment Set (DM-558451; BD Biosciences, San Jose, CA, USA). 
The lineage negative cells were cultured in 700 µL DMEM (Lonza, Basel, Switserland) 
supplemented with 10% FCS, 2 mmol/L L-glutamine, 100 U/mL penicillin, 100 µg/mL 
streptomycin, and unless specified otherwise, with 50 ng/mL murine thrombopoietin 
(mTPO, Stem Cell Technologies, Vancouver, Canada) and 70 U/mL heparin (Sigma-
Aldrich, Zwijndrecht, The Netherlands) in 12-well culture plates for up to 4 days 20.
Gene expression analysis
Total RNA was isolated from bone marrow and in vitro-cultured megakaryocytes of 
female mice by phenol-chloroform extraction. Equal amounts of RNA were reverse tran-
scribed and subsequently real-time quantitative PCR analysis was executed on the cDNA 
using an ABI Prism 7500 apparatus (Applied Biosystems, Foster City, CA, USA) according 
to the manufacturer’s instructions. Ribosomal Protein 37 (RPL37), Acidic Ribosomal 
Phosphoprotein P0 (36B4), and Peptidylprolyl Isomerase A (PPIA), were used as reference 
genes for normalization for bone marrow. Glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) was used as a reference gene for megakaryocyte cultures. Primer sequences 




A single cell suspension of bone marrow cells from female mice was obtained by straining 
flushed bone marrow from the femurs and tibiae through a 70 µm nylon mesh (Greiner 
Bio-One, Kremsmünster, Austria) with PBS. Bone marrow from scavenger receptor BI (SR-
BI) KO mice was used as a positive control for unesterified cholesterol accumulation 21. Fc 
receptors were blocked with an unconjugated antibody against CD16/CD32 (Clone 93, 
BioLegend, San Diego, California, USA). Cell viability in all samples was determined us-
ing Fixable Viability Dye eFluor® 780 (ThermoFisher Scientific, Waltham, Massachusetts, 
USA). To determine megakaryocyte free cholesterol content, 5*106 cells per sample were 
stained with Brilliant Violet 421™-conjugated anti-CD41 (clone MWReg30, BioLegend), 
fixed with 0.5% paraformaldehyde and stained with filipin III (Cayman Chemical, Ann 
Arbor, Michigan, US). Flow cytometric analysis was performed on a Cytoflex S flow cy-
tometer (Beckman Coulter, Brea, California, USA) and the acquired data were analyzed 
using FlowJo software (FlowJo LLC, Ashland, Oregon, USA). Gates were set according to 
unstained controls and fluorescence minus one (FMO) controls.
statistical analysis
Statistical analysis was performed using Graphpad Prism software (San Diego, USA, 
http://www.graphpad.com). Outlier detection was performed using Grubbs’ test for 
outliers. The significance of differences was calculated using a two-tailed unpaired t-test 
or two-way analysis of variance (ANOVA) where appropriate. Probability values (p) <0.05 
were considered significant.
ResUlTs
The expression of the ABC transporters ABCA1 and ABCG1 was investigated during ex 
vivo megakaryopoeisis from lineage negative cells isolated from wildtype C57Bl6/J mice. 
Megakaryocyte maturation was confirmed by measuring the expression of megakaryo-
cyte marker genes Itga2b (CD41), Gp9 (CD42a) and Gp1bb (CD42c) (Figure 1A). Although 
immature megakaryocytes (1 day after the start of differentiation) tended to express 
ABCA1 at a higher level than ABCG1 (p=0.16), fully mature megakaryocytes (4 days after 
start of differentiation) expressed similar levels of ABCA1 and ABCG1 mRNA (Figure 1B).
To establish the potential relevance of ABCA1 and ABCG1 for megakaryocyte cellular 
cholesterol homeostasis and function we studied megakaryopoeisis and platelet char-
acteristics in wild-type and ABCA1/ABCG1 DKO mice. ABCA1/ABCG1 DKO mice displayed 
similar amounts of megakaryocytes in the bone marrow (Figure 2A). Interestingly, there 
was a significant increase (1.7-fold, p<0.01 at 6 hours; AUC: 33±3 vs 52±7, p<0.01) in 
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proplatelet production by megakaryocytes from ABCA1/ABCG1 DKO as compared to 
wildtype mice in bone marrow explants (Figure 2B).
It was previously shown that bone marrow ABCG4 defi ciency alters the thrombopoietin 
response, through unesterifi ed cholesterol accumulation in megakaryocyte progenitors, 
leading to higher platelet counts 11. Notably, no accumulation of unesterifi ed cholesterol 
was detected in megakaryocytes from ABCA1/ABCG1 DKO and wild-type mice (Figure 
2C), while our positive controls (megakaryocytes from hypercholesterolemic scavenger 
receptor BI (SR-BI) KO mice 21 did show signifi cant unesterifi ed cholesterol accumulation 
(median fl uorescence intensity: 8398±258 in SR-BI KO vs 5531±217 and 4932±308 in 
wild-type and ABCA1/ABCG1 DKO mice). Moreover, combined deletion of ABCA1 and 
ABCG1 had no eff ect on basal platelet counts (Figure 2D) or thrombopoietin stimulated 
platelet production (Figure 2E). These combined data indicate that the mechanisms by 
which ABCA1 and ABCG1 deletion infl uence megakaryopoiesis and platelet production 
are diff erent from ABCG4 deletion. Notably, in support with an eff ect on proplatelet 
production, ABCA1/ABCG1 DKO mice displayed an increase in platelet volume (p<0.001; 
Figure 1F) and platelet distribution width (p<0.001; Figure 1G).
Single ABCG1 KO mice also exhibited virtually identical numbers of bone marrow 
megakaryocytes compared to wild-type mice (Figure 3A). Surprisingly, when measuring 
proplatelet production, we found a striking 2.2-fold increase in the amount of proplate-
let forming megakaryocytes in ABCG1 KO bone marrow explants (p<0.001 at 6 hours; 
AUC: 33±3 vs 99±11, p<0.001; Figure 3B), which was substantially higher as compared 
to ABCA1/ABCG1 DKO explants (AUC: 3-fold vs 1.6-fold compared to wild-type mice). 
ABCG1 KO mice had equal platelet counts (Figure 3C), mean platelet volume (Figure 3D), 
and platelet distribution width compared to wild-type mice (Figure 3E).
figure 1: abca1 and abcG1 are expressed in in vitro cultured megakaryocytes. (A) Relative mRNA ex-
pression of megakaryocyte markers Itga2b (CD41), Gp9 (CD42a) and Gp1bb (CD42c) in in vitro bone marrow 
stem cell-derived megakaryocytes 1 and 4 days after start of diff erentiation (n=3-4/time point). (B) Relative 
mRNA expression of ABCA1 and ABCG1 in in vitro bone marrow stem cell-derived megakaryocytes 1 and 
4 days after start of diff erentiation (n=2-4/time point). Data represent means±SEM. *p<0.05, ***p<0.001.
chapter 4
86
Similar as in single ABCG1 KO and ABCA1/ABCG1 DKO mice, bone marrow megakaryo-
cyte numbers in single ABCA1 KO mice were equal to the amounts in wild-types (Figure 
4A). However, in contrast to the observations in single ABCG1 KO and ABCA1/ABCG1 
DKO mice, megakaryocytes of single ABCA1 KO mice surprisingly showed decreased 
proplatelet formation (AUC: 17±2 vs 33±3for wild-type, p<0.05.; Figure 4B). As previ-
ously published by Lhermusier et al 22, we observed a slight, non-signifi cant increase 
in platelet counts in the circulation of ABCA1 KO mice (p=0.18; Figure 4C). Moreover, in 
agreement with the earlier study 22, and as observed in the ABCA/ABCG1 DKO mice in 
the current study, mean platelet volume (p<0.01; Figure 4D) and platelet distribution 
width were increased in single ABCA1 KO mice (p<0.01; Figure 4E).
figure 2: Double defi ciency of abca1 and abcG1 alters proplatelet production and platelet char-
acteristics. (A) Quantifi cation of bone marrow megakaryocytes in bone marrow sections from wild-type 
(n=3) and ABCA1/ABCG1 DKO mice (n=5). (B) Percentage of proplatelet-forming megakaryocytes in an ex 
vivo native bone marrow environment of wild-type (n=15) and ABCA1/ABCG1 DKO (n=4) mice, and area-
under-the-curve (AUC). (C) Filipin median fl uorescent intensity (MFI) of CD41+ cells of wild-type (n=11) and 
ABCA1/ABCG1 DKO mice (n=10). FMO indicates the Fluorescence Minus One control. (D) Basal platelet 
counts of wild-type (n=7) and ABCA1/ABCG1 DKO mice (n=4). (E) Platelet increase 5 days after thrombo-
poietin challenge (wild-type: n=7, ABCA1/ABCG1 DKO: n=6). (F) Basal mean platelet volume (MPV) and (G) 
platelet distribution width (PDW) (wild-type: n=7, ABCA1/ABCG1 DKO: n=4). Data represent means±SEM. 
**p<0.01, ***p<0.001.
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DIscUssIon
In the current study we investigated the impact of ABCA1 and ABCG1 defi ciency on pro-
platelet production. We show that absence of the cholesterol effl  ux transporters ABCA1 
and ABCG1 alters proplatelet production by megakaryocytes. Moreover, our studies 
suggest that modulation of the function of individual cholesterol effl  ux transporters 
may translate into an overall diff erential eff ect on platelet production.
Previous work by Murphy et al has shown that cholesterol effl  ux facilitated by ABCG4 is 
important for megakaryocyte progenitor proliferation and platelet production 11. ABCG4 
is highly expressed in megakaryocyte progenitors, whereas the expression of ABCA1 
and ABCG1 is much less in this cell type 11. However, despite this relatively low expres-
sion, we observed strong eff ects of deletion of these transporters on megakaryocyte 
functioning and proplatelet production. Combined deletion of ABCA1 and ABCG1 has 
detrimental eff ects on the cholesterol effl  ux capacity of myeloid cells leading to exces-
sive cholesterol accumulation, even at low plasma cholesterol conditions associated 
with ABCA1 defi ciency 23. Interestingly, no cholesterol accumulation was observed in 
megakaryocytes of ABCA1/ABCG1 DKO mice.
Platelets from ABCA1 KO and ABCA1/ABCG1 DKO mice are slightly larger in size. More-
over, platelets lacking ABCA1 exhibit aggregation and secretion defects in response to 
figure 3: abcG1 defi ciency increases proplatelet production but not platelet levels and character-
istics. (A) Quantifi cation of bone marrow megakaryocytes in bone marrow sections from wild-type (n=3) 
and ABCG1 KO (n=3) mice. (B) Percentage of proplatelet-forming megakaryocytes in an ex vivo native bone 
marrow environment of wild-type (n=15) and ABCG1 KO (n=5) mice, and area-under-the-curve (AUC). (C) 
Basal platelet counts, (D) mean platelet volume (MPV), and (E) platelet distribution width (PDW) of wild-
type (n=7) and ABCG1 KO (n=3) mice. Data represent means±SEM. *p<0.05, ***p<0.001.
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low concentrations of thrombin and collagen 22. Bone marrow transplantation of wild-
type bone marrow into ABCA1 KO mice suggested that, at least in part, this platelet 
phenotype is driven by the virtual absence of HDL cholesterol in the ABCA1 KO mice 22. 
In line with the notion that plasma cholesterol can alter platelet function and character-
istics, accumulation of HDL cholesterol in SR-BI KO mice leads to severe thrombocyto-
penia, as well as an increased platelet size and reactivity. Studies by us and others have 
shown that this phenotype is associated with increased platelet clearance rates due 
to intracellular unesterifi ed cholesterol accumulation, as well as decreased proplatelet 
formation 21,24,25. ABCG1 KO mice, which exhibit normal plasma cholesterol levels, do 
not have altered platelet characteristics. Importantly, despite the observed alterations 
in proplatelet formation in absence of ABCA1 and ABCG1 in the current study, this does 
not translate into diff erences in platelet counts. This indicates that platelet counts are 
not solely dependent on megakaryocyte platelet production rates.
The most important and novel fi nding of the current study is that deletion of ABCA1 
or ABCG1 has independent eff ects on megakaryocyte functioning, as demonstrated 
by the diff erential eff ects on proplatelet formation. ABCA1 defi ciency inhibits the early 
stages of proplatelet formation, whereas in stark contrast, absence of ABCG1 strongly 
increases proplatelet formation. In accordance with this notion, combined deletion 
figure 4: abca1 defi ciency decreases proplatelet production and alters platelet characteristics. (A) 
Quantifi cation of bone marrow megakaryocytes in bone marrow sections from wild-type (n=3) and ABCA1 
KO (n=2) mice. (B) Percentage of proplatelet-forming megakaryocytes in an ex vivo native bone marrow en-
vironment of wild-type (n=15) and ABCA1 KO (n=3) mice, and area-under-the-curve (AUC). (C) Basal plate-
let counts, (D) mean platelet volume (MPV), and (E) platelet distribution width (PDW) of wild-type (n=4) and 
ABCA1 KO (n=5) mice. Data represent means±SEM. *p<0.05, **p<0.01.
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of both transporters leads to an effect that is intermediate between the effects of the 
individual single KOs.
Proplatelet formation is a terminal process, and after the entirety of the megakaryo-
cyte cell body is converted into proplatelets, the nucleus is extruded and degraded 26. 
Currently, there is still an insufficient understanding of signals that trigger proplatelet 
formation. However, it does require an apoptotic phase and caspase activation 26. Al-
though for long it remained unsure how the apoptotic process required for proplatelet 
formation was initiated, studies by Lopez et al have shown that transient ER stress 
activation triggers this process. In support, ER stress induction peaks at the proplatelet 
formation stage 27. Moreover, treatment with salubrinal, which protects cells from ER 
stress-induced apoptosis, dose dependently inhibits the production of proplatelets 
from megakaryocytes 27. Conversely, induction of ER stress by the ER stressor thapsi-
gargin enhances the formation of functional platelet-like particles from MEG-01 mega-
karyocyte cell line cells 28. Therefore, it is likely that ER stress induced apoptosis is the 
driving force behind proplatelet formation. Although the precise cellular localization of 
ABCG1 in megakaryocytes remains elusive, in myeloid cells it is involved in intracellular 
trafficking of cholesterol over the ER membrane and endosomes, in addition to a role in 
cholesterol sensing 17,18. ABCG1 deficiency induces ER stress in endothelial cells 30. More-
over, blockade of cholesterol trafficking to the ER reversed ER stress-induced apoptosis 
of ABCG1 deficient endothelial cells, suggesting that activation of ER stress in ABCG1 
KO endothelial cells depends on trafficking of unesterified to the ER membrane 30. It is 
therefore interesting to speculate that deletion of ABCG1 in megakaryocytes enhances 
the ER stress response necessary for terminal megakaryocyte maturation, and in that 
way accelerates proplatelet formation.
Conversely, can the observed decrease in proplatelet formation in the single ABCA1 
KO megakaryocytes be explained by a decrease in ER stress response? ABCA1 facilitates 
retrograde sterol transport from the plasma membrane to the ER for sterol sensing 31. In 
vitro, lack of ABCA1 in mouse embryonic fibroblasts is associated with hyperactivation 
of the SREBP-2 pathway, even in the presence of an increase in cellular cholesterol 31. 
These data suggest that ABCA1 deficiency decreases ER cholesterol levels and disrupts 
sterol sensing in the ER. Possibly, a decrease in ER cholesterol could delay the ER stress 
response in ABCA1 KO megakaryocytes, explaining the decrease in proplatelet forma-
tion in these cells. Further studies on the effect of intracellular cholesterol trafficking 
and sterol sensing on terminal megakaryocyte maturation and proplatelet formation 
are warranted to provide further mechanistic support for this hypothesis.
In conclusion, we show that the cholesterol efflux transporters ABCA1 and ABCG1 have 
differential effects on megakaryocyte functioning, proplatelet formation and platelet 
characteristics. Our findings suggest that ABCA1 and ABCG1 do not play a major role in 
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megakaryocyte cholesterol efflux towards extracellular cholesterol acceptors, but may 
play a crucial role in the regulation of the final steps of thrombopoiesis.
acKnoWleDGeMenTs
This work was funded by Leiden University, and in part supported by a VICI grant 
91813603 from the Netherlands Organization for Scientific Research (M.V.E) and the 
Landsteiner Foundation for Blood Transfusion Research (#0912F, S.J.A.K.). M.V.E is an 
Established Investigator of the Dutch Heart Foundation (grant number 2007T056).
The authors thank Ezra van der Wel, Joya E. Nahon, Ronald J. van der Sluis, and Lidewij 
R. de Leeuw for excellent technical assistance.
effect of abca1 and abcG1 deficiency on platelet production
91
RefeRences
 1. Davì G, Patrono C. Mechanisms of disease: 
Platelet activation and atherothrombosis. 
N Engl J Med. 2007;357(24):2482-2494. 
doi:10.1056/NEJMra071014.
 2. Martin JF, Plumb J, Kilbey RS, Kishk YT. 
Changes in volume and density of platelets 
in myocardial infarction. Br Med J (Clin Res 
Ed). 1983;287(6390):456-459. doi:10.1136/
bmj.287.6390.456.
 3. Cameron HA, Phillips R, Ibbotson RM, 
Carson PH. Platelet size in myocar-
dial infarction. Br Med J (Clin Res Ed). 
1983;287(6390):449-451. doi:10.1136/
bmj.287.6390.449.
 4. Pizzulli L, Yang A, Martin JF, Lüderitz B. 
Changes in platelet size and count in 
unstable angina compared to stable 
angina or non-cardiac chest pain. Eur 
Heart J. 1998;19(1):80-84. doi:10.1053/
euhj.1997.0747.
 5. Endler G, Klimesch A, Sunder-Plassmann 
H, Schillinger M, Exner M, Mannhalter 
C, Jordanova N, Christ G, Thalhammer 
R, Huber K, Sunder-Plassmann R. Mean 
platelet volume is an independent risk 
factor for myocardial infarction but not 
for coronary artery disease. Br J Haematol. 
2002;117(2):399-404.
 6. Martin J, Bath P, Burr ML. Influence of 
Platelet Size on Outcome after Myocardial 
Infarction. Lancet. 1991;338(8780):1409-
1411. doi:0140-6736(91)92719-I [pii].
 7. Martin JF, Kristensen SD, Mathur A, 
Grove EL, Choudry FA. The causal role 
of megakaryocyte-platelet hyperactiv-
ity in acute coronary syndromes. Nat Rev 
Cardiol. 2012;9(11):658-670. http://dx.doi.
org/10.1038/nrcardio.2012.131.
 8. Martin JF, Slater DN, Kishk YT, Trowbridge 
EA. Platelet and megakaryocyte changes 
in cholesterol-induced experimental ath-
erosclerosis. Arteriosclerosis. 1985;5(6):604-
612.
 9. Schick BP, Schick PK. The effect of hyper-
cholesterolemia on guinea pig platelets, 
erythrocytes and megakaryocytes. Biochim 
Biophys Acta. 1985;833(2):291-302. http://
www.ncbi.nlm.nih.gov/pubmed/3970955.
 10. Pathansali R, Smith N, Bath P. Altered 
megakaryocyte&#150;platelet hae-
mostatic axis in hypercholesterolae-
mia. Platelets. 2001;12(5):292-297. 
doi:10.1080/09537100120058810.
 11. Murphy AJ, Bijl N, Yvan-Charvet L, Welch 
CB, Bhagwat N, Reheman A, Wang Y, Shaw 
JA, Levine RL, Ni H, Tall AR, Wang N. Choles-
terol efflux in megakaryocyte progenitors 
suppresses platelet production and throm-
bocytosis. Nat Med. 2013;19(5):586-594. 
doi:10.1038/nm.3150.
 12. Wang N, Silver DL, Costet P, Tall AR. Specific 
binding of ApoA-I, enhanced cholesterol 
efflux, and altered plasma membrane mor-
phology in cells expressing ABC1. J 
Biol Chem. 2000;275(42):33053-33058. 
doi:10.1074/jbc.M005438200.
 13. Dean M, Hamon Y, Chimini G. The human 
ATP-binding cassette (ABC) transporter 
superfamily. J Lipid Res. 2001;42(7):1007-
1017.
 14. Wang N, Lan D, Chen W, Matsuura F, Tall 
AR. ATP-binding cassette transporters G1 
and G4 mediate cellular cholesterol efflux 
to high-density lipoproteins. Proc Natl 
Acad Sci U S A. 2004;101(26):9774-9779. 
doi:10.1073/pnas.0403506101.
 15. Nakamura K, Kennedy MA, Baldan A, Bojan-
ic DD, Lyons K, Edwards PA. Expression and 
regulation of multiple murine ATP-binding 
cassette transporter G1 mRNAs/isoforms 
that stimulate cellular cholesterol efflux 
to high density lipoprotein. J Biol Chem. 
2004;279(44):45980-45989. doi:10.1074/
jbc.M408652200.
 16. Kennedy MA, Barrera GC, Nakamura K, 
Baldan A, Tarr P, Fishbein MC, Frank J, 
Francone OL, Edwards PA. ABCG1 has a 
chapter 4
92
critical role in mediating cholesterol efflux 
to HDL and preventing cellular lipid ac-
cumulation. Cell Metab. 2005;1(2):121-131. 
doi:10.1016/j.cmet.2005.01.002.
 17. Wang N, Ranalletta M, Matsuura F, Peng 
F, Tall AR. LXR-induced redistribution of 
ABCG1 to plasma membrane in mac-
rophages enhances cholesterol mass 
efflux to HDL. Arterioscler Thromb Vasc Biol. 
2006;26(6):1310-1316. doi:10.1161/01.
ATV.0000218998.75963.02.
 18. Tarling EJ, Edwards PA. ATP binding 
cassette transporter G1 (ABCG1) is an 
intracellular sterol transporter. Proc Natl 
Acad Sci U S A. 2011;108(49):19719-19724. 
doi:10.1073/pnas.1113021108.
 19. Eckly A, Strassel C, Cazenave J-P, Lanza 
F, Leon C, Gachet C. Characterization of 
megakaryocyte development in the native 
bone marrow environment. Methods Mol 
Biol. 2012;788:175-192. doi:10.1007/978-1-
61779-307-3_13.
 20. Strassel C, Eckly A, Léon C, Moog S, Caze-
nave J-P, Gachet C, Lanza F. Hirudin and 
heparin enable efficient megakaryocyte 
differentiation of mouse bone marrow 
progenitors. Exp Cell Res. 2012;318(1):25-
32. doi:10.1016/j.yexcr.2011.10.003.
 21. Ouweneel AB, Hoekstra M, van der Wel EJ, 
Schaftenaar FH, Snip OSC, Hassan J, Korpo-
raal SJA, Van Eck M. Hypercholesterolemia 
impairs megakaryopoiesis and platelet 
production in scavenger receptor BI knock-
out mice. Atherosclerosis. September 2018. 
doi:10.1016/j.atherosclerosis.2018.09.019.
 22. Lhermusier T, Severin S, Van Rothem J, 
Garcia C, Bertrand-Michel J, Le Faouder 
P, Hechler B, Broccardo C, Couvert P, 
Chimini G, Sie P, Payrastre B. ATP-binding 
cassette transporter 1 (ABCA1) deficiency 
decreases platelet reactivity and reduces 
thromboxane A2 production indepen-
dently of hematopoietic ABCA1. J Thromb 
Haemost. 2016;14(3):585-595. doi:10.1111/
jth.13247.
 23. Out R, Jessup W, Le Goff W, Hoekstra M, Ge-
lissen IC, Zhao Y, Kritharides L, Chimini G, 
Kuiper J, Chapman MJ, Huby T, Van Berkel 
TJC, Van Eck M. Coexistence of foam cells 
and hypocholesterolemia in mice lacking 
the ABC transporters A1 and G1. Circ Res. 
2008;102(1):113-120. doi:10.1161/CIRCRE-
SAHA.107.161711.
 24. Dole VS, Matuskova J, Vasile E, Yesilaltay 
A, Bergmeier W, Bernimoulin M, Wagner 
DD, Krieger M. Thrombocytopenia and 
Platelet Abnormalities in High-Density 
Lipoprotein Receptor – Deficient Mice. 
2008. doi:10.1161/ATVBAHA.108.162347.
 25. Korporaal SJA, Meurs I, Hauer AD, Hildeb-
rand RB, Hoekstra M, Cate HT, Pratico D, Ak-
kerman J-WN, Van Berkel TJC, Kuiper J, Van 
Eck M. Deletion of the High-Density Lipo-
protein Receptor Scavenger Receptor BI in 
Mice Modulates Thrombosis Susceptibility 
and Indirectly Affects Platelet Function by 
Elevation of Plasma Free Cholesterol. Arte-
rioscler Thromb Vasc Biol. 2011;31(1):34-42. 
doi:10.1161/ATVBAHA.110.210252.
 26. Machlus KR, Italiano JE. The incredible 
journey: From megakaryocyte develop-
ment to platelet formation. J Cell Biol. 
2013;201(6):785-796. doi:10.1083/
jcb.201304054.
 27. Lopez JJ, Palazzo A, Chaabane C, Albarran 
L, Polidano E, Lebozec K, Dally S, Nurden 
P, Enouf J, Debili N, Bobe R. Crucial role 
for endoplasmic reticulum stress during 
megakaryocyte maturation. Arterioscler 
Thromb Vasc Biol. 2013;33(12):2750-2758. 
doi:10.1161/ATVBAHA.113.302184.
 28. Morishima N, Nakanishi K. Proplatelet 
formation in megakaryocytes is associated 
with endoplasmic reticulum stress. Genes 
Cells. 2016;21(7):798-806. doi:10.1111/
gtc.12384.
 29. Tabas I. The role of endoplasmic reticulum 
stress in the progression of atherosclerosis. 
Circ Res. 2010;107(7):839-850. doi:10.1161/
CIRCRESAHA.110.224766.
effect of abca1 and abcG1 deficiency on platelet production
93
 30. Xue J, Wei J, Dong X, Zhu C, Li Y, Song A, Liu 
Z. ABCG1 deficiency promotes endothe-
lial apoptosis by endoplasmic reticulum 
stress-dependent pathway. J Physiol Sci. 
2013;63(6):435-444. doi:10.1007/s12576-
013-0281-8.
 31. Yamauchi Y, Iwamoto N, Rogers MA, Abe-
Dohmae S, Fujimoto T, Chang CCY, Ishigami 
M, Kishimoto T, Kobayashi T, Ueda K, Furu-
kawa K, Chang T-Y, Yokoyama S. Deficiency 
in the Lipid Exporter ABCA1 Impairs Retro-
grade Sterol Movement and Disrupts Ste-
rol Sensing at the Endoplasmic Reticulum. 
J Biol Chem. 2015;290(39):23464-23477. 
doi:10.1074/jbc.M115.662668.
Amber B. Ouweneel1*, Olga S.C. Snip1*, Robbert Wever1, Frank H. Schaftenaar1, 
Soňa Čejková2, Miranda van Eck1 & Menno Hoekstra1
1 Division of BioTherapeutics, Leiden Academic Centre for Drug Research, Leiden University, 
Leiden, The Netherlands, 2 Laboratory for Atherosclerosis Research, Centre for Experimental 
Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic, * These 
authors contributed equally to the manuscript
5
Apolipoprotein A1 modulates the ability 
of bone marrow to facilitate lymphocyte 
production after transplantation into 





Apolipoprotein A1 (APOA1) is the major structural apolipoprotein on anti-atherogenic 
HDL particles. APOA1 deficiency is therefore associated with severe reductions in plasma 
HDL cholesterol and an increased atherosclerosis susceptibility. Although APOA1 can 
directly impact on inflammation and atherosclerosis, it is also able to suppress prolifera-
tion of hematopoietic stem cells and skew hematopoiesis, and in that way alter immune 
cell numbers and function. In the current study we aimed to dissociate the direct effects 
of APOA1 deficiency on immune cells in the context of atherosclerosis from effects that 
are generated through changes in bone marrow immune cell production. Hereto, we 
transplanted bone marrow from wild-type and APOA1 knockout mice into hypercholes-
terolemic LDL receptor knockout mice.
Plasma cholesterol levels and atherosclerotic plaque size and collagen content were 
unaltered upon reconstitution with bone marrow from APOA1 knockout mice. However, 
APOA1 knockout bone marrow recipients displayed lymphocytosis, and a strong increase 
in circulating CD4 T cell numbers. This coincided with a strong increase in splenocyte 
numbers and a relative increase in splenic and circulating naïve T cells. An increase in 
thymus size and thymic CCR9 expression suggested an increase in T cell production, 
driven by an increase in hematopoietic stem cells and T lineage differentiation in the 
donor bone marrow from APOA1 knockout mice.
In conclusion, our studies show that a genetic lack of APOA1 translated into long 
term changes in immune cell production from bone marrow progenitors, leading to the 
development of naïve T cells from the thymus, resulting in lymphocytosis. Furthermore, 
our studies suggest that the effect of APOA1 deficiency on bone marrow does not un-
derlie the diet-induced increase in atherosclerosis susceptibility associated with global 
APOA1 deficiency.
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InTRoDUcTIon
Apolipoprotein A1 (APOA1) is the major structural apolipoprotein on high-density 
lipoprotein (HDL) and essential for HDL formation and function 1. After its secretion by 
hepatocytes and enterocytes, APOA1 interacts with ATP-binding cassette transporter A1 
(ABCA1) on the plasma membrane of cells to acquire phospholipids and cholesterol and 
form nascent HDL or pre-HDL particles 2,3.
It is well established that plasma APOA1 concentration is inversely correlated with the 
risk for atherosclerosis in humans 4. In accordance, atherosclerosis prone hypercholes-
terolemic low-density lipoprotein receptor (LDLR) knockout (KO) mice lacking APOA1 
(LDLR/APOA1 double KO (DKO) mice) display increased atherosclerosis susceptibility 
compared to LDLR single KO mice, both under chow 5, as well as under Western-type 
diet (WTD)-fed conditions 6. Most of the atherosclerosis-protective properties of APOA1 
and HDL are attributed to their role in cholesterol efflux and subsequent reverse 
cholesterol transport from peripheral tissues to the liver 7. However, HDL also exhibits 
anti-inflammatory properties, for which APOA1 is crucial 7–9. In line, in addition to the 
observed increase in atherosclerosis susceptibility, global APOA1 deficiency is also asso-
ciated with altered immune cell function under hypercholesterolemic conditions 6,10–12. 
As such, both a disruption of the cholesterol transport functions as well as a diminished 
anti-inflammatory response likely contribute to the increased atherosclerosis suscepti-
bility associated with APOA1 deficiency.
The primary site of immune cell production is the bone marrow, where the most 
primitive precursors, namely the hematopoietic stem cells (HSCs), and progenitor cells 
reside. During hematopoiesis, HSCs mature and differentiate into myeloid, lymphoid and 
erythroid-megakaryocytic lineages, after which the formed immune cells home towards 
their site of action or organ for final maturation. In a homeostatic setting, hematopoiesis 
is balanced between the different blood cell lineages. However, external factors, such as 
severe hemorrhage or hemolytic anemia, acute infection or chronic inflammation can 
skew hematopoiesis towards a specific lineage to aid in the restoration of homeostatic 
balance.
Hypercholesterolemia induces hyperproliferation of hematopoietic stem and pro-
genitor cells, leading to leukocytosis 13,14. We and others have shown that hypercholes-
terolemia-induced hyperproliferation of HSCs, as well as the consequent leukocytosis, 
are also evident in recipients of bone marrow from hypercholesterolemic mice 15,16. 
Thus, long-term intrinsic changes in stem cells are induced by the hypercholesterolemia. 
Interestingly, studies by Yvan-Charvet et al. have shown that APOA1 and HDL are able 
to suppress proliferation of HSCs and myeloid progenitor cells 17. This opens up the pos-
sibility that HDL-associated APOA1 not only directly interacts which specific immune 
cells to modulate their activity, but that it also modulates immune functionality at the 
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level of the bone marrow. In the current study we aimed to dissociate the direct effects 
of APOA1 deficiency on immune cells in the context of atherosclerosis from those that 
are generated through changes in bone marrow immune cell production. Hereto, we 
transplanted wild-type and APOA1 KO bone marrow into hypercholesterolemic, athero-
sclerosis susceptible LDLR KO mice and determined the effects on the immune status of 
the bone marrow recipient mice.
MaTeRIals anD MeTHoDs
Mice
Wild-type, APOA1 KO 18 and LDLR KO mice on a C57Bl6/J background were bred in house 
at the Gorlaeus Laboratories (Leiden, the Netherlands). All animal experiments were 
performed in accordance with the national guidelines for animal experimentation. All 
experimental protocols were approved by the Ethics Committee for Animal Experiments 
of Leiden University.
For experiments regarding the comparison of wild-type and APOA1 KO mice, 
14-18-week-old age-matched male mice were used (wild-type: n=6; APOA1 KO: n=8). All 
mice were fed a regular chow diet (Special Diet Services, Witham, UK) and were group-
housed in filter top cages. Mice were anesthetized with a mix of xylazine (70 mg/kg), 
ketamine (350 mg/kg), and atropine (1.8 mg/kg) and sacrificed by orbital exsanguina-
tion, after which the organs, femurs and tibias were collected for further analysis.
bone marrow transplantation
Donor bone marrow of 12-week-old age-matched male wild-type and APOA1 KO mice 
(n=2/genotype) was isolated by flushing the femurs and tibias with PBS. Recipient LDLR 
KO (11-22 weeks old) female mice (n= 15/group) were irradiated with 2x4.5 Gy total 
body radiation using a 225 Smart Röntgen source (YXLON international, Copenhagen, 
Denmark) one day before transplantation, and received a single cell suspension of 5x106 
bone marrow cells in PBS by intravenous injection into the tail vein. The drinking water 
of the recipient mice was supplemented with antibiotics (83 mg/L ciprofloxacin and 67 
mg/L polymixin B sulfate) and 6.5 g/L sucrose starting 7 days prior to transplantation 
up to 4 weeks after transplantation. After transplantation, mice were fed a regular chow 
diet (Special Diet Services) during recovery for 11 weeks, after which blood was drawn 
from the tail vein for blood cell and plasma cholesterol analysis. Following recovery, 
mice were fed a WTD; 0.25% cholesterol and 15% cocoa butter; Special Diet Services, 
Witham, Essex, U.K.) for 6 weeks. At 17 weeks post transplantation (6 weeks WTD feed-
ing), mice were anesthetized with a mix of xylazine (70 mg/kg), ketamine (350 mg/kg) 
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and atropine (1.8 mg/kg) and sacrificed by orbital exsanguination and perfusion with 
PBS, after which the organs, femurs and tibias were collected for further analysis.
Verification of bone marrow, blood and thymus repopulation
Genotyping of bone marrow, white blood cells and thymus was routinely performed 
using PCR and agarose gel separation. Primer sequences are available on request.
Gene expression
Total RNA was isolated from bone marrow and thymus by phenol-chloroform extraction. 
Equal amounts of RNA were reverse transcribed and subsequently real-time quantitative 
PCR analysis was executed on the cDNA using an ABI Prism 7500 apparatus (Applied Bio-
systems, Foster City CA, USA) according to the manufacturer’s instructions. Ribosomal 
Protein 37 (RPL37), Acidic Ribosomal Phosphoprotein P0 (36B4), and Peptidylprolyl 
Isomerase A (PPIA), were used as reference genes for normalization. Primer sequences 
are available upon request.
blood cell analysis
Blood obtained from the tail vein was collected in EDTA-coated tubes and diluted 4x 
in PBS for analysis of blood cell count. Blood cell counts were analyzed using an auto-
mated XT-2000iV veterinary hematology analyzer (Sysmex Europe GMBH, Norderstedt, 
Germany).
flow cytometry
To obtain a single cell suspension of bone marrow cells, flushed bone marrow from 
the femurs and tibias was strained through a 70 µm nylon mesh (Greiner Bio-One, 
Kremsmünster, Austria) with PBS. Single cell suspensions of splenocytes were obtained 
by straining spleen tissue through a 70 µm nylon mesh (Greiner Bio-One). Blood was 
obtained from the tail vein and collected in EDTA-coated tubes. Both splenocytes and 
blood were treated with ammonium-chloride-potassium erythrocyte lysing buffer. In 
all samples, Fc receptors were blocked with an unconjugated antibody against CD16/
CD32 (Clone 93, BioLegend, San Diego, California, USA). Cell viability in all samples was 
determined by staining with Fixable Viability Dye eFluor® 780 (ThermoFisher Scientific, 
Waltham, Massachusetts, USA). For intracellular staining, cells were permeabilized with 
Foxp3 Transcription Factor Staining Buffer Set (eBioscience, San Diego CA, USA). Samples 
were then stained with anti-mouse fluorochrome-conjugated antibodies (Supplemental 
table 1). Flow cytometric analysis was performed on a Cytoflex S flow cytometer (Beck-
man Coulter, Brea, California, USA) and the acquired data were analyzed using FlowJo 





Blood obtained from orbital exsanguination was collected in EDTA-coated tubes. Plasma 
from orbital bleeding-obtained blood was attained by centrifugation (10 minutes, 
6000 RPM, room temperature) and stored at −20°C until further use. Plasma free and 
total cholesterol levels were measured by enzymatic colorimetric assays as described 
by Out et al. 19. The distribution of cholesterol over the different lipoproteins in serum 
was determined by fractionation of 30 μL of pooled plasma using a Superose 6 column 
(3.2×300 mm, Smart-System; Pharmacia, Uppsala, Sweden). Total cholesterol content of 
the effluent was determined as described.
atherosclerosis
After perfusion with PBS, hearts were fixed for 4 hours with 3.7% formalin (Formal-fixx; 
Shandon Scientific Ltd, UK). Fixed hearts were embedded in Sakura O.C.T. Compound™ 
(Sakura Finetek Europe B.V., Alphen aan de Rijn, The Netherlands), for sectioning. Serial sec-
tions (10 μm, 70 μm interval) of the aortic root were cut using the Leica CM3050S cryostat. 
Plaque size in the aortic root was determined by staining for neutral lipids using Oil-Red-O 
and Mayer’s hematoxylin (Sigma-Aldrich, Zwijndrecht, The Netherlands). Corresponding 
sections were stained for collagen fibers using a Masson’s Trichrome staining (Sigma-
Aldrich). All images were analysed by blinded computer aided morphometric analysis 
using the Leica DM-RE microscope and LeicaQwin software (Leica Ltd, Cambridge, UK).
statistical analysis
Statistical analysis was performed using Graphpad Prism software (San Diego CA, USA, 
http://www.graphpad.com). Outlier detection was performed using Grubbs’ test for 
outliers. The significance of differences was calculated using a two-tailed unpaired t-test 
or two-way analysis of variance (ANOVA) with Bonferroni post-test where appropriate. 
Probability values (p) <0.05 were considered significant.
ResUlTs
To investigate the indirect effect of APOA1 deficiency on bone marrow-derived immune 
cells, lethally-irradiated hypercholesterolemic LDLR KO mice were reconstituted with 
either bone marrow from wild-type or APOA1 KO mice (Figure 1A). Following transplan-
tation, bone marrow recipient mice were fed a regular chow diet for 11 weeks to allow 
repopulation with the donor bone marrow. Bone marrow transplantation was successful 
and similarly effective in recipients of both the wild-type and APOA1 KO bone marrow 
cells, as judged from the practically complete repopulation by the donor bone marrow 
cells (Supplemental Figure 1).
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Following recovery, mice were fed WTD to exacerbate the hypercholesterolemia. 
Previous studies have shown that APOA1 defi ciency in WTD-fed LDLR KO mice leads 
to similar or increased atherosclerosis, despite a marked decrease in very low-density 
lipoproteins (VLDL) and low-density lipoproteins (LDL) 6,10. In the current study, no dif-
ference in total cholesterol levels or the lipoprotein distribution profi le was observed 
between WTD-fed wild-type and APOA1 KO bone-marrow transplanted LDLR KO mice 
(Figure 1B). The 6 weeks WTD feeding resulted in early stage atherosclerotic lesion for-
mation. Atherosclerotic plaques from APOA1 KO bone-marrow transplanted mice were 
of a similar size as plaques from wild-type bone marrow transplanted mice after 6 weeks 
of WTD-feeding (252±33 x106 µm2 vs. 249±22 x106 µm2, Figure 1C). Collagen contents of 
the plaques were also similarly low in both groups of mice, as expected for early lesions 
(2.5±0.4% vs. 3.0±0.4%, Figure 1D).
figure 1: bone marrow donor aPoa1 Ko does not alter plasma cholesterol and atherosclerosis in 
lDlR Ko mice on WTD. (A) Experimental design. Bone marrow from male wild-type or APOA1 KO mice 
was transplanted into lethally irradiated female LDLR KO mice. During 11 weeks of recovery mice were 
maintained on a chow diet. After recovery, mice were switched to a WTD for 6 weeks until sacrifi ce. (B) 
Plasma free cholesterol (FC), total cholesterol (TC), and lipoprotein distribution of cholesterol in wild-type 
and APOA1 KO bone marrow transplanted mice at sacrifi ce. (C) Aortic root plaque size as measured by Oil 
Red O stained area. Bars represent 250 µm. (D) Aortic root atherosclerotic plaque collagen content as mea-
sured by Masson Trichrome staining. Bars represent 250 µm. BM: bone marrow. Data represent mean±SEM.
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After bone marrow transplantation, the newly reconstituted bone marrow starts 
replacing circulating immune cells. In agreement, recipient blood cells had the antici-
pated genotypes (Figure 2A). Notably, as evident from routine hematological analysis, 
transplantation with APOA1 KO bone marrow was associated with a 1.5-fold increase in 
circulating white blood cell numbers (Figure 2B). The leukocytosis was driven by a strik-
ing 1.7-fold increase in circulating lymphocytes, since no signifi cant eff ect on monocytes 
or neutrophils was observed (Figure 2C). Subsequent fl ow cytometric analysis to identify 
figure 2: bone marrow from aPoa1 Ko 
donor mice causes lymphocytosis and 
an increase in circulating naïve T cells in 
lDlR Ko mice on WTD. (A) Representative 
samples of verifi cation of successful recon-
stitution of blood cells by donor hematopoi-
etic cells by PCR. HZ ctrl: heterozygous con-
trol. (B) Circulating white blood cell (WBC) 
numbers. (C) Circulating leukocyte subsets. 
Lympho: lymphocytes; Mono: monocytes; 
Neutro: neutrophils; Eo: eosinophils. (D) Cir-
culating B cell numbers. (E) Circulating CD4 T 
cell numbers. (F) Circulating CD8 T cell num-
bers. (G) Activation state of circulating CD4 
and CD8 T cells. Naïve: CD62LhighCD44low, 
Eff ector memory: CD62LlowCD44high, Central 
memory: CD62LhighCD44high. BM: bone mar-
row. All measurements were done at sacri-
fi ce (6 weeks WTD feeding). Data represent 
mean±SEM. *p<0.05, **p<0.01, ***p<0.001.
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specifi c leukocyte subsets revealed that APOA1 KO bone-marrow transplanted mice 
tended to have higher circulating B cell counts (p=0.18; Figure 2D), displayed a 2.8-fold 
increase in CD4 T cell counts (p<0.05; Figure 2E), and had similar circulating CD8 T cell 
levels (Figure 2F). Interestingly, in both the CD4 and CD8 T cell populations, a strong 
shift towards more naïve cells was observed as evidenced by a strong relative increase 
in naïve cells (CD4: p<0.01; CD8: p<0.001; Figure 2G).
The relatively high lymphocyte counts in blood of mice transplanted with APOA1 KO 
bone marrow were paralleled by an 1.4-fold increase of overall spleen weight (p<0.001; 
Figure 3A) and a strong 2.9-fold increase (p<0.001) in the number of splenocytes (Figure 
figure 3: bone marrow from aPoa1 Ko 
donor mice increases splenic lymphocyte 
numbers and skews T cell population to-
wards naïve T cells in lDlR Ko mice on 
WTD. (A) Spleen weight of recipient LDLR 
KO mice. (B) Splenocyte counts of recipient 
LDLR KO mice. (C) Splenic B cell numbers. (D) 
Splenic CD4 T cell numbers. (E) Splenic CD8 
T cell numbers. (F) Activation state of splenic 
CD4 and CD8 T cells. Naïve: CD62LhighCD44low, 
Eff ector memory: CD62LlowCD44high, Central 
memory: CD62LhighCD44high. (F) Splenic CD4 
T cell subsets. BM: bone marrow. All mea-
surements were done at sacrifi ce (6 weeks 




3B). As a result, spleens from APOA1 KO bone marrow-transplanted mice showed a 
strong increase in B cells, CD4 T cells, and CD8 T cell counts (Figure 3C-E). Similar as 
found in the blood, the increase in splenic CD4 and CD8 T cells was accompanied by 
a relative increase in naïve T cells (p<0.001 for both; Figure 3F). In further support of a 
relative increase in naïve T cells, APOA1 KO bone marrow-transplanted mice had lower 
percentages of splenic T helper 1 (Th1) cells, Th2 cells, and Th17 cells, while regulatory T 
cell (Treg) percentages also tended to be lower (Figure 3G).
In the adult mouse, naïve T cells are produced in the thymus 20. However, as the thy-
mus is incapable of supporting long-term self-renewal of progenitors, the thymus must 
periodically import bone marrow progenitors from the blood to maintain thymopoiesis 
throughout adult life 21–24. In both APOA1 and wild-type bone marrow-transplanted mice, 
the thymus was completely repopulated with progenitors from donor bone marrow 17 
weeks after transplantation (Figure 4A). Interestingly, APOA1 bone marrow recipient mice 
showed a striking 1.8-fold increase (p<0.001) in thymus size as compared to wild-type bone 
marrow recipients (Figure 4B). Thymus size is partly determined by the level of thymocyte 
figure 4: bone marrow from aPoa1 Ko 
mice increases thymus size and increased 
thymic bone marrow progenitor im-
migration in lDlR Ko mice on WTD. (A) 
Representative samples of verifi cation of 
successful reconstitution of thymic cells by 
donor hematopoietic cells by PCR. HZ ctrl: 
heterozygous control. (B) Thymus weight of 
recipient LDLR KO mice. (C) Relative gene 
expression of thymic apoptosis markers. (D) 
Relative gene expression of thymic bone 
marrow progenitor markers. (E) Relative 
gene expression of thymic chemoattrac-
tants. BM: bone marrow. All measurements 
were done at sacrifi ce (6 weeks WTD feed-
ing). Data represent mean±SEM. **p<0.01, 
***p<0.001.
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apoptosis 25. Transcription of thymocyte apoptosis mediators BAX and BCL2 were similar in 
APOA1 KO compared to wild-type bone marrow transplanted mice (Figure 4C), suggesting 
that a decreased apoptosis rate does not underlie the thymus hypertrophy. T cell progeni-
tors that migrate to the thymus from the bone marrow express CCR7 and CCR9 26,27. CCR7 
expression was not significantly higher in the thymus of APOA1 KO bone marrow recipi-
ents. However, APOA1 KO bone marrow-transplanted mice did display a strong significant 
increase in thymic CCR9 expression (Figure 4D), suggesting a relatively higher presence 
of newly infiltrated bone marrow progenitors in the thymus of these mice. In response 
to the presence of open thymic niches, the thymus produces the chemokines CCL21 and 
CCL25, the respective ligands of CCR7 and CCR9, to attract circulating progenitor cells 28. 
Thymic CCL21 and CCL25 gene expression is subsequently subject to negative feedback 
regulation 29. In accordance with the notion that APOA1 KO bone marrow-transplanted 
mice have a lower number of open thymic niches, probably as a result of an increased 
bone marrow progenitor influx, thymic CCL21 and CCL25 gene expression levels tended 
to decrease in APOA1 KO bone marrow-transplanted mice (Figure 4E).
Multiple bone marrow progenitors have T-lineage potential, including pluripotent 
self-renewing long-term (LT) HSCs and non-renewing, short-term (ST) HSCs, among 
which are non-renewing lymphocyte-primed multipotent progenitors (LMPPs), lym-
phoid committed common lymphoid progenitors (CLPs), and cells downstream of the 
CLP 28 (Figure 5A; bold outline). To uncover the mechanism behind the increased thymic 
seeding in APOA1 KO bone-marrow transplanted mice, we next examined the bone 
marrow from the APOA1 KO donor mice. Bone marrow from APOA1 KO mice showed 
a striking increase in Lineage- Sca+ c-KIT+ (LSK) cells as compared to that of wild-type 
controls (Figure 5B). This increase was driven by a strong increase in non-renewing ST-
HSCs (Figure 5C). To determine specific effects of APOA1 deficiency on hematopoiesis, 
several determining factors for lineage differentiation were measured. As evident from 
Figure 5D, no changes were found in genes determining differentiation towards mega-
karyocyte-erythroid progenitors, granulocyte-macrophage progenitors, monocyte and 
granulocyte lineages were found. However, we did observe a striking 6.4-fold (p<0.001) 
increase in Lyl1 expression, which is required in lymphoid specification and the main-
tenance of early T-lineage progenitors 30 (Figure 5D). Expression of Ebf-1 and MEF-2c, 
transcription factors involved in B cell differentiation were unchanged, but expression 
of Notch1, which skews lymphocyte progenitors towards the T cell lineage, tended to 
increase (+86%, p=0.07; Figure 5D). In line with an overall increased T cell progenitor 
production in the bone marrow, APOA1 KO mice had an increased thymus weight as 
compared to wild-type controls (Supplemental figure 2A). The changes in bone marrow 
hematopoiesis did not lead to differences in circulating blood cells, as APOA1 KO mice 
had similar levels of white blood cells and lymphocytes as compared to wild-type mice 




In the current study for the fi rst time evidence is provided that bone marrow from APOA1 
KO mice is characterized by altered hematopoietic lineage potential which translates 
into long term changes in immune cell production under hypercholesterolemic condi-
tions after bone marrow transplantation. We found that bone marrow of APOA1 KO mice 
figure 5: bone marrow from aPoa1 Ko mice displays increased Hsc numbers and T lineage pro-
genitor production. (A) Overview of hematopoiesis. Grey shading: LSK cells. Bold outline: potential thymic 
seeding cells. LT-HSC: long-term hematopoietic stem cell (CD34-); ST-HSC: short-term hematopoietic stem 
cell (CD34+); CMP: common myeloid progenitor; LMPP: lymphoid primed multipotent progenitor; MEP: 
megakaryocyte-erythroid progenitor; GMP: granulocyte-macrophage progenitor; CLP: common lymphoid 
progenitor; MK: megakaryocyte; Ery: erythrocyte; M: monocyte; GR: granulocyte; T: T cell; B: B cell. (B) Per-
centage of bone marrow LSK cells in wild-type and APOA1 KO mice. (C) LSK subsets. (D) Bone marrow gene 
expression of key transcription factors that determine hematopoietic lineage production. Data represent 
mean±SEM. **p<0.01, ***p<0.001.
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displayed increased numbers of short-term HSCs. A large body of evidence indicates 
that bone marrow functioning and hematopoiesis are aff ected by changes in HSC cho-
lesterol homeostasis. Feeding hypercholesterolemic LDLR KO or apolipoprotein E (APOE) 
KO mice a high cholesterol diet induces hyperproliferation of hematopoietic stem cells 
13,14. Moreover, bone marrow cholesterol accumulation due to ablated cholesterol effl  ux 
capacity through deletion of the cholesterol effl  ux transporters ABCA1 and ABCG1 is 
associated with increased HSC numbers 17. Interestingly, infusion or genetic overexpres-
sion of APOA1 can rescue this phenotype. Infusion of APOA1 into LDLR/APOA1 DKO 
mice reduced the number of LSK cells in bone marrow 31. Moreover, increased HSC num-
bers caused by combined deletion of ABCA1/ABCG1 in bone marrow could be rescued 
by transgenic overexpression of APOA1 in recipient mice 17. Together with our data, this 
suggests that APOA1 is an essential protective factor against hyperproliferation of HSCs, 
even in the absence of the major cholesterol effl  ux transporters ABCA1 and ABCG1.
The increase in HSCs in APOA1 KO mice was paralleled by lymphocytosis after trans-
plantation of the bone marrow into LDLR KO mice. In contrast, in hypercholesterolemic 
APOE KO mice, the increase in HSCs was not associated with lymphocytosis, but rather 
with monocytosis and granulocytosis 13. Similar changes in peripheral immune cell num-
bers as in APOE KO mice were found in ABCA1/ABCG1 DKO mice 17. Both APOE KO mice 
and ABCA1/ABCG1 DKO bone marrow transplanted wild-type mice display HSC choles-
terol accumulation 13,17. Interestingly, our group previously showed that transplantation 
of ABCA1 KO bone marrow into LDLR KO mice is associated with lymphocytosis 32, similar 
to what we observed in the current study after transplantation of APOA1 KO bone mar-
row into LDLR KO recipients. Both ABCA1 and APOA1 KO mice are hypocholesterolemic, 
and no studies thus far have reported bone marrow cholesterol accumulation in these 
mice. Moreover, lymphocytosis is not present in hypocholesterolemic ABCA1 or APOA1 
KO donor mice, but only occurs after transplantation to a hypercholesterolemic environ-
ment. Together, these data suggest that cholesterol accumulation in HSCs may lead to 
an increase in monocyte and granulocyte production, whereas HDL defi ciency without 
the observed bone marrow cholesterol accumulation may skew hematopoiesis towards 
lymphocyte progenitor production. Further studies on the eff ect of cholesterol load-
ing on HSC functionality and hematopoietic skewing is warranted to provide further 
mechanistic support for this hypothesis.
Several studies have described a role for APOA1 in regulation of immune cell function 
in a hypercholesterolemia-induced infl ammatory environment, especially on lympho-
cytes. Previous studies by the group of Mary Sorci-Thomas have shown that LDLR/
APOA1 DKO mice display an unusual expansion and activation of T cells in their skin 
draining lymph nodes, which eventually led to an autoimmune phenotype 6. APOA1 
also aff ects Treg plasticity and conversion to follicular T helper cells 12. In line, decreased 
concentrations of APOA1 are associated with autoimmune disorders such as systemic 
chapter 5
108
lupus erythematosus and rheumatoid arthritis in mice and humans 33–35. In the current 
study, we found a strong increase in T cell production and a corresponding increase 
in naïve T cells. However, we observed no changes in the relative amount of splenic 
Tregs and effector T cells. Moreover, no signs of skin inflammation or autoimmunity were 
observed, suggesting that these are direct effects of APOA1 deficiency in LDLR/APOA1 
DKO mice, rather than a long-term effect of APOA1 deficiency on the bone marrow. In 
accordance with this notion, a study by Wilhelm et al. showed that administration of 
APOA1 to APOA1/LDLR DKO mice resulted in a decrease in T effector to Treg ratios in the 
skin draining lymph nodes, and reduced the autoimmune phenotype in these mice 11.
In this study, the bone marrow of APOA1 KO mice displayed an increased capacity to 
repopulate the thymus after bone marrow transplantation. Previous studies have shown 
that LSK cells are the only progenitors with potent T lineage potential that normally 
circulate in adult murine blood 36. Most of these LSK cells in the blood are non-renewing 
LSKs, including LMPPs. Interestingly, when injected into the circulation, bone marrow 
LSK cells can directly seed the thymus of non-irradiated mice 37. During the procedure 
of bone marrow transplantation, lethal irradiation depletes the bone marrow, as well as 
the thymus from all proliferating cells. Upon intravenous injection of donor bone mar-
row, the thymus will be repopulated with progenitors from the bone marrow. Notably, T 
lymphocyte lineages reconstitution after bone marrow transplantation is limited by the 
availability of progenitors for thymic seeding 38.
We found that the bone marrow from APOA1 KO mice has higher levels of LSK 
progenitor cells, driven by a strong increase in non-renewing LSK cells. The observed 
parallel increase in bone marrow Lyl-1 expression suggests a concomitant stimulated 
differentiation of LSK cells towards LMPPs. In accordance with an important role for Lyl-1 
in determining LMPP differentiation and the associated rise in lymphocyte concentra-
tions in blood, Lyl1 genetic alterations predispose to acute lymphoblastic leukemia that 
is characterized by development of large numbers of immature lymphocytes 39,40. When 
considering that an increase in the amount of LMPPs is probably driving the overall 
increase in non-renewing LSK cells found in APOA1 KO mice, it is anticipated that this 
actually serves the primary underlying cause of the more potent reseeding of the thy-
mus upon transplantation of APOA1 KO bone marrow.
Despite the major changes in circulating and peripheral tissue leukocyte numbers, we 
observed no changes in diet-induced atherosclerosis development. It thus appears that 
the observed change in bone marrow functionality and possible associated effects on 
immune cell numbers/activation do not underlie the increased atherosclerosis suscep-
tibility seen in hypercholesterolemic APOA1 KO mice. This indicates that the increase 
in atherosclerosis development found in APOA1/LDLR DKO mice is likely caused by a 
combination of decreased reverse cholesterol transport and reduced anti-atherogenic, 
anti-inflammatory effects of APOA1.
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In conclusion, our studies show that a genetic lack of APOA1 modulates the bone 
marrow compartment in such a way that it predisposes to the development of naïve 
T cells from the thymus, leading to lymphocytosis. Furthermore, our studies suggest 
that the effect of APOA1 deficiency on bone marrow does not underlie the increased 
atherosclerosis susceptibility associated with global APOA1 deficiency. Moreover, our 
studies provide additional support for our working hypothesis, generated through the 
use of hypercholesterolemic donor mice 16, that the effect of specific interventions on 
bone marrow stem cells can generate a long-term and transplantable impact on hema-
topoiesis.
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sUPPleMenTaRY DaTa
supplemental table 1: flow cytometry antibodies
Marker fluorochrome clone supplier
cD105 PE-CF594 MJ7/18 BD Biosciences
cD117 (c-KIT) APC 2B8 eBioscience
cD11b FITC M1/70 eBioscience
cD11b PE M1/70 eBioscience
cD11c perCP-Cy5.5 N418 Biolegend
cD19 FITC MB19.1 eBioscience
cD19 PE-Cy7 1D3 eBioscience
cD19 BV 605 6D5 Biolegend
cD3 FITC 145-2C11 eBioscience
cD3 epsilon V500 500A2 BD Horizon
cD34 Pacific Blue RAM34 eBioscience
cD4 FITC GK1.5 Biolegend
cD4 PerCP RM4-5 BD Pharming
cD4 V500 RM4-5 BD Horizon
cD44 PE-Cy7 IM7 eBioscience
cD45 Alexa Fluor 700 30-F11 Thermo Fisher Scientific
cD45 Alexa Fluro 700 30-F11 Biolegend
cD62l APC MEL-14 eBioscience
cD8a FITC 53-6.7 eBioscience
cD8a PE-Texas Red 5H10 Thermo Fisher Scientific
cD8a Alexa Fluor 750 53-6.7 eBioscience
f4/80 FITC BM8 eBioscience
foxp3 eFluor 450 PCH101 Thermo Fisher Scientific
GaTa-3 PE TWAJ eBioscience
Ki-67 FITC SolA15 eBioscience
ly6a/e (sca-1) PE Sca-1 E13-161.7 BD Pharming
ly6c PE-CF594 AL-21 BD Biosciences
ly6G FITC RB6-8C5 eBioscience
ly6G BV 421 1A8 Biolegend
nK1.1 APC PK136 Thermo Fisher Scientific
nK1.1 FITC PK136 BD Pharming
RoRγt Brilliant Violet 650 Q31-378 BD Biosciences
T-bet PE-Cy7 eBio4B10 eBioscience
TeR-119 FITC TER-119 eBioscience
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supplemental fi gure 1: Verifi cation of successful reconstitution of bone marrow. Representative sam-
ples of verifi cation of successful reconstitution of bone marrow by donor hematopoietic cells by PCR. BM: 
bone marrow. HZ ctrl: heterozygous control.
supplemental fi gure 2: aPoa1 Ko mice have normal white blood cell and lymphocyte counts. (A) 
Thymus weight of wild-type and APOA1 KO mice. (A) Circulating white blood cell (WBC) counts in wild-type 
and APOA1 KO mice. (C) Circulating lymphocyte counts in wild-type and APOA1 KO mice. Data represent 
mean±SEM. *p<0.05.
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Atherothrombotic events such as myocardial infarction and ischemic stroke are a major 
cause of morbidity and mortality worldwide. Understanding the molecular and cellular 
mechanisms of atherosclerotic plaque destabilization or erosion, and developing new 
therapeutics to prevent acute cardiovascular events are important points for vascular bi-
ology research and clinical cardiovascular medicine. However, basic research on plaque 
destabilization, rupture and erosion, is hampered by the lack of appropriate animal 
models of atherothrombosis. Unprovoked atherothrombosis is very scarce in commonly 
used mouse models for atherosclerosis, the low-density lipoprotein receptor knockout 
and apolipoprotein E knockout mice. Therefore, specific interventions are required to 
induce atherothrombosis in these models. Two strategies can be employed to induce 
atherothrombosis: 1) plaque destabilization and 2) induction of blood hypercoagula-
bility. Although the individual strategies yield atherothrombosis at low incidence, it 
appears that the combination of both plaque destabilization and an increase in blood 
coagulability is the most promising strategy to induce atherothrombosis on a larger 
scale. In this review we summarize the recent developments on mouse models for the 
investigation of atherothrombosis.
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InTRoDUcTIon
Acute cardiovascular events, caused by atherosclerosis and subsequent superimposed 
thrombus formation after plaque rupture or superficial erosion of the overlying endo-
thelium1,2, are a major cause of morbidity and mortality worldwide. Understanding the 
molecular and cellular mechanisms of atherosclerotic plaque destabilization or erosion, 
and developing new therapeutics to prevent acute cardiovascular events are important 
points for vascular biology research and clinical cardiovascular medicine. However, even 
after decades of extensive research into the pathophysiology of atherosclerosis, predict-
ability of which plaques will progress to atherothrombosis, and when, still remain largely 
elusive. Major advances in the prevention of acute cardiovascular events will require 
early detection of rupture- and erosion-prone plaques. However, basic research on 
plaque destabilization, rupture and erosion, and superimposed thrombus formation is 
hampered by the lack of appropriate animal models of spontaneous atherothrombosis. 
In this review, we summarize the recent development of and use of mouse models for the 
investigation of plaque vulnerability, atherothrombosis and acute cardiovascular events.
MURIne MoDels of aTHeRoscleRosIs
Murine models of atherosclerosis are widely used in basic research to study the mo-
lecular mechanisms underlying the development of atherosclerosis and potential thera-
peutic strategies to inhibit plaque progression and even stimulate plaque regression. 
Genetically engineered mice with disorders of lipid metabolism, develop spontaneous 
atherosclerosis, which can be accelerated by feeding the mice a high cholesterol diet. 
By far the most commonly used mouse models for atherosclerosis are Apolipoprotein 
E (ApoE) knockout and low-density lipoprotein receptor (LDLr) knockout mice, which 
were both first described to develop hypercholesterolemia and atherosclerosis in the 
early 1990s 3–5. One of the first arterial region where these mice develop atherosclerotic 
plaques is the tricuspid aortic valve area of the aortic root, and this area is therefore of-
ten used as a standard for the quantification of atherosclerotic burden 6. Moreover, rapid 
spontaneous atherosclerosis development occurs in the coronary arteries and along the 
entire aorta at branch points of major arteries in ApoE knockout mice 3,4,7–9. Another 
approach to stimulate the onset of atherosclerosis in ApoE or LDLr knockout mice is by 
placing an external silastic collar around the carotid artery, which results in rapid athero-
sclerotic plaque development proximal of the collar 10. The particular advantage of this 
technique is that, in contrast to the aortic and coronary artery, atherosclerotic plaques 
develop at a site that is very easily accessible to local manipulation and visualization. The 
plaques that develop in ApoE and LDLr knockout models are reproducible in size and 
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composition, and have architectural features reminiscent of human plaques. However, 
these models were not specifically developed to study atherothrombosis.
aTHeRoTHRoMbosIs anD VUlneRabIlITY of THe PlaQUe
The concept of the vulnerable plaque and risk for developing atherothrombosis is de-
duced from early postmortem pathological studies in human cases of fatal coronary ath-
erothrombosis. These studies showed that plaques prone to rupture and superimposed 
thrombus formation are typically characterized by a thin fibrous cap, a large lipid core, 
and a relative abundance of inflammatory leukocytes 11. In these studies, the rupture 
of these so-called vulnerable plaques was found to be the cause of the acute coronary 
event in the majority of cases.
In the commonly used ApoE knockout mouse model plaque rupture only occurs after 
prolonged feeding with very high-cholesterol diets. One study that aimed to retro-
spectively quantify spontaneous atherothrombosis in intervention studies with ApoE 
knockout mice found aortic plaque rupture and/or thrombi in only 3 out of 82 untreated 
mice (aged 9-12 months) fed various cholesterol-enriched diets for up to 6 months 12. 
Moreover, screening the hearts of 33 older ApoE knockout mice (age 9-20 months) 
showed extensive atherosclerosis in one or more coronary arteries of 18 animals, 3 of 
which with blood-filled channels inside the plaques 12. This suggests the occurrence of 
previous plaque disruption/thrombotic events followed by recanalization. In the aortic 
root of these mice, 4 deep plaque ruptures (or erosions reaching necrotic core areas) 
and a large thrombus originating from the core of a disrupted atherosclerotic plaque 
were observed 12. Although this study comprised a limited sample size, it is indicative of 
the scarcity of spontaneous atherothrombotic events and highlights the need for better 
mouse models to study this phenomenon.
The brachiocephalic artery is a short communicating vessel originating at the 
aortic arch, that bifurcates into the right common carotid and right subclavian arter-
ies. In ApoE knockout mice (C57Bl/6 background) aged 42-54 weeks fed a standard 
chow diet, intraplaque hemorrhage was found in the brachiocephalic artery in 75% 
of the animals  13. Moreover, there was fibrotic conversion of necrotic zones and loss 
of the fibrous cap 13. However, no plaque rupture, erosion or thrombi were observed. 
Another study reported that of 11 ApoE knockout mice fed a diet supplemented with 
21% lard and 0.15% cholesterol for up to 14 months, 8 mice died after 37–59 weeks 
of diet feeding. Luminal thrombi associated with atherosclerotic plaque rupture were 
observed in 7 of these mice, in 6 of which an atherosclerotic plaque rupture was found 
in the  brachiocephalic artery  14. More recently, this model was developed further by 
outbreeding the ApoE knockout mice to a mixed C57Bl/6 and 129 background (71% 
Mouse models for spontaneous atherothrombosis
121
and 29% respectively). These mice developed pronounced atherosclerotic plaques in 
the brachiocephalic artery after only 5 weeks challenge with a high-fat/high-cholesterol 
diet 15. The plaques displayed a high lipid content and a relatively thin fibrous cap, and 
were thereby very similar to vulnerable plaques in coronary arteries of human patients 
suffering from cardiovascular disease. Most importantly, plaques in the brachiocephalic 
artery of this mixed-background ApoE knockout model showed signs of acute plaque 
rupture (62% at 8 weeks diet-feeding) with thinning and discontinuity of the fibrous 
cap and intrusion of blood into the plaque 14,15. Moreover, the plaques also displayed a 
high incidence of buried fibrous caps, suggestive of prior silent plaque rupture, making 
the model specifically pertinent of the human vulnerable plaque 16,17. However, in none 
of the models, there is convincing evidence of the formation of platelet and fibrin-rich 
occlusive thrombi at the site of presumed rupture, which is characteristic of the human 
plaque rupture leading to coronary heart disease and stroke. Therefore, in order to study 
this phenomenon in mice, various methods have been explored to provoke this event.
Collar-induced atherosclerotic plaques in the carotid arteries of mice are easily ac-
cessible for local manipulation. In one model described by Von der Thüsen et al in 2001 
atherosclerotic plaques, induced by placement of a perivascular silastic collar, were 
locally incubated with a recombinant adenovirus carrying the apoptosis promoting pro-
tein p53 into the temporarily ligated artery 18. One day following transfection, increased 
apoptosis is evident in the cells of the fibrous cap, while cap thinning was observed at 
later timepoints. Although thinning of the fibrous caps upon p53 transfection induced 
plaque rupture in 40% of the animals, upon challenge with the vasopressor phenyleph-
rine, no spontaneous atherothrombosis was observed 18.
Another model used a different type of carotid artery ligation, in which the left com-
mon carotid arteries of male ApoE knockout mice were ligated just proximal to their 
bifurcations 19. Ligation of the carotid artery in ApoE knockout mice after 4 weeks on a 
chow diet induced marked intimal hyperplasia, which is a lipid- and collagen-rich plaque 
that contains a number of macrophages, T lymphocytes, and smooth muscle cells. At 4 
weeks after ligation, the mice received polyethylene cuff placement just proximal to 
the ligated site. Cuff placement evoked intraplaque hemorrhage and plaque rupture, 
accompanying a decrease in collagen content. At 4 days after cuff placement, plaque 
rupture associated with fibrin(ogen)-positive thrombus formation in the lumen was 
detected in 63% of plaques 19. Together, these studies suggest that initiation of plaque 
vulnerability may be a good strategy to induce atherothrombosis.
As indicated above, the concept of the vulnerable plaque is widely used in the car-
diovascular field. However, this concept is largely based on findings in postmortem 
pathological studies, which are essentially retrospective. It is important to be aware that 
these studies did not consider the amount of plaques with morphological characteris-
tics associated with vulnerability that did not cause fatal cardiovascular events. Plaques 
chapter 6
122
with vulnerability characteristics often are asymptomatic, and seldom cause events due 
to rupture, debating the inevitable nature of the vulnerable plaque-concept 20,21.
Fatal cardiovascular events can also be the consequence of superficial erosion of the 
plaque 11,22. In contrast to plaques associated with plaque rupture, eroding plaques with 
superimposed thrombi do not have thin fibrous caps, large lipid pools and abundant 
inflammatory cells 23. Interestingly, over the past decade, there has been a shift in the 
morphology of human atherosclerotic plaques. Plaques obtained from patients with 
symptomatic carotid artery disease in recent years show significantly more fibrous, non-
inflammatory characteristics. This trend is also visible in asymptomatic patients 24–26. 
Possibly, this shift in plaque characteristics could lead to a subsequent shift in plaque 
rupture versus erosion occurrence 27,28. More studies that delve into the causes of hu-
man atherothrombotic events are therefore warranted and of vital importance to the 
development of a representative spontaneous animal model.
aTHeRoTHRoMbosIs anD VUlneRabIlITY of THe blooD
Species differences in anticoagulation could contribute to the low atherothrombosis 
susceptibility of mouse models. The half-life of active coagulation factor IIa in mouse 
plasma is significantly shorter as compared to its human counterpart, pointing towards 
more potent natural anticoagulation in mice29. Therefore, besides manipulation of 
plaque stability and/or erosion, another strategy to induce spontaneous atherothrom-
bosis is by increasing the coagulability of the blood.
Mice carrying a null mutation of a gene regulating intracellular cholesterol transport 
(the Niemann-Pick C1 (Npc1) gene, BALB background) that were crossed with ApoE 
knockout (C57BL/6J background) mice developed large, protruding thrombi associated 
with the plaques in 24% (6 of 26) of the mice 30. These thrombi were formed primarily 
on the surface of atherosclerotic plaques with loss of the endothelial monolayer at the 
plaque-thrombus interface. Genetic studies suggested that the ~25% BALB background 
was permissive for plaque complications compared with the commonly used C57BL/6J 
background. Moreover, increased thrombin generation was indicated by a significant 
elevation in mean thrombin-antithrombin levels in the double-mutant mice compared 
with controls. Together, these data suggested that the double-mutant mice harbor a 
procoagulant state. Moreover, the combination of the underlying prothrombotic state 
and Npc1 deficiency-related plaque vulnerability led to atherothrombosis in the double-
mutant mice, albeit at low incidence 30.
We have recently published a proof-of-principle study in which we showed that tran-
sient (7 days) siRNA mediated lowering of the natural anticoagulant protein C in athero-
sclerotic ApoE knockout mice induced large, organized, and fibrin- and leukocyte-rich 
Mouse models for spontaneous atherothrombosis
123
thrombi on top of advanced atherosclerotic plaques in the aortic root 31. Although the 
incidence of atherothrombosis was low (14%), it is the first report of provoked spontane-
ous atherothrombosis in the aortic root. In a second study, we investigated if plaque 
characteristics or circulating factors could be linked to atherothrombosis susceptibil-
ity. Moreover, we aimed to increase the incidence of atherothrombosis by transiently 
increasing blood pressure, and to direct atherothrombosis to an additional predefined 
vascular site by placement of a perivascular silastic collar around the carotid artery 32. 
Spontaneous atherothrombosis in the aortic root of protein C-targeted siRNA-treated 
ApoE knockout mice was reproduced and occurred at an incidence of 23%, while the 
incidence of collar-induced atherothrombosis in the carotid artery was only 2.6%. 
Treatment with phenylephrine, to transiently increase blood pressure, did not increase 
the incidence of atherothrombosis in the aortic root of the ApoE knockout mice, nor in 
the carotid arteries with collars. Plaques in the aortic root with an associated thrombus 
were lower in collagen and macrophage content, and mice with atherothrombosis had 
significantly more circulating platelets. Remarkably, our data revealed that thrombus 
formation preferentially occurred on plaques in the right coronary sinus of the aortic 
root. The identification of factors that drive the predilection for the right coronary sinus 
may provide novel clues on factors that drive atherothrombosis in mice and humans.
Another strategy focused on disruption of the protein C pathway was described by 
Borissoff et al in 2013. They used a model in which ApoE knockout mice had a muta-
tion in the thrombomodulin gene, resulting in diminished trombomodulin-dependent 
generation of activated protein C33. The collar-induced carotid artery plaques of these 
mice had large necrotic cores and a decreased collagen content, resulting in thin fibrous 
caps. Moreover, carotid artery plaques from these mice tended to rupture and dissect in 
both a nonocclusive phase, leading to non-occlusive thrombus formation, as well as in 
more advanced stages, leading to full occlusion of the artery by thrombosis. Also, strong 
evidence of buried caps was found, indicating multiple consecutive plaque ruptures, 
similar as in the human situation. Unfortunately, the percentage of plaques that pro-
gressed to atherothrombosis in the carotid artery, nor indications of atherothrombosis 
in the aorta or aortic root were mentioned in the paper.
In a study by Liu and colleagues published in 2015, it was shown that the best strat-
egy to induce atherothrombosis is to use a combination of factors that destabilize the 
plaque together with augmentation of blood coagulability. In this study ApoE knockout 
mice that overexpress thrombin were exposed to long term restraint stress, which led 
to atherothrombosis in collar-induced carotid artery plaques of 70% of the animals 34. 
Moreover, pathohistological examination revealed that many of the atherothrombotic 
plaques were associated with both fresh and organized thrombi, indicating that they 
had undergone plaque disruption more than once, thereby showing considerable 
similarity to human coronary plaques. Finally, thrombosis was substantially reduced by 
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dual antiplatelet therapy, suggesting that this model may be useful in preclinical drug 
development.
conclUsIons anD PeRsPecTIVes
In summary, two strategies can be employed to induce atherothrombosis: plaque de-
stabilization and/or erosion and induction of blood hypercoagulability. Although the 
single use of both strategies yields atherothrombosis at low incidence, it appears that 
a combination of plaque destabilization and an increase in blood coagulability is the 
most promising strategy to induce atherothrombosis on a larger scale (Table 1). Efforts 
in developing new models for atherothrombosis should therefore be aimed at targeting 
both parameters. Importantly, caution is warranted in the interpretation of studies that 
describe loss of collagen and increase in plaque macrophages as markers for plaque vul-
nerability, in the context of models that do not develop spontaneous atherothrombosis. 
Further studies in mouse models that do develop atherothrombosis should provide the 
proof for the predictive power of these vulnerability markers in mice.
Table 1: Mouse models of spontaneous atherothrombosis.
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Silencing of anticoagulant protein C 
evokes low-incident but spontaneous 
atherothrombosis in apolipoprotein 
E-deficient mice




Murine atherosclerosis models do not spontaneously develop atherothrombotic com-
plications. We investigated whether disruption of natural anticoagulation allows pre-
existing atherosclerotic plaques to progress towards an atherothrombotic phenotype. 
Upon lowering of plasma protein C levels with small interfering (si) RNA (siProc) in 8 
weeks Western-type diet (WTD) fed atherosclerotic apolipoprotein E deficient (Apoe-/-) 
mice, one out of four mice displayed a large, organized, and fibrin- and leukocyte-rich 
thrombus on top of an advanced atherosclerotic plaque located in the aortic root. Al-
though again at low incidence (3 in 25), comparable thrombi at the same location were 
observed during a second independent experiment in 9 weeks WTD-fed Apoe-/- mice. 
Mice with thrombi on their atherosclerotic plaques did not show other abnormalities 
and had equally lowered plasma protein C levels as siProc treated Apoe-/- mice without 
thrombi. Fibrinogen and thrombin-antithrombin concentrations and blood platelet 
numbers were also comparable, and plaques in siProc mice with thrombi had a similar 
composition and size as plaques in siProc mice without thrombi. 7 out of 25 siProc mice 
featured clots in the left atrium of the heart. Our findings indicate that siRNA-mediated 
silencing of Proc in Apoe-/- mice creates a condition that allows the occurrence of spon-
taneous atherothrombosis, albeit at a low incidence. Lowering natural anticoagulation 
in atherosclerosis models may help to discover factors that increase atherothrombotic 
complications.
Atherosclerosis Atherothrombosis 
siRNA targeting protein C 
in Apoe  knockout mice 
Graphical abstract. Silencing of anticoagulant protein C evokes low-incident but spontaneous athero-
thrombosis in Apoe-/- mice.
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InTRoDUcTIon
Atherothrombosis, characterized by superimposed luminal thrombus formation on a 
ruptured or eroded atherosclerotic plaque, is a major cause of acute coronary syndromes 
and cardiovascular death in humans1. Pathological changes of the atherosclerotic 
plaque, such as thinning of the fibrous cap and the development of a large necrotic 
core, are known to make the plaque prone to rupture, and thereby expose triggers for 
thrombosis2.
Murine models of atherosclerosis, such as hyperlipidemic apolipoprotein E deficient 
(Apoe-/-) mice, have been instrumental to study atherosclerosis pathophysiology and 
the search for highly needed novel therapeutic targets. However, in these murine mod-
els the final stage of atherosclerosis i.e plaque rupture and the subsequent induction 
of atherothrombosis, does not occur spontaneously. Factors suggested to underlie the 
absence of spontaneous atherothrombosis include resistance of murine plaques to 
rupture, because of a different plaque composition, and differences in hemodynamics3. 
Moreover, species differences in anticoagulation could contribute to the absence of 
progression to atherothrombosis in mice. The half-life of active coagulation factor IIa in 
mouse plasma is significantly shorter as compared to its human counterpart, pointing 
towards more potent natural anticoagulation in mice4. In line, atherosclerotic plaques in 
hyperlipidemic mice with impaired hemostasis revealed markers of thrombotic events 
in carotid artery plaques5,6.
In the present study, we tested whether small interfering (si) RNA-mediated lowering 
of natural anticoagulants antithrombin (Serpinc1) and protein C (Proc) in Apoe-/- mice 
allowed plaques to progress towards an atherothrombotic phenotype. We found that 
lowering of Proc evokes low incident spontaneous atherothrombosis in Apoe-/- mice.
MaTeRIals anD MeTHoDs
Mice
All mice used in this experiment have the Apoetm1Unc mutation and were originally ob-
tained from Jackson Laboratories (Bar Harbour (MA) USA) on a C57BL/6J background 
(catalogue nr. 002052), and were inbred in house at the Gorlaeus Laboratories (Leiden, 
the Netherlands). All animal experiments were performed in accordance with the na-
tional guidelines for animal experimentation. All experimental protocols were approved 
by the Ethics Committee for Animal Experiments of either Leiden University or the 




Female Apoe-/- mice (C57BL/6J background, 6 weeks old, n=9 per group) were fed a 
Western-Type diet (WTD; Special Diet Services, Sussex, UK) for 2 weeks to exacerbate 
hyperlipidemia, followed by an intravenous injection (tail vein) with 5 mg/kg synthetic 
siRNAs (Ambion, Life Technologies, Carlsbad (CA), USA) targeting Serpinc1 (siSerpinc1, 
cat. #S62673) or Proc (siProc, cat. #S72192), or control siNEG (cat. #4404020), complexed 
with Invivofectamine 2.0 (Life Technologies) as described previously7. Mice were sacri-
ficed at 3 and 7 days post siRNA injection by anesthesia with a subcutaneous injection 
with a mixture of ketamine (100 mg/kg), xylazine (12.5 mg/kg) and atropine (125 µg/kg), 
followed by exsanguination and in situ perfused with PBS after which the heart, liver, 
lungs, spleen, and aorta were collected. Organs were either snap frozen or fixed for 24 h 
in 3.7% neutral-buffered formalin (Formal-Fixx, Shandon Scientific Ltd, UK) for analysis.
Experiment 2
Female Apoe-/- mice (4 weeks old, n=4 per group) were fed a WTD for 8 weeks to induce 
atherosclerotic plaque development, followed by an intravenous injection (tail vein) 
with 8 mg/kg siProc, Serpinc1, or control siNEG. Mice were sacrificed 2 days post siRNA 
injection as described above, after which blood and organs were collected and snap 
frozen or formalin-fixed for analysis.
Experiment 3
Female Apoe-/- mice (4-7 weeks old) were fed a WTD for 9 weeks to induce atheroscle-
rotic plaque development, followed by an intravenous injection (tail vein) with 8 mg/
kg siProc (n=25) or control siNEG (n=3). Mice were sacrificed 7 days post siRNA injection 
as described above, after which blood and organs were collected and snap frozen or 
formalin-fixed for analysis.
blood and plasma analysis
For the analysis of plasma (anti)coagulation proteins, a blood sample on sodium citrate 
(final concentration 0.32%) was drawn from the inferior caval vein upon sacrifice. Plasma 
was obtained by centrifugation and stored at −80°C until further use. Plasma protein C 
levels were determined using a polyclonal sheep anti-murine antibody (Haematologic 
Technologies Inc. Essex Junction (VT), USA). Plasma fibrinogen antigen levels were as-
sessed with a commercial murine ELISA kit from Affinity Biologicals (Ancaster (ON), 
Canada). Thrombin-antithrombin levels were determined exactly according to the 
manufacturer’s protocol (Siemens Healthcare, Frederick (MD), USA).
After blood sampling from the inferior caval vein, the mice were exsanguinatated via 
orbital bleeding. Orbital blood was collected in EDTA-coated tubes. Whole blood cell 
and platelet counts were analyzed using an automated XT-2000iV veterinary hematol-
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ogy analyzer (Sysmex Europe GMBH, Norderstedt, Germany). Plasma from the orbital 
bleeding-obtained blood was attained by centrifugation and stored at −20°C until fur-
ther use. Plasma total cholesterol levels were measured by enzymatic colorimetric assay 
(Roche diagnostics, Almere, The Netherlands).
Hepatic gene expression analysis
siRNA-mediated hepatic silencing of Serpinc1 and Proc silencing was routinely confirmed 
using quantitative PCR, with Actb as a reference gene8.
Histology and immunohistochemistry
Formalin-fixed hearts were embedded in Sakura O.C.T. Compound™ (Sakura Finetek Eu-
rope B.V., Alphen aan de Rijn, The Netherlands), for sectioning. Serial sections (10 μm, 70 
μm interval) of the aortic root were cut using the Leica CM3050S cryostat and routinely 
stained with hematoxylin and eosin for general histology. Plaque size per valve was de-
termined by staining for neutral lipids using Oil-Red-O and hematoxylin (Sigma-Aldrich, 
Zwijndrecht, The Netherlands). Corresponding sections were stained for collagen fibers 
using the Masson’s Trichrome methods (Sigma-Aldrich). To determine the macrophage 
positive area, corresponding sections were immunohistochemically stained for CD68 
(rat monoclonal anti-CD68 antibody 1:1000, AB53444, Abcam, Cambridge, UK). A goat 
α-rat alkali phosphatase antibody (1:100, A8438-1ML, Sigma-Aldrich) was used as sec-
ond antibody. The sections were developed using ready-to-use substrate solution (BCIP/
NBT Substrate system, code K0598, Dako, Heverlee, Belgium). Necrotic core area was 
determined as non-stained area within the atherosclerotic plaques. The percentage of 
collagen, macrophages and necrotic core in the plaques was determined by dividing the 
collagen- or CD68-positive or non-stained area by the total plaque surface area. All im-
ages were analysed by blinded computer aided morphometric analysis using the Leica 
DM-RE microscope and LeicaQwin software (Leica Ltd, Cambridge, UK).
Martius Scarlett Blue staining (Atom Scientific, Manchester, UK) was performed as 
described by the manufacturer, with the exception of staining with Methyl Blue. Step 
involving Methyl Blue was excluded, enabling a brighter and more specific signal for the 
red-stained fibrin.
The aorta, liver, kidney, and lung were sectioned using Leica RM2235 microtome at 
4 μm with an 36 μm interval for the aorta and 8 μm with an 40 μm interval for other 
organs. Serial sections were routinely stained with hematoxylin and eosin for general 
histology.
Data analysis
Statistical analysis was performed using Graphpad Instat (GraphPad Software, La Jolla 
(CA), USA). The significance of the differences was calculated using a non-parametric 
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Mann-Whitney U test. Probability values <0.05 were considered significant. All data are 
presented as median and range. Descriptive statistic and calculate proportions of the 
observations and the 95% confidence intervals (Wilson-score) were calculated using re-
sources provided by the Open Source Epidemiologic Statistics for Public Health website: 
www.openepi.com/proprotions).
ResUlTs
Mouse (C57BL/6J) hepatic Serpinc1 and Proc expression can be effectively lowered using 
specific siRNAs7. To investigate whether this siRNA approach also allowed successful 
downregulation of both anticoagulants in a hyperlipidemic background, Apoe-/- mice 
fed a Western-type diet (WTD) for 2 weeks were injected with siSerpinc1, siProc, or 
siNEG (9 mice per group) and monitored for 7 days (experiment 1; median plasma total 
cholesterol levels 7.2 mg/mL (range: 4.4-12.7)) (supplemental figure I). Within 4 days 
after siRNA injection, several siSerpinc1 mice demonstrated lethargy, weight loss (1.5 g 
(0.1-2.4)), exophthalmos, periocular hemorrhages, and swelling of the mandibular area. 
Two mice died within this time frame. This phenotype has been described before in wild 
type C57BL/6J mice treated with siSerpinc1 and siProc, and is likely spontaneous venous 
thrombosis7. In contrast to the siSerpinc1 group, all WTD-fed Apoe-/- mice that received 
only siProc remained grossly healthy for up to 7 days. Liver transcript analysis showed 
that the siSerpinc1 mice had a Serpinc1 transcript level of 6.0% (4.4-11.4; day 3; n=3) of 
the level in siNEG mice and 3.4% (3.2-3.7; n=3) compared to non-siRNA treated mice. 
Proc transcript levels in the siProc mice were 21.2% of siNEG (17.3-27.5; day 7; n=4) and 
10.7% (3.8-17.4, n=3) of non-siRNA treated mice.
To investigate whether inhibition of anticoagulation affects the atherosclerotic phe-
notype, Apoe-/- mice were fed WTD for 8 weeks to induce advanced atherosclerosis in 
the aortic root, prior to siSerpinc1 or siProc treatment. In this experiment (experiment 2; 
4 mice per group; siSerpinc1, siProc, and siNEG), mice were sacrificed 2 days after siRNA 
injection, which enabled us to include also siSerpinc1 treated mice to study the impact 
on the atherosclerotic phenotype. Moreover, the siRNA dosage was increased to achieve 
a higher knockdown of Proc. Already within 2 days, one mouse in the siSerpinc1 group 
demonstrated the characteristic venous thrombotic coagulopathy, while siProc and siNEG 
mice again remained healthy. Histological analysis of the head, heart, kidneys, lungs, and 
liver of the remaining healthy siSerpinc1 mice revealed no abnormalities (including no 
signs of coagulopathy). The early onset of spontaneous venous thrombosis in Apoe-/- 
mice precluded studies using siSerpinc1 to inhibit Serpinc1 for a longer time period.
Upon histological analysis, siProc and siNEG mice appeared identical to the healthy 
siSerpinc1 mice. However, one mouse in the siProc group revealed an organized and 
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large structure superimposed on one of the advanced atherosclerotic plaques in the 
aortic root, which was identifi ed as a fi brin-positive thrombus (Martius Scarlet staining, 
fi gure 1). The thrombus consisted of layers of eosin positive-structures, and was infi l-
trated by leukocytes typically at the luminal side. Serial sections demonstrated that this 
thrombus was superimposed on the plaque for at least 320µm (supplemental fi gure II).
Although at a low incidence, the presence of an organized and large thrombus super-
imposed on an aortic root atherosclerotic plaque is unique and has, to our knowledge, 
not been reported before. To investigate the reproducibility of this fi nding, 25 mice were 
treated solely with siProc (experiment 3). Silencing of Proc for 7 days in atherosclerotic 
Apoe-/- mice was again well-tolerated and no (macroscopic) abnormalities were seen. 
Importantly, 3 mice had organized and large fi brin-rich thrombi superimposed on 
atherosclerotic plaques in the aortic roots, with a similar size and composition as in 
experiment 2 (fi gure 1). Combining this result with experiment 2, a total of 4 out of 29 
mice in 2 independent experiments showed atherothrombosis, resulting in a proportion 
of 13.8% with 95% confi dence limits of 5.5%-30.5%).
Longitudinal sections of the aorta (arch, abdominal, and descending) demonstrated 
limited advanced atherosclerotic plaques at this location. In one mouse (out of 25), we 
observed Martius-Scarlett positive structures (indicative for fi brin) within an advanced 













Experiment 2 Experiment 3 
Reference siProc plaque 
without thrombus 
figure 1: siRna-mediated inhibition of plasma protein c causes atherothrombosis in the aortic root 
in apoe-/- mice. Microhistological images of aortic root atherothrombosis in Apoe-/- mice fed WTD for 8 
weeks (1/4 mice; experiment 2) and 9 weeks (3/25 mice; experiment 3). Reference plaque without throm-
bus from siProc mouse from experiment 3. Top 2 rows: Hematoxylin and eosin staining; bottom row: Mar-
tius Scarlet staining (red is indicative for fi brin). t = thrombus.
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spleen, and liver of all siProc mice were subjected to detailed microscopic analysis and 
did not exhibit any abnormalities or signs of thrombosis. Of note, in 7 out of 25 siProc 
treated mice the left atrium of the heart featured clots (28% with 95% confi dence limits 
of 14.3%-47.6%), composed of fi brin (red) and erythrocytes (green/yellow) without a 
thrombus-like layered organization (Martius Scarlet staining, supplemental fi gure IV).
The three mice with an atherosclerotic plaque-associated thrombus had comparable 
knockdown of plasma protein C compared to siProc mice without such features (10.1% 
(4.4-16.5) vs. 9.7% (7.6-10.2) of normal pool plasma; p=0.87; fi gure 2A). In addition, for 
the mice with and without plaque-associated thrombosis blood platelets numbers, 
plasma fi brinogen, and thrombin-antithrombin levels were comparable and in the nor-
mal range (fi gure 2B-2D), indicating that the atherothrombotic events in the aortic root 
did not coincide with, or are part of, a consumptive coagulopathy. Furthermore, plaques 
with a superimposed thrombus were of similar size and composition (collagen, necrotic 
core and CD68-positive area, fi gure 2E-H) as plaques without a thrombus.
figure 2: blood coagulation parameters and atherosclerotic plaque characteristics of siProc-treated 
WTD-fed apoe-/- mice without aortic root atherothrombosis are not signifi cantly diff erent compared 
to mice and plaques with atherothrombosis. (A) Residual plasma protein C levels, (B) Blood platelets, (C) 
Plasma fi brinogen levels, (D) Plasma thrombin-antithrombin complex levels, (E) Plaque size per aortic valve, 
(F) Collagen area as a percentage of total plaque size, (G) Necrotic core area as a percentage of total plaque 
size, (H) Macrophage (CD68 positive) area as a percentage of total plaque size. Lines represent medians. 
Grey zones in panels represent median and range of 2-9 weeks WTD-fed Apoe-/- siNEG mice (panels A-D, 
n=9-11) and 9 weeks WTD-fed Apoe-/- siNEG mice (panels E-H, n=4-5). nnp = normal pool plasma.
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DIscUssIon
In the present study we have demonstrated that silencing the natural anticoagulant 
Proc in Apoe-/- mice evokes low incidence atherothrombosis in the aortic root. While 
our brief report was reviewed, data from another independent mouse experiment be-
came available, again showing the unique spontaneous, low incident atherothrombosis 
phenotype in the aortic root of Apoe-/- mice after Proc silencing (25%), highlighting that 
our original observations are reproducible. Our findings concur with other studies in 
which atherosclerotic plaques in hyperlipidemic mice with a stronger coagulation or an 
impaired anticoagulation were positive for markers of thrombotic events5,6. Altogether, 
these data indicate that a strong natural anticoagulation system protects mice against 
atherothrombosis. For now, the low incidence of low protein C-associated atherothrom-
bosis precludes (1) detailing the mechanism why some mice and/or some plaques trigger 
thrombosis formation and (2) using the current concept as a mouse model for validating 
anti-atherothrombotic drugs and/or genes. We speculate that, similar as in humans, the 
plaques that are associated with atherothrombosis in low protein C mice are those that 
have a thin fibrous cap, demonstrate plaque erosion and/or are highly inflamed. Possible 
ways to increase the incidence of atherothrombosis may be to study the effects of siProc 
treatment in mice with even more advanced atherosclerosis, or introduce a “second hit” 
which is thought to predispose to atherothrombosis (e.g. higher blood pressure, stress, 
genetic modifications). Future studies should clarify this.
Lowering antithrombin resulted in a phenotype suggestive of spontaneous venous 
thrombosis, which was unexpected given studies in normal C57BL/6 mice7, but no 
atherothrombosis. Although it is tempting to speculate on different roles in vivo for an-
tithrombin and protein C in atherothrombosis, the extensive venous thrombosis in the 
siSerpinc1 group precluded the study of this important anticoagulant in the potential 
protection fagainst thrombosis in the arterial system, like protein C.
In several siProc treated mice, signs of clotting were observed in the left atrium, a 
phenotype which has not been reported before in hyperlipidemic or hemostasis mouse 
models. The absence of clots in major organs and normal levels of blood coagulation 
parameters in siProc mice indicates that this clot formation is a local cardiac event, and 
does not represent siProc-mediated disseminated intravascular coagulopathy. Interest-
ingly, Pepler et al. reported cardiac clotting, albeit in the ventricle, when providing a 
procoagulant challenge to endothelial protein C receptor (Epcr) mutant mice9. In addi-
tion, lethal perinatal thrombosis in FvQ/Q mice on a 129Sv genetic background has been 
reported, including features of thrombus formation in the left atrium of the heart10. 




In conclusion, our findings indicate that siRNA-mediated silencing of Proc in Apoe-/- 
mice creates a condition that allows the formation of spontaneous atherothrombosis, 
albeit at low incidence. Our unique approach may be of value as a tool to identify factors 
that increase atherothrombotic complications.
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supplemental fi gure I: Plasma total cholesterol before siRNA treatment of the mice in experiment 1. Lines 
represent medians. Grey zones in panels represent median and range of total cholesterol prior to siNEG 
treatment (n=9).
supplemental fi gure II: Thrombus formation on top of an atherosclerotic plaque. Hematoxylin and eosin 
staining of serial sections of a thrombus superimposed on an atherosclerotic plaque in the aortic root of 
siProc-treated WTD-fed Apoe-/- mice (experiment 2), with intervals of 80 µm. The thrombus was superim-
posed on the plaque for at least 320 µm. Arrows indicate the location of the thrombus.












supplemental fi gure III: Plaque formation in the aortic arch of siProc treated mice. Upper panels: Hema-
toxylin-eosin, lower panels: Martius-Scarlett. (A) Representative images of an atherosclerotic plaque in the 
aortic arch. Plaques stained negative for fi brin (lower panel). (B) Single observation of a plaque in the aortic 
arch. Within the plaque, fi brin-positive sections were identifi ed in pink (asterisks, lower panels). Of note, this 
animal also featured aortic root atherothrombosis (fi gure 1, fourth lane of panels). V: Vessel wall, P: Athero-
sclerotic plaque. Scale bars represent 100 µm.
supplemental fi gure IV: siProc-induced clotting in the left atrium. Representative Martius Scarlet-stained 
sections of clotting events in an WTD-fed Apoe-/- mice treated with siProc (experiment 2). One out of these 
7 mice also displayed a thrombus on top of an atherosclerotic plaque. The clots are enriched for erythro-
cytes (green/yellow) and fi brin (red/pink).
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Predilection of low protein C-induced 
spontaneous atherothrombosis 
for the right coronary sinus in 





Silencing of anticoagulant protein C using RNA interference (siProc) evokes low incident 
but spontaneous atherothrombosis in the aortic root of apolipoprotein E–deficient 
(Apoe-/-) mice. The aims of the current study were 1) to analyze if plaque characteristics 
or circulating factors could be linked to atherothrombosis susceptibility, 2) to increase 
the incidence of atherothrombosis by transiently increasing blood pressure, and 3) to 
direct atherothrombosis to an additional predefined vascular site by applying a semi-
constrictive collar around the carotid artery.
siProc-driven spontaneous atherothrombosis in the aortic root of Apoe-/- mice was 
reproduced and occurred at an incidence of 23% (9 out of 39 mice), while the incidence 
of collar-induced atherothrombosis in the carotid artery was 2.6% (1 out of 39 mice). 
Treatment with phenylephrine, to transiently increase blood pressure, did not increase 
atherothrombosis in the aortic root of the Apoe-/- mice nor in the carotid arteries with 
collars. Plaques in the aortic root with an associated thrombus were lower in collagen 
and macrophage content, and mice with atherothrombosis had significantly more 
circulating platelets. Plasma protein C, white blood cell counts, total cholesterol, fibrino-
gen, serum amyloid A, and IL-6 were not different amongst siProc treated mice with or 
without thrombosis. Remarkably, our data revealed that thrombus formation preferably 
occurred on plaques in the right coronary sinus of the aortic root.
In conclusion, there is a predilection of low protein C-induced spontaneous athero-
thrombosis in Apoe-/- mice for the right coronary sinus, a process that is associated with 
an increase in platelets and plaques lower in collagen and macrophage content.
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InTRoDUcTIon
Atherothrombosis, characterized by superimposed thrombus formation overlying a 
ruptured or eroded atherosclerotic lesion, is the cause of death for more than 14 mil-
lion individuals per year worldwide (in 2015, World Health organization, www.who.
int). Atherogenesis, which can eventually lead to atherothrombosis, has been studied 
extensively in genetically modified mouse models: When mice are deficient for genes 
involved in cholesterol metabolism, such as in apolipoprotein E knockout (Apoe-/-) mice 
or low-density lipoprotein receptor knockout (Ldlr-/-) mice, are fed a cholesterol-rich diet, 
they rapidly develop atherosclerotic plaques1-3. These mouse models have proven to be 
valuable for unraveling the pathophysiology of atherosclerosis4,5. However, unlike in 
humans, atherothrombosis does not occur spontaneously in mice, although some signs 
of rupture or erosion and intraplaque hemorrhage have been recorded6-8.
Recently, we showed that transient (7 days) siRNA mediated lowering of the natural 
anticoagulant protein C (siProc) in atherosclerotic Apoe-/- mice induced superimposed 
thrombus formation on atherosclerotic plaques in the aortic root9. Although the inci-
dence of this unique phenotype was low (1 out of 4 and 3 out of 25 in two independent 
experiments, cumulative incidence of 14%), our novel mouse model might be of use to 
better understand the pathophysiology of atherothrombosis. Moreover, a mouse model 
of atherothrombosis will be instrumental for the development of novel strategies for the 
treatment and prevention of atherothrombosis in humans in the future.
Currently, the factors which determine when and where a thrombus develops on top of 
an atherosclerotic plaque are still largely unknown. We hypothesized that the incidence 
of atherothrombosis may increase when an additional risk factor for atherothrombosis is 
introduced on top of the impaired anticoagulant activity by knockdown of protein C. An 
important risk factor for the development of atherothrombosis and consequent cardio-
vascular hospitalization is pulse pressure10. A transient increase in blood pressure can be 
achieved in animal models by the administration of phenylephrine (PE), a selective α1-
adrenergic receptor agonist. This will increase the strain on atherosclerotic plaques and 
thereby stimulate the risk of plaque rupture/erosion and subsequent atherothrombosis. 
In line, PE administration was associated with increased rupture of p53 treated plaques 
in Apoe-/- mice11. In the current study we therefore also applied PE treatment to increase 
the strain on the atherosclerotic plaques and stimulate atherothrombosis incidence in 
the siProc treated Apoe-/- mice. Moreover, we attempted to direct atherothrombosis to 
the carotid artery by placing perivascular collars around the carotid artery, a procedure 
which induces rapid atherogenesis proximal of the collars12. This allowed us to investi-
gate the impact of low protein C on plaques at an additional predefined vascular site 





Female C57BL/6 Apoe-/- mice (4-7 weeks old, n=57) were fed a Western-type diet (WTD 
containing 0.15% cholesterol; Special Diet Services, Sussex, UK). After 6 weeks on WTD, 
mice received silicone collars around both common carotid arteries, as previously de-
scribed11. After 10 weeks on WTD, synthetic siRNA (5 mg/kg; Ambion, Life Technologies, 
Carlsbad (CA), USA) targeting protein C (siProc, cat. #S72192; n=40), or a control siRNA 
without a known target in mice (siNEG, cat. #4404020; n=17) was injected intravenously 
(IV). siRNA was complexed using invivofectamine 3.0, and each mouse received 2.5 
nmol siRNA. Prior to siRNA injection, mouse groups were randomized based on weight 
and age (table 1). siNEG- and siProc treated mice received two intravenous injections 
of either phenylephrine (PE, 8 μg/kg IV, Sigma-Aldrich cat. #P6126-10G, Zwijndrecht, 
The Netherlands; siProc: n=20, siNEG: n=8) or Phosphate-Buffered Saline (PBS; siProc: 
n=20, siNEG: n=9) as control. PE/PBS injections were performed 4 and 6 days after the 
siRNA injection. In both the siNEG and the siProc group, one mouse was removed from 
the experiment due to procedural errors, and thus not represented in the analyses. 
For an overview of the experimental procedure, see supplemental figure 7. The animal 
experimental protocol was in agreement with the national guidelines for animal experi-
mentation and was approved by the Ethics Committee for Animal Experiments (Leiden 
University, Leiden, The Netherlands).
Tissue harvesting and preparation
7 days after siRNA injection, mice were anesthetized with a subcutaneous injection of 
a mixture of ketamine (100 mg/kg), xylazine (12.5 mg/kg) and atropine (125 µg/kg). 
Citrated blood (300 μL) was drawn from the inferior vena cava, and plasma was collected 
as described previously40. For whole blood cell and platelet analysis, an EDTA blood 
Table 1: Group sizes, age, and body weight for all Apoe-/- mice. For age and body weight, the median 
and range is displayed of both parameters before siRNA injection. There were no significant differences 
between groups of mice.
Group Group size (n) age (weeks) body weight (g)
siNEG 17 14 (13-16) 22.5 (20.9-27.9)
siProc 40 14 (13-16) 22.7 (20.1-25.7)
Group Group size (n) age (weeks) body weight (g)
siNEG + PBS 9 14 (13-16) 22.4 (20.9-27.9)
siNEG + PE 8 15 (13-15) 22.9 (22.1-24.2)
siProc + PBS 20 14 (13-16) 22.6 (20.3-24.9)
siProc + PE 20 14 (13-16) 22.8 (20.1-25.7)
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sample (approximately 50 μL) was collected through retro-orbital bleeding after blood 
withdrawal from the vena cava. Subsequently, mice were further exsanguinated and 
perfused in situ with PBS, after which organs were harvested. Tissues were either snap 
frozen (liver and spleen, stored at -80°C), or fixed for 24 hours in 3.7% neutral-buffered 
formalin (heart and carotid arteries, Formal-Fixx, Shandon Scientific Ltd, UK) and stored 
at room temperature for analysis.
Gene expression evaluation
Transcript of Proc was assessed by routinely quantitative PCR of hepatic tissue, with Actb 
as a reference housekeeping gene41.
Histology
Hearts (aortic roots) and carotid arteries were formalin fixed and embedded in OCT 
compound (Optimum Cutting Temperature; Sakura Finetek Europe B.V., Alphen aan 
de Rijn, The Netherlands) before sectioning. Cryosections (10mm, 70mm interval) of 
the aortic root were prepared and mounted in a parallel series on 1% gelatin coated 
slides. Thrombi and clot structures in the aortic root were identified and scored blindly 
by two independent researchers on hematoxylin and eosin-stained sections. Plaque 
size per valve was determined after staining of the cyrosections for neutral lipids using 
Oil-Red-O and hematoxylin (Sigma-Aldrich, Zwijndrecht, The Netherlands). Correspond-
ing sections were stained using the Masson’s Trichrome method (Sigma-Aldrich) for 
further morphometric analysis of the atherosclerotic plaques, including the percentage 
of collagen, necrotic core, and macrophage foam cells. All images were analyzed by 
blinded computer aided morphometric analysis using the Leica DM-RE microscope and 
LeicaQwin software (Leica Ltd, Cambridge, UK). Transverse serial cryosections (10mm; 
80mm interval) of the carotid arteries (and the collars) were made. Sections were rou-
tinely stained with hematoxylin and eosin for a general assessment of histology, and 
were analyzed blindly by two independent researchers.
blood and plasma analysis
Whole blood cell and platelet analysis were performed using an automated XT-2000iV 
veterinary hematology analyzer (Sysmex Europe GMBH, Norderstedt, Germany). 
Plasma cholesterol levels were measured by an enzymatic colorimetric assay (Roche 
diagnostics, Almere, The Netherlands). Protein C plasma levels were determined using 
an ELISA with a sheep anti-murine protein C polyclonal antibody (Haematologic Tech-
nologies Inc. Essex Junction (VT), USA), conjugated with Horseradish peroxidase with 
the EZ-Link Plus Activated Peroxidase Kit (Thermo Scientific, #31489, Waltham (MA), 
USA), as described previously41. Fibrinogen and Serum Amyloid A plasma levels were 
determined using commercial ELISA kits (Affinity Biologicals, Ancaster (ON), Canada and 
chapter 8
148
R&D systems, Minneapolis (MN), USA, respectively). Plasma IL-6 levels were determined 
using a commercially available ELISA kit (BD Biosciences, San Jose CA, USA) following 
the manufactures instructions.
statistics
Statistical analyses were performed in Graphpad Instat (GraphPad Software, La Jolla (CA), 
USA). Data are presented with median and range. Statistical differences were assessed 
using the Mann-Whitney U test. A P-value <0.05 was considered significant. Descriptive 
statistic and calculate proportions of the observations and the 95% confidence intervals 
(Wilson-score) were calculated using resources provided by the Open Source Epide-
miologic Statistics for Public Health website (www.openepi.com). A Chi-Square test was 
performed for the valve-incidence was done in SPSS (IBM SPSS Statistics for Windows, 
Version 23.0, Armonk (NY), USA).
ResUlTs
At the time of sacrifice, all Apoe-/- mice treated with PBS or phenylephrine (PE) and 
siRNA (both siNEG and siProc) appeared healthy and did not show any abnormalities. 
Histological analysis of the aortic root of 10 weeks WTD-fed siProc treated mice dem-
onstrated the presence of atherosclerotic plaque-associated thrombi, with a similar size 
and composition as previously reported9. In total, 9 out of 39 siProc treated Apoe-/- mice 
(23.0%, CI (95%): 16.7-47.9) were categorized as atherothrombosis-positive in the aortic 
root (siProc +THR, figure 1A-D and figure 2). In addition to the 9 siProc +THR mice with 
typical plaque-associated thrombi, 2 mice developed atypical clots in the aortic root. 
One atypical clot, although fibrin-positive and clearly associated with an atherosclerotic 
plaque, did not have the layered structure and did not contain leukocytes as the typical 
thrombi. These are histological arguments for being a fresh thrombus (supplemental 
figure 1A). The second atypical thrombus was associated with a valve, although present 
in the aortic sinus. Despite its unusual location, the thrombus was similar to the typical 
thrombi found on top of the atherosclerotic plaques. The valve with which it was associ-
ated contained a high number of leukocytes, but this was not unique for this specific 
heart valve (supplemental figure 1B). Mice with atypical thrombi were included in the 
siProc mice without a thrombus (siProc –THR) during further analyses.
siProc mice treated with PE had a similar incidence of atherothrombosis compared to 
PBS treated siProc mice (4 out of 19 vs. 5 out of 20 mice, respectively, figure 2).
To investigate if an additional predefined site allowing atherothrombosis develop-
ment could be created, perivascular collars were placed around both the carotid arteries 
of the Apoe-/- mice, 4 weeks prior to siRNA treatment. In line with previous studies12,13, 
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siProc - THR                                                        siProc + THR
figure 1: atherothrombosis in the aortic root of siProc treated Apoe-/- mice. (A) Representative section 
of the aortic root of a mouse treated with siNEG. (B) Representative section of the aortic root of a mouse 
treated with siProc, without a thrombus (siProc –THR). (C and D) Representative section of the aortic root of 
a mouse treated with siProc, with a thrombus associated with an atherosclerotic plaque (siProc +THR, panel 
D is a magnifi cation of the black square in panel C). (E) Representative section of the common carotid artery 
containing an atherosclerotic lesion upon collar placement, derived from an siProc treated mouse. (F) A 
thrombus-like structure associated with an atherosclerotic lesion in the common carotid artery. All sections 
are hematoxylin and eosin (HE) stained. The scattered black lines in panels A, B, and C mark borders of the 
plaque. LCS: Left coronary sinus, NCS: Non-coronary sinus, RCS: Right coronary sinus. *: Thrombus. Black 
bars represent 200 μm.
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figure 2: overview of all siProc associated atherothrombotic events in the aortic root of Apoe-/- mice. 
(A) In 5 mice in the siProc group without phenylephrine (siProc - PE) treatment atherothrombosis in the 
aortic root was observed. (B) In 4 mice in the siProc group with phenylephrine (siProc + PE) treatment ath-
erothrombosis in the aortic root was observed. All sections were HE stained. Black bars represent 500 μm. 
LCS: Left coronary sinus, NCS: Non-coronary sinus, RCS: Right coronary sinus. *: Thrombus.
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histological analysis of the carotid arteries showed that collar placement resulted in 
atherosclerotic plaque formation proximal to the collar. Although gross visual inspec-
tion revealed a large variation in plaque size and composition within groups, these 
were not different at the site of maximal stenosis between mice in the different groups 
(supplemental figure 2). In total, 1 out of 39 siProc mice presented a structure identified 
as a thrombus in one of the carotid arteries (figure 1E-F). The thrombus was associ-
ated with the plaque, was rich in erythrocytes, and had a layered structure, and it was 
comparable to the thrombi found in the aortic root. siNEG treated mice did not show 
events or structures identified as a thrombus, neither in the aortic root and nor in the 
carotid arteries. It should however be noted that in our long term experience with collar 
placement around the carotid arteries of Apoe-/- mice, the occurrence of thrombosis as a 
complication of the procedure is not a rare event. Hence, atherothrombosis induced by 
silencing of Proc seems to be restricted to the aortic root.
Livers and blood/plasma were analyzed to determine whether specific markers could 
be correlated to atherothrombosis susceptibility. As expected, siProc treatment strongly 
decreased hepatic Proc transcript levels, compared to siNEG treated mice (remaining 
Proc transcript: siProc -THR: 32.0% (18.0-63.7), siProc +THR: 25.8% (18.8-40.0), P<0.001, 
figure 3A as compared to siNEG treated mice). Interestingly, the Proc transcript in siProc 
treated mice was significantly lower in siProc +THR, compared to the siProc -THR mice 
(P=0.013, figure 3A). Protein C plasma levels were also reduced in siProc treated mice, 
as compared to the siNEG treated mice (remaining plasma protein C: siProc -THR: 49.4% 
(18.4-118.7), siProc +THR: 40.5% (33.2-50.3), P<0.001, figure 3B as compared to siNEG 
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figure 3: Proc liver transcript and plasma protein c levels of sineG and siProc treated Apoe-/- mice. 
(A) Proc transcript in the liver upon sacrifice (7 days after siProc treatment) compared to the mean value of 
siNEG treated mice (100%). (B) Plasma protein C levels, measured by ELISA, compared to the mean value 
of siNEG treated mice (100%). Black bars indicate the median. **: P<0.01 for siNEG vs. siProc. $: P<0.05 for 
siProc –THR vs. siProc +THR.
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did not reach statistical significance between siProc -THR and siProc +THR mice (P=0.11, 
figure 3B). No differences were observed in mice treated with PE in both the siNEG or 
siProc group (supplemental figure 3).
Blood cell counts (total white blood cells, neutrophils, lymphocytes, monocytes, 
eosinophils, and red blood cells) were comparable between siNEG, siProc –THR, and 
siProc +THR mice (figure 4). Interestingly, platelet levels were significantly higher in 
siProc treated mice compared to siNEG treated mice (siNEG: 800x109/L (508-1112), siProc 
-THR: 1280x109/L (728-1632), siProc +THR: 1512x109/L (1004-1696), P<0.001, figure 5A). 
Within the siProc treated groups, siProc +THR mice had even more platelets (P=0.043 as 
compared to siProc -THR, figure 5A). To follow-up on this observation, we determined 
mRNA levels of megakaryocytes in the spleen of genes associated with platelet produc-
tion. In agreement with the increased platelet counts, upon siProc treatment, expression 
of some of these genes (Gata1, Itga2b, Nfe2, and Fog1) were increased as compared to 
siNEG treated mice (data not shown). siProc +THR treated mice showed an increased 
expression for Fog1, while for the other spleen-expressed genes expression levels were 
not different between siProc -THR and siProc +THR mice.
Plasma analysis showed that total cholesterol levels were not significantly different 
between mice treated with siNEG or siProc, in both -THR or +THR mice (siNEG: 10.1 mg/
mL (5.4-11.9), siProc -THR: 9.5 mg/mL (6.4-12.8), siProc +THR: 10.1 mg/mL (9.1-13.9), 
P=0.43, figure 5B). Besides total cholesterol, fibrinogen, serum amyloid A (SAA, an 
acute-phase mouse protein associated with inflammation14), and interleukin 6 (IL-6, a 
well-established plasma marker for inflammation (see 15) were determined as putative 
systemic markers for atherothrombosis susceptibility. In line with fibrinogen being a 
cardiovascular risk factor in epidemiological studies16, plasma fibrinogen levels in all 
groups of Apoe-/- mice were significantly higher than levels measured in normal pool 
plasma (NPP, pool of C57BL/6 mouse plasma). However, among siRNA treated Apoe-/- 
mice no differences were observed (siNEG: 363% (83-598), siProc -THR: 394% (35-562), 
siProc +THR: 463% (2.6-564), P=0.74, figure 5C). SAA levels were slightly increased in 
plasma of the Apoe-/- mice compared to NPP (<0.5 ng/mL), but no differences among the 
Apoe-/- groups were found (siNEG: 0.9 ng/mL (0.4-3.0), siProc -THR: 1.3 ng/mL (0.4-3.1), 
siProc +THR: 0.8 ng/mL (0.5-3.8), P=0.33, figure 5D). A similar pattern was observed for 
IL-6 plasma levels (siNEG: 9.4 pg/mL (0-28.4), siProc -THR: 9.7 pg/mL (0-25.9), siProc +THR: 
7.7 pg/mL (0-15.8), P=0.59, figure 5E). In line with previous results, PE treatment did not 
influence blood platelets or plasma levels of the measured parameters (supplemental 
figure 4).
In our previous study9, we found no significant correlation between plaque size and 
phenotype and the susceptibility to aortic root atherothrombosis. However, with only 
4 siProc +THR mice the power in that study was low. Therefore, in the current study the 
atherosclerotic plaques in the aortic root were also morphometrically analyzed to assess 
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figure 4: blood cell populations of sineG and siProc treated Apoe-/- mice. Blood cell numbers from 
the siProc treated group is divided in plaques without a thrombus (siProc – THR) and plaques containing 
a thrombus (siProc +THR). (A) Total white blood cells, (B) neutrophils, (C) lymphocytes, (D) monocytes, (E) 
eosinophils, and (F) red blood cells are displayed. Black bars indicate the median. No significant differences 
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figure 5: blood platelet levels and plasma analysis of sineG and siProc treated Apoe-/- mice. (A) Total 
blood platelet levels, (B) plasma total cholesterol levels, (C) plasma fibrinogen levels, measured by ELISA, 
and expressed as % of normal pool plasma. We did not have any reason to exclude outliers with a low value 
(e.g. due to coagulation upon blood withdrawal). (D) Serum Amyloid A levels, and (E) plasma IL-6 levels 
(negative measurements were set to 0 pg/mL). Black bars indicate the median. **: P<0.01 for siNEG vs. 
siProc. $: P<0.05 for siProc –THR vs. siProc +THR.
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whether plaque size and characteristics could be linked to the presence of atherothrom-
bosis (for examples of plaque stainings, see figures 6A and 6B). Plaque analysis revealed 
that PE treatment, similar to the atherothrombosis incidence, did not influence any of 
the plaque characteristics (supplemental figure 5). For this reason, data of the mice 
with and without PE treatment were pooled to increase statistical power. In the siProc 
groups, the plaque area (-THR: 191x103 μm2 (55.0-888), +THR: 191x103 μm2 (112-343), 
P=0.59, figure 6C), was not different. Interestingly, collagen and macrophage content 
were significantly lower in plaques with an associated thrombus (-THR: 13.4% (2.1-29.6), 
+THR: 8.3% (6.4-15.3), P=0.031, figure 6D, and -THR: 9.1% (0.8-34.9), +THR: 6.7% (4.5-
13.7), P=0.028, figure 6E, respectively), unlike the necrotic core (-THR: 19.5% (4.3-80.2), 
+THR: 15.3% (7.8-67.0), P=0.30, figure 6F). No evidence was found for the occurrence of 
intraplaque hemorrhages or other abnormalities in the atherosclerotic plaques (neither 
in -THR nor in +THR plaques).
Since in our studies thrombi were exclusively found in the aortic root, we hypoth-
esized that local hemodynamics, which can influence endothelial integrity, plays a role 
in atherothrombosis formation. For this reason, we re-examined the individual plaques 
formed in the different cusps within the aortic root (sinuses) for the presence of thrombi, 
by dividing the aortic root into the left coronary sinus (LCS), right coronary sinus (RCS), 
and non-coronary sinus (NCS, see 17-19 and figure 7A). We noticed that thrombi had a 
preference for the RCS, over the LCS and the NCS (figure 7B, P=0.018). When combin-
ing these data with the data obtained from our previous study, where we detected 4 
thrombi for in total 29 siProc injected Apoe-/- mice 9, the preference for the RCS was even 
more pronounced (P=0.008).
To study whether the predilection for the RCS was the consequence of differences in 
plaque size and composition, the plaque parameters from figure 6 were reanalyzed for 
the LCS, NCS, and RCS. Interestingly, when we pooled the data from the three groups of 
mice (siNEG, siProc -THR, and siProc +THR) to compare the plaque area, collagen content, 
macrophage content, and necrotic core size, we found that plaques in the NCS were 
significantly smaller and contained a larger necrotic core, as compared to their coun-
terparts in the LCS and RCS (figure 8). No significant differences among plaques were 
found when mice were separated in siNEG, siProc –THR, and siProc +THR (supplemental 
figure 6).
DIscUssIon
Transgenic mice with an impaired lipoprotein metabolism, such as Apoe-/- and Ldlr-/- 
mice, which are fed a cholesterol-rich diet rapidly develop advanced atherosclerosis1,2. 
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figure 6: Plaque composition of sineG and siProc treated Apoe-/- mice. (A-B) Representative photo-
micrograph of a Masson’s Trichrome stained plaque in the aortic root (RCS) of mice treated with siProc, 
without (A) and with (B) a thrombus associated to a plaque from the aortic root. Blue areas were assessed 
as collagen-positive, non-stained areas as necrotic core, and pink nucleated areas as macrophage content/
foam cells. The scattered black lines mark borders of the plaque. Black bars represent 200 μm. (C-F) Indi-
vidual plaques from the siProc treated group are divided in plaques without a thrombus (siProc – THR) and 
plaques containing a thrombus (siProc + THR). (C) Total plaque area, (D) collagen, (E) cellular content, (F) 
necrotic core. For all panels, the indicated values represent an average measurement of three sections. 
Black bars indicate the median. $: P<0.05 for siProc –THR vs. siProc +THR.
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upon additional (invasive) plaque damaging interventions20. The cause for the absence 
of atherothrombosis is unknown, but it is likely that multiple species-specific factors 
such as hemodynamics, plaque composition, metabolism, and life span are involved21. 
Recently, our group showed that transient lowering of the natural anticoagulant protein 
C in Apoe-/- mice resulted in spontaneous atherothrombosis at plaques formed in the 
Study LCS NCS RCS
Ouweneel et al. 0 2 3
LCS NCS RCS
Current 1 1 7*
LCS NCS RCS
Overall 1 3 10**
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LCS                  
NCS                  





500μm                  
figure 7: siProc induced atherothrombosis in the different sinuses of the aortic root of Apoe-/- mice. 
(A) HE stained section of the aortic root and surrounding tissues. The non-coronary sinus (NCS) of the aor-
tic root is covered by the two atria of the heart (atria are indicated with HA). Left and right of the NCS the 
left and right coronary sinuses (LCS and RCS, respectively) are present, which are both partly covered by 
a muscle-rich area, from which the largest part is the right ventricle (indicated with RV). *: thrombus. The 
scattered black lines mark borders of the plaque. Black bar represents 500 μm. (B) Overview of three inde-




sinuses of the aortic root9. This implies that potent anticoagulation (co)contributes to 
absence of atherothrombosis in mice. In the current study we aimed to increase the 
insight into the factors which associate with and possibly determine when and where a 
thrombus develops on top of an atherosclerotic plaque. For the first time we provide evi-
dence that atherosclerotic plaques located in the RCS of the aortic root are more prone 
to the development of atherothrombosis, compared to the LCS and NCS. Interestingly, 
plaques with a thrombus were modestly but significantly lower in collagen and macro-
phage content. Therefore, we conclude that low protein C-induced atherothrombosis in 
mice is a low incident but reproducible phenomenon, and that it is determined by the 
location of the plaque, possibly in combination with differences in plaque composition.
Since Leonardo da Vinci in the beginning of the XVI century, scientists have been 
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figure 8: Plaque composition of the lcs, ncs, and lcs. Individual plaques from all groups were pooled 
and analyzed for (A) total plaque area, (B) collagen, (C) cellular content, (D) and necrotic core. For all panels, 
the indicated values represent an average measurement of three sections. Black bars indicate the median. 
LCS: Left coronary sinus, NCS: Non-coronary sinus, RCS: Right coronary sinus. **: P<0.01.
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root22-24. The mouse aortic sinuses (in humans, sinuses of Valsalva) play a crucial role in 
regulating the closing mechanism of the valve leaflets25. The oscillating shear stress due 
to the opening and closing of the valves renders the cusps susceptible for the develop-
ment of atherosclerotic plaques. A limited number of studies have distinguished between 
the three different sinuses and their plaques during their analyses. It has been reported 
that plaque size is reduced specifically in the RCS upon treatment with two different liver 
X receptor agonists18. This means that differences in local anatomy of the aortic root do 
not only cause the flow to be different, but also can induce different expression patterns 
of proteins, possibly linked to coagulation. Moreover, Bentzon et al. suggested a causal 
relation between lesion formation and expansive remodeling of the aortic root sinuses, 
which was different when comparing plaques in the LCS, NCS, and RCS26. In our study, we 
found that plaques formed in the RCS, the location where most thrombi are identified, 
and the LCS are significantly larger than their counterparts NCS. In addition, plaques in 
the NCS have a larger necrotic core as compared to the LCS and RCS. This observation 
again suggests that the plaques in the different sinuses are not similar, but since no 
outlying characteristics were scored for the RCS we cannot speculate on whether plaque 
composition contributes to atherothrombosis. The observed preference for the RCS for 
the development of atherothrombosis suggests that in mice local hemodynamics and 
wall shear stress are not only involved in atherogenesis27,28, but also in the development 
of atherothrombosis, as has been proposed for the human disease29,30. The identification 
of factors that drive the predilection for the RCS may provide novel clues on factors that 
drive atherothrombosis in mice and humans.
Plaques in the aortic root which were associated with a thrombus appeared to be 
lower in macrophage and collagen content. Although the measured values fell within 
the normal range, the difference was considered statistically different. Macrophages 
(foam cells) are crucially involved in atherogenesis and a high content of this cell popu-
lation within a plaque has been associated with instability31,32. These observations make 
our findings in the current study, where in atherothrombotic plaques relatively fewer 
macrophages were found, unexpected. However, it should be noted that the plaques 
were advanced and that as a result the macrophage foam cell content was low. It has 
been described that lower collagen levels in atherosclerotic plaques are associated with 
instability and risk of rupture33. However, because of the current study setup, we cannot 
conclude whether the observed difference is a cause or consequence of the formation 
of a thrombus.
In the current study, siProc treatment of Apoe-/- mice and subsequent thrombus forma-
tion did not coincide with altered levels of red and white blood cells or plasma markers 
of inflammation (fibrinogen, SAA, and IL-6). The only blood cell population which was 
altered upon siProc treatment were the platelets. Most likely due to increased platelet 
production, atherosclerotic siProc treated mice showed significant higher levels of plate-
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lets in the circulation. To measure platelet production, a transcript analysis for genes 
associated with platelet production was performed in the spleen. The spleen does not 
contribute equally to production of platelets in mice, as compared to the bone marrow34. 
However, the spleen does contain megakaryocytes, which derive from hematopoietic 
stem cells35. In addition, mice deficient for the Apoe gene have increased extramedul-
lary hematopoiesis36, which means that the contribution of the spleen to total platelet 
production is increased in these animals. Measuring spleen megakaryocytes to detect 
alterations of platelet production upon siProc treatment is thus a valid alternative for the 
bone marrow in Apoe-/- mice. Indeed we measured an upregulation of genes associated 
with platelet production. In addition, a follow-up study showed that in the absence of 
an atherosclerotic phenotype (in an independent experiment, in which wild type female 
C57BL/6 mice were fed a normal chow diet) platelet numbers were also increased in 
mice treated with an siRNA against Proc (data not shown). Both findings suggest that the 
anticoagulant protein C directly or indirectly influences platelet production (and pos-
sibly consumption and/or clearance), a phenomenon that, to our knowledge, has not 
been described before. In human studies, it has been suggested that increased platelet 
levels are a risk factor for atherothrombotic events, making it tempting to speculate 
that the higher platelet levels upon siProc-treatment contribute to the development of 
atherothrombosis in the aortic root37,38. For now, it is however not clear whether the in-
creased platelets predict aortic root atherothrombosis susceptibility or whether they are 
a consequence of the event. For future studies, it would be of interest to dig deeper into 
the role of platelets and platelet activation during siProc-mediated atherothrombosis in 
the aortic root. For instance, modulation of platelet function (e.g. via GPVI, see 39) in com-
bination with protein C silencing may coincide with a different onset and progression of 
this unique atherothrombotic phenotype in mice. Moreover, the role of platelets during 
the local event of atherothrombosis can be studied in intravital microscopy experiments 
with fluorescently labeled platelets. However, because it is technically not possible to 
perform these type of studies in the aortic root, this is currently not feasible.
In conclusion, atherosclerotic plaques in the RCS are a predilection site for low protein 
C-induced spontaneous atherothrombosis in Apoe-/- mice, a process associated with vul-
nerable plaques displaying a lower macrophage and collagen content and vulnerable 
blood with augmented platelet counts.
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supplemental figure 1: atypical thrombi in the aortic root of siProc treated Apoe-/- mice. (A) Atypical 
thrombus which associated with an atherosclerotic plaque. In contrast to other thrombi, it did not have a 
layered structure and did not contain leukocytes. (B) Atypical thrombus associated with a valve within a 
sinus of the aortic root, and not with the atherosclerotic plaque. The composition of the thrombus was simi-
lar to other thrombi. During the analysis, both mice were included in the siProc –THR group. Black bars rep-








supplemental fi gure 2: atherosclerotic plaques upon collar placement in the common carotid arter-
ies. Overview of sectioned common carotid arteries, at the site of maximal stenosis. (A) Two representative 
sections of common carotid arteries of mice treated with siNEG (- PE), (B) Two representative sections of 
common carotid arteries of mice treated with siNEG (+ PE), (C) Sections of common carotid arteries of mice 
treated with siProc (- PE), (D) Sections of common carotid arteries of mice treated with siProc (+ PE). All sec-
tions were HE stained. Black bar represents 200 μm. *: Thrombus (for enlargement, see fi gure 1F).
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supplemental figure 3: Proc liver transcript and plasma protein c levels in sineG and siProc treated 
Apoe-/- mice, with and without phenylephrine (Pe). (A) Proc transcript in the liver upon sacrifice (7 days 
after siProc treatment), compared to the mean value of siNEG treated (100%) and (B) plasma protein C lev-
els, compared to the mean value of siNEG treated (100%). Black bars indicate the median. – PE: PBS control 
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supplemental figure 4: blood platelets and plasma markers of sineG and siProc treated Apoe-/- mice, 
with and without phenylephrine (Pe). (A) Whole blood platelet levels, (B) plasma total cholesterol levels, 
(C) plasma fibrinogen levels, measured by ELISA and expressed as % of normal pool plasma. We did not 
have any reason to exclude outliers with a low value (e.g. due to coagulation upon blood withdrawal), (D) 
Serum Amyloid A levels, and (E) plasma IL-6 levels (negative measurements were set to 0 pg/mL). Black bars 
indicate the median. – PE: PBS control treated mice, + PE: Phenylephrine treated mice **: P<0.01 for siNEG 
vs. siProc.
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supplemental figure 5: atherosclerotic plaque composition of sineG and siProc treated Apoe-/- mice, 
with and without phenylephrine (Pe). (A) Total plaque area, (B) collagen, (C) macrophage content, (D) 
necrotic core. For all panels, the indicated values represent an average measurement of three sections. 
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supplemental figure 6: composition of atherosclerotic plaques formed in the lcs, ncs, and Rcs. (A) 
Total plaque area, (B) collagen, (C) macrophage content, (D) necrotic core. LCS: Left coronary sinus, NCS: 
Non-coronary sinus, RCS: Right-coronary sinus. For all panels, the indicated values represent an average 
measurement of three sections. Black bars indicate the median.








supplementary figure 7: experimental setup. 4-7 weeks old female Apoe-/- mice were fed a Western type 
diet (WTD) for 10 weeks (wk). After 6 weeks of WTD, perivascular collars were placed around both the com-
mon carotid arteries. After 10 weeks of WTD, mice were treated with either siNEG or siProc. 4 and 6 days 
after siRNA treatment (post-injection, p.i.), mice were injected with PBS control or phenylephrine (PE). One 
week after siRNA treatment (age: 15-18 weeks), mice were sacrificed.
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sR-bI is required for siProc model for atherothrombosis
To the editor,
Atherothrombosis, characterized by the development of a superimposed thrombus 
upon rupture or erosion of an atherosclerotic plaque, is the underlying cause of com-
mon acute cardiovascular events, such as myocardial infarction or ischemic stroke  1. 
Although atherosclerosis development is widely studied in (genetically modified) 
mouse models, these atherosclerotic plaques do not spontaneously progress towards 
the atherothrombosis stage. For this purpose, we have recently developed the first 
spontaneous atherothrombosis mouse model. As previously reported in Arteriosclerosis, 
Thrombosis and Vascular Biology 2, siRNA-mediated lowering of the natural anticoagu-
lant protein C (siProc) induced the occurrence of atherothrombosis in the aortic root of 
hypercholesterolemic apolipoprotein E (APOE) knockout mice at one week after siRNA 
administration. However, spontaneous thrombus formation only occurred at a low inci-
dence (12-25%) 2,3, which highlights that further optimization of the model is necessary 
before we can identify conditions that affect the atherothrombosis incidence.
Platelets play an important role in the pathogenesis of atherothrombosis 4. In this con-
text, mice lacking a functional high-density lipoprotein receptor, i.e. scavenger receptor 
BI (SR-BI) knockout mice, exhibit an interesting platelet phenotype. More specifically, 
SR-BI deficiency-associated hypercholesterolemia in plasma results in cholesterol ac-
cumulation in platelets, causing them to circulate in an activated state 5–7. Importantly, 
this activated platelet phenotype is associated with a higher susceptibility for FeCl3 
damage-induced arterial thrombosis in the carotid artery 5. Hence, it is of clear inter-
est to study whether modifying SR-BI functionality can also increase the incidence of 
atherothrombosis in siProc-treated mice.
In order to determine if SR-BI deficiency increases the susceptibility for siProc-induced 
atherothrombosis, we challenged age- and sex-matched wild-type and SR-BI knockout 
mice with an atherogenic diet containing 15% fat, 1% cholesterol, and 0.5% cholic acid for 
8 weeks before injection with siProc or a non-targeting control siRNA (siNEG). After 8 weeks 
dietary challenge, wild-type mice developed significant hypercholesterolemia (plasma 
total cholesterol level: 205±8 mg/dL; n=26) and early lesions in the aortic root (14±2x103 
µm2; n=24). In line with the notion that early lesions are not susceptible for atherothrom-
bois, no atherothrombosis was observed in the aortic root of siProc-treated wild-type mice 
despite a 50% reduction in hepatic mRNA levels of Proc (siNEG: 0.064±0.009 (n=7), siProc: 
0.032±0.0005 (n=20); p<0.0001). We previously consistently observed an atherothombosis 
incidence of 12-25% in APOE knockout mice 2,3. However, the previously used APOE knock-
out mice had advanced aortic root atherosclerotic plaques (plaque size ~400-600x103 µm2). 
Moreover, the extent of hypercholesterolemia in APOE knockout mice (~1000 mg/dL) was 
much larger than in the wild-type mice of the current study, possibly resulting in increased 
inflammatory and plaque destabilizing conditions. Dedicated studies on the effect of 
plaque size and hypercholesterolemia on atherothrombosis susceptibility are warranted.
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Atherogenic diet-fed SR-BI knockout mice developed exacerbated hypercholesterol-
emia (plasma total cholesterol levels: 1549±85 mg/dL; n=29). As a result, SR-BI knockout 
mice did develop advanced plaques in the aortic root with an average size of 425±21x103 
µm2 (n=26). Surprisingly, despite the advanced stage of the lesions, no aortic root 
atherothrombosis was observed in these animals. Analysis of Proc mRNA expression 
in livers of siProc treated SR-BI knockout mice revealed that this was probably due to 
an impaired hepatic targeting of the siRNA complex. Instead of a decrease, the relative 
expression of Proc actually tended to increase (0.064±0.005 for siNEG (n=6), 0.083±0.005 
for siProc (n=19); p=0.058). Therefore, unfortunately no conclusions regarding the pos-
sible prothrombotic effects of SR-BI deficiency under conditions of Proc silencing can be 
drawn from this study.
In order to inhibit Proc production, we complexed our siRNA with commercially avail-
able Invivofectamine™ 3.0 Reagent (Invitrogen). This reagent is specifically designed to 
target hepatocytes and has previously been shown to be highly effective and non-toxic 
when used for liver-targeted RNA interference 8. Although the exact composition of this 
compound is not publicly known for competitive reasons, the supplier has indicate that 
it is an animal-origin free lipid nanoparticle 9. Previous studies have described a role for 
APOE and the LDL receptor in the uptake of neutral, cationic and ionizable nanoparticles 
(liposomes) in mice 10,11. However, in our earlier studies Invivofectamine™ 2.0 Reagent 
and Invivofectamine™ 3.0 Reagent-complexed siProc silencing was successful  2,3. 
Moreover, transfection was also efficient in APOE*3Leiden.CETP mice (unpublished 
data). Our current study suggests that SR-BI is rather involved in the hepatic uptake 
of Invivofectamine™ 3.0 Reagent-complexed siRNA. SR-BI is widely recognized as a 
multi-ligand scavenger protein, and it clears, among other things, native and modified 
lipoproteins 12, and anionic phospholipids 13. Therefore, it is not unlikely that SR-BI is also 
directly mediating the uptake of Invivofectamine™ complexed siRNA.
In conclusion, our studies show that SR-BI is required for an Invivofectamine™ 
3.0-based siRNA approach to silence Protein C in hepatocytes in vivo. Our studies high-
light that caution is warranted in the design and interpretation of experiments involving 
liver-targeted siRNA in mouse models of disturbed scavenger receptor functioning.
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InTRoDUcTIon
Cardiovascular disease is the leading cause of death worldwide 1. The primary underly-
ing pathology of cardiovascular disease is atherosclerosis. Atherosclerosis is a chronic, 
multifactorial disease in which lipid accumulates in the arterial wall, leading to a local 
inflammatory reaction and atherosclerotic plaque formation. Atherosclerotic disease 
develops largely asymptomatic over a lifetime. However, plaque rupture or erosion can 
cause the formation of a superimposed thrombus, blocking the flow of blood, and cause 
acute cardiovascular events such as myocardial infarction or ischemic stroke 2,3. Defects 
in cholesterol metabolism and hypercholesterolemia, which are major risk factors for 
atherosclerosis 4, have been shown to affect hematopoiesis, immune cell production 
and platelet counts and reactivity 5–8. Therefore, bone marrow cholesterol handling is 
an interesting target in the battle against cardiovascular disease, and acute cardiovas-
cular events in particular. This thesis describes novel interactions between cholesterol 
metabolism and the production of immune cells and platelets, and its effects on athero-
sclerosis and atherothrombosis development.
cHolesTeRol MeTabolIsM In HeMaToPoIesIs
cholesterol metabolism in megakaryopoiesis and platelet production
Platelets are key players in atherothrombosis, as they are the first responders to changes 
in the endothelial integrity and exposure of sub-endothelial structures 9. Platelet char-
acteristics such as density and volume are associated with the risk of acute coronary 
syndromes 10–13. Moreover, mean platelet volume, a determinant of platelet reactivity, 
is implied as both a causal and prognostic factor in cardiovascular disease 14 (see also 
chapter 2).
Platelets are produced by megakaryocytes in the bone marrow through the process 
of thrombopoiesis. Dyslipidemia alters megakaryocyte functioning, and can in this 
way modulate the risk of atherothrombosis via the megakaryocyte-platelet hemostatic 
axis 15. High-cholesterol diet-fed rabbits and guinea pigs develop megakaryocytes with 
increased ploidy and size 16,17. Moreover, hypercholesterolemia in humans is associated 
with higher megakaryocyte ploidy, indicative of altered megakaryocyte maturation, and 
a larger mean platelet volume 18. Together, these data imply regulation of megakaryo-
cyte cholesterol homeostasis as a potential therapeutic target to modulate platelet 
characteristics and to prevent or treat cardiovascular disease.
Previous studies have shown that genetic disruption of scavenger receptor BI (SR-BI) 
function is associated with thrombocytopenia in mice 6,19,20. This thrombocytopenia was 
suggested to result from augmented platelet clearance induced by elevated intracel-
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lular unesterified cholesterol (UC) levels. In chapter 3 we investigated if SR-BI deficiency 
impacts on megakaryopoiesis and platelet production, and in that way contributes to 
the thrombocytopenia found in SR-BI knockout (KO) mice. We show that SR-BI KO mice 
exhibit an increased megakaryocyte UC content and minor changes in megakaryo-
poiesis. The ability of megakaryocytes to form proplatelets, however, was markedly 
decreased in SR-BI KO mice. Importantly, these effects were not a direct effect of the 
absence of megakaryocyte SR-BI but are rather due to an indirect effect of the SR-BI 
deficiency associated UC accumulation.
Previous work has shown that cholesterol efflux facilitated by ATP binding cassette 
(ABC) transporters is important for megakaryocyte progenitor proliferation and platelet 
production 8. ABCG4 KO megakaryocyte progenitors showed defective cholesterol efflux 
to HDL, and increased unesterified cholesterol accumulation, with prominent accumula-
tion in the plasma membrane 8. This is accompanied by increased surface expression 
of the thrombopoietin receptor c-MPL and enhanced proliferation of megakaryocyte 
progenitor cells, leading to increased platelet production.
ABCG4 is highly expressed in megakaryocyte progenitors, whereas the expression of 
ABCA1 and ABCG1 is much less in this cell type 8. Notably, stimulation of the nuclear oxy-
sterol receptor liver X receptor (LXR) upregulates ABCA1 and ABCG1 in megakaryocyte-
erythrocyte progenitors, suggesting that these transporters may play a physiological 
role in the control of megakaryocyte cholesterol homeostasis in a cholesterol-loading 
context, i.e. under hyperlipidemic conditions 8. In chapter 4, we describe strong effects 
of deletion of these transporters on proplatelet production. Genetic deletion of ABCA1, 
ABCG1, or combined deletion of both transporters did not alter megakaryopoiesis, 
as evident from similar bone marrow megakaryocyte numbers. However, deletion of 
ABCA1 or ABCG1 had independent effects on megakaryocyte functioning, in particular 
thrombopoiesis, as demonstrated by the differential effects on proplatelet formation. 
Notably, ABCA1 deficiency inhibited the early stages of proplatelet formation, whereas 
in stark contrast, absence of ABCG1 strongly increases proplatelet formation. Combined 
deletion of both transporters leads to an effect that is intermediate between the effects 
of the individual single KOs. Interestingly, no megakaryocyte cholesterol accumulation 
was observed in ABCA1/ABCG1 double KO mice. Our findings thus suggest that ABCA1 
and ABCG1 do not play a major role in megakaryocyte intracellular cholesterol levels, 
but are important for the regulation of the final steps of thrombopoiesis.
The studies described in this thesis underline the importance of megakaryocyte 
cholesterol metabolism in platelet production. However, still very little is known about 
cholesterol metabolism in megakaryocytes. Therefore, more research into megakaryo-
cyte cholesterol handling is warranted. Deficiency in ABCA1 and ABCG1 does not alter 
megakaryocyte cholesterol content. Possibly, upregulation of efflux through ABCG4 or 
other cholesterol efflux pathways such as ApoE contribute to maintaining cholesterol 
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homeostasis in megakaryocytes under these conditions. Besides the limited knowledge 
about cholesterol efflux in megakaryocytes, little is known about the relative contribution 
of the different sources of cholesterol, i.e. circulating lipoproteins or de novo synthesis, 
present in megakaryocytes and their platelet progeny. Moreover, future studies should 
investigate to what extent megakaryocyte cholesterol is transferred to platelets, and 
how this affects platelet characteristics and functioning. Lastly, it is currently unknown 
what the clinical relevance is of the findings described in this thesis. Further research 
in hypercholesterolemic settings in both preclinical as well as clinical settings, such as 
LDLr KO mice or familial hypercholesterolemia patients, is warranted to underscore the 
therapeutic potential of megakaryocyte cholesterol homeostasis in atherothrombosis.
apolipoprotein a1 deficiency in immune cell production
It is well established that the plasma Apolipoprotein A1 (ApoA1) concentration is 
inversely correlated with the risk for atherosclerosis in humans 21. ApoA1 is the major 
structural apolipoprotein on high-density lipoprotein (HDL) and essential for HDL 
formation and function 22. After its secretion by hepatocytes and enterocytes, ApoA1 
interacts with ABCA1 on the plasma membrane of cells to acquire phospholipids and 
cholesterol and form nascent HDL or preβ-HDL particles 23,24. However, HDL also exhibits 
anti-inflammatory properties, for which ApoA1 is crucial 25–27. In line, in addition to the 
observed increase in atherosclerosis susceptibility, global ApoA1 deficiency is also as-
sociated with altered immune cell function under hypercholesterolemic conditions 28–31. 
As such, both a disruption of the cholesterol transport functions as well as a diminished 
anti-inflammatory response likely contribute to the increased atherosclerosis suscepti-
bility associated with ApoA1 deficiency.
The primary site of immune cell production is the bone marrow, where the most primi-
tive precursors, namely the hematopoietic stem cells (HSCs), and dedicated progenitor 
cells reside. Although ApoA1 can directly impact on inflammation and atherosclerosis, 
it also suppresses proliferation of HSCs and skews hematopoiesis, and in that way alter 
immune cell numbers and function 32. Importantly, hypercholesterolemia-induced 
hyperproliferation of HSCs, as well as the consequent hematopoietic skewing, are also 
evident in recipients of bone marrow from hypercholesterolemic mice, indicating that 
cholesterol metabolism exerts long term effects on HSCs 33,34. In chapter 5 we aimed 
to dissociate the direct effects of ApoA1 deficiency on immune cells in the context of 
atherosclerosis from effects that are generated through changes in bone marrow im-
mune cell production. Hereto, we transplanted bone marrow from wild-type and ApoA1 
KO mice into hypercholesterolemic LDL receptor (LDLr) KO mice.
Plasma cholesterol levels and atherosclerotic plaque size and collagen content were 
unaltered upon reconstitution with bone marrow from ApoA1 KO mice. However, APOA1 
KO bone marrow recipients displayed lymphocytosis, and a strong increase in circulating 
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CD4 T cell numbers. This coincided with a strong increase in splenocyte numbers and a 
relative increase in splenic and circulating naïve T cells. Moreover, an increase in thymus 
size and thymic CCR9 expression suggested augmented T cell production, driven by an 
increase in hematopoietic stem cells and T lineage differentiation in the donor bone 
marrow from ApoA1 KO mice.
In conclusion, our studies show that a genetic lack of ApoA1 modulates the bone 
marrow compartment in such a way that it predisposes to the development of naïve T 
cells from the thymus, leading to lymphocytosis. Furthermore, we show that the effect 
of ApoA1 deficiency on bone marrow does not underlie the increased atherosclerosis 
susceptibility associated with global ApoA1 deficiency. Moreover, the described work 
provides additional support for our working hypothesis, generated through the use of 
hypercholesterolemic donor mice 34, that the effect of specific interventions on bone 
marrow stem cells can generate a long-term and transplantable impact on hematopoi-
esis.
The general notion is that HDL exerts its anti-atherogenic effects mainly by facilitating 
reverse cholesterol transport. In accordance with this notion, it is tempting to hypoth-
esize that HDL deficiency causes lipid accumulation and changes in HSC functioning, 
similar as observed in ABCA1/ABCG1 double KO mice that exhibit spontaneous foam cell 
formation in stem cells in normolipidemic conditions 32. However, in both ABCA1 single 
KO mice and ApoA1 KO mice this has never been reported. Notably, upon transplanta-
tion to a hypercholesterolemic environment, i.e. LDLr KO mice on high-cholesterol diet, 
both recipients of ABCA1 and ApoA1 KO bone marrow display lymphocytosis 35. No 
mechanism was previously provided for this finding in ABCA1 KO bone marrow trans-
plantation studies. In this thesis, we now show that donor HDL deficiency in the context 
of normal ABCA1 functioning already causes lymphocytosis. Thus, it is likely that the 
HDL deficiency of the donor ABCA1 KO mice (at least partly) drives the lymphocytosis 
in ABCA1 KO bone marrow recipient mice. In support of this notion, unpublished data 
show that ABCA1 KO bone marrow recipients exhibit similar features as ApoA1 KO bone 
marrow recipients, such as an increase in thymus weight, relative and absolute blood 
CD4 T cell counts, and a clear trend towards increased thymic CCR9 expression (Snip & 
Ouweneel et al., unpublished results).
These studies highlight that HDL deficiency exerts differential effects on bone marrow 
HSCs besides its commonly known function in cellular cholesterol efflux. Dedicated stud-
ies should elucidate the mechanism of HDL deficiency on bone marrow hematopoiesis.
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sIlencInG of PRoTeIn c as a PoTenTIal MoUse MoDel foR 
aTHeRoTHRoMbosIs
The high morbidity and mortality rate associated with cardiovascular disease is largely 
the result of acute cardiovascular events, caused by superimposed thrombus formation 
after plaque rupture or superficial erosion of the overlying endothelium 36,37. Understand-
ing the molecular and cellular mechanisms of atherosclerotic plaque destabilization or 
erosion, and developing new therapeutics to prevent acute cardiovascular events are 
important points for vascular biology research and clinical cardiovascular medicine. 
However, even after decades of extensive research into the pathophysiology of athero-
sclerosis, the predictability of which plaques are going to develop atherothrombosis, 
and when, remains still largely unknown. Major advances in the prevention of acute car-
diovascular events will require early detection of rupture- and erosion-prone plaques. 
However, as elaborately described in chapter 6, basic research on plaque destabilization, 
rupture and erosion, is hampered by the lack of appropriate animal models of athero-
thrombosis.
Species differences in anticoagulation could contribute to the virtual absence of 
atherothrombosis susceptibility in mice. The half-life of active coagulation factor IIa in 
mouse plasma is significantly shorter as compared to its human counterpart, pointing 
towards more potent natural anticoagulation in mice 38. Therefore, one strategy to in-
duce spontaneous atherothrombosis can be by increasing blood coagulability. In chap-
ter 7 a proof-of-principle study is described in which we showed that transient siRNA 
mediated lowering of the natural anticoagulant protein C (siProc) in atherosclerotic 
apolipoprotein E (ApoE) KO mice induced large, organized, and fibrin- and leukocyte-
rich thrombi on top of advanced atherosclerotic plaques in the aortic root 39. Although 
the incidence of atherothrombosis was low (14%), it is the first report of induced 
spontaneous atherothrombosis in the aortic root. In chapter 8, we investigated if plaque 
characteristics or circulating factors could be linked to atherothrombosis susceptibil-
ity. Moreover, we aimed to increase the incidence of atherothrombosis by transiently 
increasing blood pressure, and to direct atherothrombosis to an additional predefined 
vascular site by placement of a perivascular silastic collar around the carotid artery 40. 
Spontaneous atherothrombosis in the aortic root of siProc-treated ApoE KO mice was 
reproduced and occurred at an incidence of 23%, while the incidence of collar-induced 
atherothrombosis in the carotid artery was only 2.6%. Treatment with phenylephrine, to 
transiently increase blood pressure, did not increase the incidence of atherothrombosis 
in the aortic root of the ApoE KO mice, nor in the carotid arteries with collars. Plaques 
in the aortic root with an associated thrombus were lower in collagen and macrophage 
content, and mice with atherothrombosis had significantly more circulating platelets. 
Remarkably, our data revealed that thrombus formation preferably occurred on plaques 
chapter 10
186
in the right coronary sinus of the aortic root. The identification of factors that drive the 
predilection for the right coronary sinus may provide novel clues on factors that drive 
atherothrombosis in mice and humans.
Platelets play an important role in the pathogenesis of atherothrombosis 9. In this 
context, mice lacking a functional HDL receptor, i.e. SR-BI KO mice, exhibit an interesting 
platelet phenotype. More specifically, SR-BI deficiency-associated hypercholesterolemia 
in plasma results in cholesterol accumulation in platelets, causing them to circulate 
in an activated state 6,19,20. Importantly, this activated platelet phenotype is associated 
with a higher susceptibility for FeCl3 damage-induced arterial thrombosis in the carotid 
artery 20. Hence, it is of clear interest to study whether modifying SR-BI functionality can 
also increase the incidence of atherothrombosis in siProc-treated mice.
In chapter 9, we aimed to determine if SR-BI deficiency increases the susceptibility 
for siProc-induced atherothrombosis, by challenging wild-type and SR-BI KO mice with 
an atherogenic diet. After 8 weeks challenge with an atherogenic diet, wild-type mice 
developed significant hypercholesterolemia and early lesions in the aortic root. In line 
with the notion that early lesions are not susceptible for atherothrombois, no athero-
thrombosis was observed in the aortic root of siProc-treated wild-type mice despite 
a 50% reduction in hepatic mRNA levels of Proc. Atherogenic diet-fed SR-BI KO mice 
developed exacerbated hypercholesterolemia. As a result, SR-BI KO mice did develop 
advanced plaques in the aortic root. Surprisingly, despite the advanced stage of the 
lesions, no aortic root atherothrombosis was observed in these animals. Analysis of Proc 
mRNA expression in livers of siProc treated SR-BI KO mice revealed that this was prob-
ably due to an impaired hepatic targeting of the siRNA complex. Instead of a decrease, 
the relative expression of Proc actually tended to increase. Therefore, unfortunately no 
conclusions regarding the possible prothrombotic effects of SR-BI deficiency under 
conditions of Proc silencing could be drawn from this study.
Studies described in this thesis, as well as research by other groups has shown that 
two strategies can be employed to induce atherothrombosis: plaque destabilization and 
induction of blood hypercoagulability. Although the single use of both strategies yields 
atherothrombosis at low incidence, it appears that a combination of plaque destabiliza-
tion and an increase in blood thrombogenicity together is the most promising strategy 
to induce atherothrombosis on a larger scale. Efforts in creating a usable model for 
atherothrombosis should therefore be aimed at targeting both parameters.
fUTURe PeRsPecTIVes
Acute cardiovascular events caused by atherothrombosis are still a major cause of death 
worldwide 1. Atherothrombosis is a complex, multifactorial disease. In line, several 
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pathological processes can be targeted in order to lower the risk and severity of the dis-
ease, in which inhibition of atherosclerosis development, risk of atherosclerotic plaque 
rupture and the development of an arterial thrombus can be inhibited.
The studies described in this thesis highlight that modulation of cholesterol metabo-
lism, and HDL specifi cally, is not only driving the known risk factors of atherothrombosis 
(i.e. atherosclerosis development 41, atherosclerotic plaque stability 42–44, immune cell 
function 45, endothelial function 46, coagulation 46, and platelet function 46), but also 
immune cell production and megakaryocyte functioning (this thesis). As such, distur-
bances in cholesterol metabolism appear to contribute to all underlying mechanisms 
that drive atherothrombosis development (Figure 1).
However, in order to eff ectively therapeutically target atherothrombosis risk though 
modulation of cholesterol metabolism, more research is warranted into which aspects 
of cholesterol metabolism yields the highest potential therapeutic value.
HDL-cholesterol (HDL-C) is a robust, consistent, and independent predictor for car-
diovascular disease 21,47–49. As such, it has been included as a critical component in risk 
prediction by both the European and American Heart Associations 50,51. Raising HDL-C 
levels pharmacologically has been a much-sought-after therapeutic strategy. However, 
even though several clinical trials showed that HDL-C could be eff ectively raised through 
inhibition of cholesteryl ester transfer protein (CETP), HDL-C-raising did not consistently 
improve cardiovascular outcome 52–55. Moreover, in genome-wide association studies 
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artery disease. The failure of these trials and genetic association initially significantly 
lowered the interest in HDL-C as a therapeutic target. However, it has also led to a shift 
of interest towards the therapeutic potential of HDL functionality. It is now widely rec-
ognized that, besides reverse cholesterol efflux, HDL particles have a myriad of functions 
ranging from anti-inflammatory and antioxidative effects, as well as anti-thrombotic and 
anti-apoptotic activity 56. In line, technical advances have shown that HDL carries a com-
plex array of lipids, proteins, metabolites, and microRNAs, and the composition of any of 
these individual components may impact on HDL functionality 57–60. The HDL lipidome, 
which comprises around half of the particle’s mass, includes over 200 individual species 
of lipid 60–62. Moreover, besides ApoA1 (70% of total HDL protein content), and ApoAII 
(10-15% of total HDL protein) 63, more than 85 other proteins and have been shown to be 
associated with HDL, among which are mediators of inflammation such as complement 
and acute-phase proteins 57,58,64. Interestingly, in cardiovascular disease patients, the 
HDL proteome is enriched with pro-inflammatory proteins 64,65. Whether this association 
is causally contributing to the development of cardiovascular disease, or secondary to 
the presence of cardiovascular disease remains to be elucidated. The recent discovery 
that HDL carries and delivers microRNA adds a novel layer of complexity to HDL particles 
that adds to their potential functionality 59,66. HDL can deliver microRNAs to recipient 
cells, demonstrating a novel mechanism of HDL-to-cell communication in vivo 66. In con-
clusion, the knowledge on HDL composition and function has been greatly increased in 
the past decade. However, the consequence of changes in composition on subsequent 
biological activities of HDL is currently still very poorly understood. Increased knowl-
edge of HDL composition, function and mechanisms of action will greatly increase the 
potential therapeutic value of HDL. Moreover, elucidation of novel HDL functionalities 
will shed light on the unknown factors in the interplay between cholesterol metabolism 
and the production immune cells and platelets described in this thesis, and its effects on 
atherosclerosis and atherothrombosis development, and will be an important avenue 
for the field to explore in the future.
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Hart- en vaatziekten zijn de meest voorkomende doodsoorzaak wereldwijd. De primaire 
onderliggende oorzaak van hart- en vaatziekten is atherosclerose. Atherosclerose is een 
chronische, multifactoriële ziekte, die wordt gekarakteriseerd door een ontstekingsreac-
tie op cholesterol afzettingen in de arteriële vaatwand, wat resulteert in de vorming van 
een atherosclerotische plaque. Atherosclerose ontwikkelt zich voornamelijk asympto-
matisch gedurende het leven. Ruptuur of erosie van een atherosclerotische plaque kan 
echter zorgen voor de vorming van een bloedprop die het bloedvat verstopt (athero-
trombose). Atherotrombose is de primaire oorzaak van cardiovasculaire aandoeningen 
zoals een hartinfarct of beroerte.
De voornaamste risicofactoren voor het ontwikkelen van atherosclerose zijn defecten 
in het cholesterol metabolisme, zoals bijvoorbeeld het hebben van hypercholesterole-
mie. Deze factoren beïnvloeden echter niet alleen de ontwikkeling van een atheroscle-
rotische plaque, maar beïnvloeden ook de productie van bloed- cellen (hematopoëse), 
waaronder witte bloedcellen (leukopoëse) en de productie en karaktereigenschappen 
van bloedplaatjes (thrombopoëse), cellen die allen een belangrijke rol spelen in het 
ontstaan van atherotrombose. Aangezien hematopoëse voornamelijk plaatsvindt in 
het beenmerg compartiment, is het cholesterol metabolisme in het beenmerg een 
potentieel interessant aangrijpingspunt in het voorkomen van hart- en vaatziekten, en 
atherotrombose in het bijzonder. Dit proefschrift beschrijft nieuwe interacties tussen 
cholesterol metabolisme en de productie van immuuncellen en bloedplaatjes, en het 
effect van deze interactie op de ontwikkeling van atherosclerotische plaques en het 
ontstaan van atherotrombose.
nIeUWe InZIcHTen In De RelaTIe TUssen cHolesTeRol 
MeTabolIsMe en HeMaToPoËse
effecten van modulatie van het cholesterol metabolisme op 
megakaryopoëse en de productie van bloedplaatjes
Bloedplaatjes zijn kleine cellen in het bloed die snel reageren op verlies van de integri-
teit van het endotheel en de daarmee samenhangende blootstelling van bloed aan het 
onderliggende weefsel. Zodoende spelen zij een belangrijke rol in de ontwikkeling van 
atherotrombose. Veranderingen in de karakteristieke eigenschappen van bloedplaatjes, 
zoals de dichtheid en volume, zijn geassocieerd met een direct effect op het risico op 
acute hart- en vaatziekten.
Bloedplaatjes worden geproduceerd door megakaryocyten in het beenmerg. 
Dyslipidemie beïnvloedt het functioneren van megakaryocyten, en modulatie van 
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het cholesterol metabolisme in megakaryocyten kan daarom een potentieel aangrij-
pingspunt vormen voor het verminderen van het risico op atherotrombose. Eerdere 
studies hebben reeds aangetoond dat het verlies van de functie van de receptor voor 
hogedichtheidslipoproteïnen (HDL), scavenger receptor BI (SR-BI), in muizen resulteert 
in de ontwikkeling van trombocytopenie. Er is gesuggereerd dat dit wordt veroorzaakt 
door ophoping van vrij cholesterol in bloedplaatjes en een daarmee samenhangende 
versnelde klaring van bloedplaatjes. In hoofdstuk 3 van dit proefschrift is met behulp 
van zogenaamde SR-BI knockout muizen onderzocht of SR-BI deficiëntie mogelijk ook 
het megakaryopoëse proces en de productie van bloedplaatjes beïnvloedt. Het is geble-
ken dat de megakaryocyten in SR-BI knockout muizen een verhoogde concentratie vrij 
cholesterol hebben, wat is geassocieerd met kleine veranderingen in megakaryopoëse. 
De vorming van voorlopers van bloedplaatjes (proplatelets) was echter sterk verminderd 
in SR-BI knockout muizen, wat mogelijk deels kan verklaren waarom afwezigheid van 
SR-BI is geassocieerd met de ontwikkeling van trombocytopenie. Door middel van het 
uitvoeren van beenmerg transplantaties in muizen is aangetoond dat de effecten van 
SR-BI deficiëntie op megakaryopoëse en proplatelet formatie niet veroorzaakt worden 
door het ontbreken van SR-BI op specifiek de megakaryocyten, maar secundair zijn aan 
de SR-BI deficiëntie-geassocieerde verhoging van de concentraties vrij cholesterol in 
het bloed.
Eerder onderzoek heeft gesuggereerd dat het manipuleren van de efflux van choles-
terol uit cellen ook invloed kan hebben op de productie van bloedplaatjes. In hoofdstuk 
4 is daarom onderzocht of het genetisch verwijderen van de cholesterol transport eiwit-
ten ABCA1 en ABCG1 een invloed zou hebben op de productie van bloedplaatjes. Het 
is gebleken dat inactivatie van de functie van zowel ABCA1 als ABCG1 geen effect heeft 
op megakaryopoëse. Het ontbreken van ABCA1 of ABCG1 bleek echter contrasterende 
effecten op het functioneren van de megakaryocyten en de productie van bloedplaatjes 
in het bijzonder te hebben. ABCA1 deficiëntie remt de productie van proplatelets, terwijl 
het ontbreken van ABCG1 juist een sterke verhoging van de proplatelet productie tot 
gevolg heeft. Ondanks dat onze eerdere studies in macrofagen hebben aangetoond dat 
afwezigheid van beide transporters een significant effect kan hebben op de intracellu-
laire cholesterol hoeveelheid, was de afwezigheid van beide eiwitten verassend genoeg 
niet geassocieerd met accumulatie van vrij cholesterol in de megakaryocyten. Deze 
resultaten suggereren dat ABCA1 en ABCG1 geen grote rol van betekenis spelen in het 
reguleren van de intracellulaire cholesterol concentratie in megakaryocyten, maar dat 
deze eiwitten mogelijk wel belangrijk zijn voor de regulatie van de laatste stappen in het 
productieproces van bloedplaatjes.
Deze nieuwe bevindingen onderstrepen het belang van cholesterol metabolisme in 
megakaryocyten voor de productie van bloedplaatjes. Meer onderzoek is nodig om te 
begrijpen hoe veranderingen in het cholesterol metabolisme de functie van megaka-
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ryocyten en de productie van bloedplaatjes specifiek beïnvloedt. Daarnaast is het zeer 
interessant om meer inzicht te krijgen in de klinische relevantie van onze bevindingen 
in het kader van diagnose en mogelijke genezing van atherotrombose-gerelateerde 
aandoeningen.
Het effect van apolipoproteine a1 deficiëntie op de productie van 
immuuncellen
In mensen is de plasma apolipoproteine A1 (ApoA1) concentratie negatief gecorreleerd 
met het risico op de ontwikkeling van atherosclerotische plaques. ApoA1 is het meest 
voorkomende en belangrijkste eiwit op HDL deeltjes. Het eiwit wordt gemaakt in hepa-
tocyten in de lever en enterocyten in de darm. Na uitscheiding door deze cellen gaat 
ApoA1 een interactie aan met ABCA1 om fosfolipiden en cholesterol te vergaren voor 
de vorming van HDL deeltjes. ApoA1 is ook essentieel voor de anti-inflammatoire eigen-
schappen van HDL. In lijn met deze laatste functie is ApoA1 deficiëntie geassocieerd 
met veranderingen in de functie van immuuncellen onder hypercholesterolemische 
condities. Het wordt verondersteld dat zowel de verstoring van de cholesterolopname 
door HDL als veranderingen in het functioneren van immuuncellen bijdragen aan het 
verhoogde risico voor atherosclerose geassocieerd met ApoA1 deficiëntie.
Het belangrijkste orgaan dat immuuncellen produceert is het beenmerg, waar de 
hematopoëtische stamcellen zich bevinden. Het is aangetoond dat ApoA1, naast een 
direct effect op volwassen immuuncellen, ook de deling van hematopoëtische stam-
cellen remt en de hematopoëse richting bepaalde celtypen kan dirigeren. Op deze 
manier kan ApoA1 een directe invloed uitoefenen op het aantal en type circulerende 
immuuncellen. Uit eerder onderzoek is gebleken dat hypercholesterolemie ook het 
functioneren van hematopoëtische stamcellen kan beïnvloeden. Meer specifiek laten 
stamcellen in hypercholesterolemische muizen een verhoogde proliferatie snelheid 
zien. Dit wordt gedreven door lange-termijn veranderingen in de stamcellen, aangezien 
de hypercholesterolemie-geïnduceerde veranderingen in stamcelfunctie behouden 
blijven na beenmergtransplantatie. In het onderzoek beschreven in hoofdstuk 5 heb-
ben we gepoogd, in een atherosclerotische context, de directe effecten van ApoA1 
deficiëntie op circulerende immuuncellen los te koppelen van indirecte effecten op hun 
functioneren als gevolg van een effecten van de afwezigheid van ApoA1 op beenmerg-
functie. Om dit te onderzoeken hebben we beenmerg van wild-type en ApoA1 knockout 
muizen getransplanteerd naar hypercholesterolemische lage-dichtheidslipoproteïne 
receptor (LDLr) knockout muizen met normale apoAI concentratis in het bloed. Plasma 
cholesterolwaarden en de grootte van en collageen hoeveelheid in de atheroscleroti-
sche plaques was gelijk in ontvangers van wild-type en ApoA1 knockout beenmerg. 
Ondanks dat de atherosclerosegevoeligheid niet veranderd was, lieten LDLr knockout 
muizen getransplanteerd met ApoA1 knockout beenmerg wel lymphocytose zien als 
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gevolg van een sterke toename in het aantal circulerende CD4-positieve helper T cellen. 
Dit ging gepaard met een sterke toename in het totaal aantal cellen in de milt en een 
relatieve toename van het aantal naïeve T cellen in zowel de milt als de circulatie. Een 
toename in het gewicht van de thymus en de parallelle verhoging in relatieve thymus 
CCR9 genexpressie van de ApoA1 beenmerg ontvangers suggereerden dat de productie 
van T cellen in deze muizen verhoogd was. Verder onderzoek heeft aangetoond dat dit 
gedreven wordt door een verhoogd aantal hematopoëtische stamcellen en T cel voorlo-
pers in het beenmerg van ApoA1 knockout muizen ten opzichte van wild-type muizen. 
ApoA1 deficiëntie beïnvloedt het beenmerg dus zodanig dat het de productie van na-
ieve T cellen door de thymus stimuleert. De resultaten van dit onderzoek ondersteunen 
de hypothese dat het effect van een specifieke interventie op beenmerg stamcellen een 
lange-termijn en transplanteerbaar effect kan hebben op de hematopoëse. Daarnaast 
heeft dit onderzoek nieuw bewijs geleverd dat het effect van ApoA1 deficiëntie op het 
beenmerg geen onderliggende oorzaak is van de verhoogde atherosclerotische plaque 
vorming die geassocieerd is met ApoA1 deficiëntie.
Remming van de productie van Proteine c als nieuwe methode om 
atherotrombose in muizen te induceren
De hoge mortaliteit die geassocieerd is met hart- en vaatziekten is voornamelijk het 
resultaat van de vorming van een bloedprop op een geruptureerde of geërodeerde 
atherosclerotische plaque. Het begrijpen van moleculaire en cellulaire mechanismen 
die destabilisatie of erosie van atherosclerotische plaques veroorzaken is een belangrijk 
speerpunt van het huidige cardiovasculaire onderzoek. Ondanks vele jaren onderzoek 
naar de pathofysiologie van atherosclerose is het echter nog steeds zeer lastig te 
voorspellen welke plaques mogelijk gevaar geven op het ontstaan van atherotrom-
bose. Zoals beschreven in hoofdstuk 6 wordt de voortgang van het wetenschappelijk 
onderzoek naar plaque destabilisatie, ruptuur en erosie sterk geremd door een gebrek 
aan geschikte muismodellen om het atherotromboseproces te bestuderen. Er zijn veel 
muismodellen beschikbaar voor het bestuderen van atherosclerose. Deze muismodel-
len ontwikkelen echter geen spontane atherotrombose. De exacte oorzaak van het ont-
breken van atherotrombose in muizen is onbekend, maar mogelijk vormen verschillen 
tussen muizen en mensen in de samenstelling van het bloed de onderliggende oorzaak. 
De anticoagulatie activiteit is sterker in muizen dan in mensen. Het inhiberen van de 
anticoagulatie vormt daarom een mogelijke strategie om atherotrombose te induceren 
in muizen. Hoofdstuk 7 beschrijft een proof-of-principle studie die laat zien dat small 
interfering RNA (siRNA)-gemedieerde remming van het anticoagulatie-eiwit Proteine C 
leidt tot spontane vorming van atherotrombose in het gebied van hart waar zich de aor-
takleppen bevinden in atherosclerotische apolipoproteine E knockout muizen. Hoewel 
de atherotrombose incidentie laag was (14%) in deze experimentele setting, is dit wel de 
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eerste keer dat spontane atherotrombose in de aortakleppen kon worden aangetoond. 
In hoofdstuk 8 hebben we (1) onderzocht of verschillende karaktereigenschappen van 
de atherosclerotische plaques of specifieke factoren in de circulatie van invloed zijn 
op de gevoeligheid voor de ontwikkeling an atherotrombose in dit diermodel en (2) 
geprobeerd atherotrombose te induceren op een tweede anatomische locatie, door 
middel van het plaatsen van een perivasculaire collar om de halsslagader. Spontane 
atherotrombose incidentie in deze studie was 23% in de aortakleppen en 2.6% in de 
halsslagader. Verhoging van de bloeddruk had op beide locaties geen invloed op de 
incidentie van atherotrombose. Atherosclerotische plaques die geassocieerd waren 
met een trombus hadden gemiddeld een lagere hoeveelheid collageen en macrofagen. 
Daarnaast hadden muizen met atherotrombose relatief meer bloedplaatjes in de circu-
latie. Bovendien kwam atherotrombose significant meer voor in de rechter coronaire 
sinus van de aortakleppen, wat suggereert dat mogelijk het stromingsprofiel van het 
bloed een rol speelt bij de ontwikkeling van atherotrombose.
Bloedplaatjes spelen een belangrijke rol bij atherotrombose ontwikkeling. Zoals 
hierboven beschreven hebben SR-BI knockout muizen minder bloedplaatjes. Echter 
de bloedplaatjes in SR-BI knockout circuleren wel in een geactiveerde staat. Dit laatste 
fenotype is geassocieerd met een hogere gevoeligheid voor schade-geïnduceerde arte-
riële trombose. Dit heeft geleid tot de hypothese dat modulatie van SR-BI functionaliteit 
mogelijk de incidentie van atherotrombose kan veranderen. Hoofdstuk 9 beschrijft het 
toepassen van het siRNA-gemedieerde remming van Proteine C in wild-type en SR-BI 
knockout muizen na het voeden van een atherogeen dieet. Wild-type muizen op een 
atherogeen dieet ontwikkelden beginnende plaques. Echter, zoals verwacht waren deze 
beginnende plaques niet gevoelig voor de ontwikkeling van atherotrombose. Ondanks 
een reductie van 50% in de productie van Proteine C, werd in wild-type muizen geen 
atherotrombose gevonden. SR-BI knockout muizen op een atherogeen dieet ontwik-
kelden wel geavanceerde plaques. Verassend genoeg werd echter ook geen athero-
trombose aangetroffen in deze muizen. Uit analyse van de genexpressie in de levers van 
SR-BI knockout muizen bleek dat de gebruikte Proteine C siRNA in deze experimentele 
groep niet de verwachte vermindering gaf, maar zelfs een verhoging van de Proteine C 
productie veroorzaakte. Daarom kan uit deze studie geen conclusie worden getrokken 
wat betreft de vatbaarheid voor atherotrombose van SR-BI knockout muizen.
De studies beschreven in dit proefschrift, tezamen met het onderzoek gedaan door 
andere onderzoeksgroepen, laten zien dat er twee strategieën zijn om atherotrombose 
te induceren in muizen: plaque destabilisatie en inductie van hypercoagulatie van het 
bloed. Hoewel beide strategieën afzonderlijk atherotrombose kunnen induceren met 
een lage incidentie, zullen toekomstige inspanningen zich moeten richten op een com-




Atherotrombose vormt een belangrijke doodsoorzaak wereldwijd. Atherotrombose is 
een complex proces, waarin atherosclerose ontwikkeling, plaque destabilisatie en de 
vorming van een arteriële trombus de belangrijkste aangrijpingspunten zijn om het 
ontstaansrisico te verlagen.
De studies beschreven in dit proefschrift onderstrepen dat modulatie van cholesterol 
metabolisme, en in het bijzonder HDL functionaliteit, niet alleen een drijvende kracht 
is achter de reeds bekende risicofactoren voor atherotrombose, zoals atherosclerose 
ontwikkeling, plaque (de-)stabiliteit, immuuncel functie, endotheel functie, coagulatie, 
en bloedplaatjes functie), maar dat HDL ook een effect heeft op de productie van im-
muuncellen en de functie van megakaryocyten. Als zodanig zijn verstoringen in choles-
terol metabolisme betrokken bij alle onderliggende mechanismen die de ontwikkeling 
van atherotrombose beïnvloeden. Om het risico op atherotrombose effectief te kunnen 
verlagen is echter meer inzicht nodig in welk aspecten van het HDL metabolisme de 
meeste therapeutische potentie heeft. In het afgelopen decennium is de kennis over 
HDL, zowel de compositie als de functie, sterk gegroeid. Over de consequenties van 
veranderingen in compositie op de biologische activiteit van HDL is helaas nog steeds 
zeer weinig bekend. Meer kennis over de effecten van wijzigingen in de compositie van 
HDL op de daarmee samenhangende functionaliteit zal het therapeutische potentieel 
van HDL sterk vergroten. Bovendien zullen deze nieuwe inzichten bijdragen aan het 
ontrafelen van de onbekende factoren in de interactie tussen cholesterol metabolisme 
en de productie van immuuncellen en bloedplaatjes, zoals beschreven in dit proefschrift, 
en de effecten op atherosclerose en atherotrombose ontwikkeling. Vergroting van de 
kennis over de werking van HDL zal daarom, mijns inziens, een zeer belangrijk thema 
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